CA2496249C - 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments - Google Patents

8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments Download PDF

Info

Publication number
CA2496249C
CA2496249C CA2496249A CA2496249A CA2496249C CA 2496249 C CA2496249 C CA 2496249C CA 2496249 A CA2496249 A CA 2496249A CA 2496249 A CA2496249 A CA 2496249A CA 2496249 C CA2496249 C CA 2496249C
Authority
CA
Canada
Prior art keywords
methyl
xanthine
piperidin
esi
mass spectrum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2496249A
Other languages
French (fr)
Other versions
CA2496249A1 (en
Inventor
Frank Himmelsbach
Elke Langkopf
Matthias Eckhardt
Michael Mark
Roland Maier
Ralf Richard Hermann Lotz
Mohammad Tadayyon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31947613&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2496249(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE10238243A external-priority patent/DE10238243A1/en
Priority claimed from DE10312353A external-priority patent/DE10312353A1/en
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of CA2496249A1 publication Critical patent/CA2496249A1/en
Application granted granted Critical
Publication of CA2496249C publication Critical patent/CA2496249C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)

Abstract

The present invention relates to substituted xanthines of general formula (see formula I), wherein R1 is a substituted methyl or ethyl, R2 is a methyl, isopropyl or phenyl, and R3 is an optionally substituted alkenyl or substituted methyl, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Description

8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PRODUCTION THEREOF
AND THE USE OF THE SAME AS MEDICAMENTS

The present invention relates to new substituted xanthines of general formula R'`
N
om (I), NN

the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV), the preparation thereof, the use thereof for the prevention or treatment of diseases or conditions associated with an increased DPP-IV activity or capable of being prevented or alleviated by reducing the DPP-IV activity, particularly. type I or type II diabetes mellitus, the pharmaceutical compositions containing a compound of general formula (I) or a physiologically acceptable salt thereof as well as processes for the preparation thereof.

In the above formula I

R' denotes a methyl group, a methyl group which is substituted by a dimethylaminocarbonyl, pyrrolidin-1-ylcarbonyl, piperidin-1-ylcarbonyl, tert.-butylcarbonyl or a cyclohexylcarbonyl-group, a methyl group which is substituted by a naphthyl, methylnaphthyl, methoxynaphthyl, nitronaphthyl or dimethylaminonaphthyl group, a methyl group which is substituted by a 2-phenylethenyl or a biphenylyl group, a methyl group which is substituted by a phenyloxadiazolyl, 5-methyl-3-phenyl-isoxazolyl, phenylpyridinyl, indolyl, benzothiophenyl, quinolinyl, isoquinolinyl, methylisoquinolinyl, (methoxycarbonylmethylamino)-isoquinolinyl, cinnolinyl, quinazolinyl, methylquinazolinyl, 1,2-dihydro-1-methyl-2-oxo-quinolinyl, 1,2-dihydro-2-methyl-1-oxo-isoquinolinyl, 3,4-dihydro-4-oxo-phthalazinyl, 3,4-dihydro-3-methyl-4-oxo-phthalazinyl, 3,4-dihydro-4-oxo-quinazolinyl, 3,4-dihydro-3-methyl-4-oxo-quinazolinyl or a 2-oxo-2H-chromenyl group, a 2-methoxyethyl, 2-phenyloxyethyl or 2-cyanoethyl group, a phenylcarbonylmethyl or a 1-(phenylcarbonyl)-ethyl group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by an amino, cyanomethylamino, methylcarbonylamino, ethylcarbonylamino, isopropylcarbonylamino, methoxycarbonylamino, (ethyloxycarbonylamino)-carbonylamino or a 2-oxo-imidazolidin-1-yl group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a carboxy, methoxycarbonyl, ethyloxycarbonyl, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl or morpholin-4-ylcarbonyl group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a methylsuiphanyl, methylsulphinyl or methylsulphonyl group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a carboxymethoxy, ethyloxycarbonylmethoxy, isopropyloxycarbonylmethoxy, aminocarbonylmethoxy, methylaminocarbonylmethoxy, ethyl aminocarbonylmethoxy, isopropylaminocarbonylmethoxy, dimethylaminocarbonylmethoxy, pyrrolidin-1-ylcarbonylmethoxy or morpholin-4-ylcarbonylmethoxy group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a 1-(methoxycarbonyl)-ethyloxy or a 1-(aminocarbonyl)-ethyloxy group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a methylsulphinylmethoxy group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by two methoxy groups or a phenylcarbonylmethyl group wherein in the phenyl moiety two adjacent hydrogen atoms are replaced by a -O-CH2-O, -O-CH2-CH2-O or a -N(CH3)-CO-O group, R2 denotes a hydrogen atom, a methyl, isopropyl, 2-propen-1-yl, 2-propyn-1-yl or phenyl group or a cyanomethyl or methoxycarbonylmethyl group and R3 denotes a 2-cyanobenzyl or 2,6-dicyanobenzyl group, a 2-methyl-2-propen-1-yl, 2-chloro-2-propen-1-yl or 3-bromo-2-propen-1-yl group a 2-buten-1-yl, 3-methyl-2-buten-1-yl or 2,3-dimethyl-2-buten-1-yl group, a 2-butyn-1-yl group, a 1-cyclopenten-1-ylmethyl group or a 2-furanylmethyl group.

The carboxy groups mentioned in the definition of the above mentioned groups may be replaced by a group which can be converted into a carboxy group in vivo or by a group which is negatively charged under physiological conditions, and furthermore the amino and imino groups mentioned in the definition of the above mentioned groups may be substituted by a group which can be cleaved in vivo. Such groups are described for example in WO 98/46576 and by N.M.
Nielsen et al. in International Journal of Pharmaceutics 39, 75-85 (1987).
Compounds which contain a group that can be cleaved in vivo are prodrugs of the corresponding compounds wherein this group that can be cleaved in vivo has been cleaved.

By a group which can be converted in vivo into a carboxy group is meant, for example, a hydroxymethyl group, a carboxy group esterified with an alcohol wherein the alcohol moiety is preferably a C1_6-alkanol, a phenyl-C1.3-alkanol, a C3.9-cycloalkanol, while a C5-8-cycloalkanol may additionally be substituted by one or two C1_3-alkyl groups, a C5.5-cycloalkanol wherein a methylene group in the 3 or 4 position is replaced by an oxygen atom or by an imino group optionally substituted by a C1_3-alkyl, phenyl-C1.3-alkyl, phenyl-C1_3-alkyloxycarbonyl or C2_6-alkanoyl group and the cycloalkanol moiety may additionally be substituted by one or two C1_3-alkyl groups, a C4_7-cycloalkenol, a C3.5-alkenol, a phenyl-C3.5-alkenol, a C3.5-alkynol or phenyl-C3.5-alkynol with the proviso that no bonds to the oxygen atom start from a carbon atom which carries a double or triple bond, a C3.8-cycloalkyl-C1.3-alkanol, a bicycloalkanol with a total of 8 to 10 carbon atoms which may additionally be substituted in the bicycloalkyl moiety by one or two C1.3-alkyl groups, a 1,3-dihydro-3-oxo-1-isobenzofuranol or an alcohol of formula Rp-CO-O-(RgCRr)-OH, wherein Rp denotes a C,_8-alkyl, C5_7-cycloalkyl, C1_8-alkyloxy, C5.7-cycloalkyloxy, phenyl or phenyl- C1_3-alkyl group, Rq denotes a hydrogen atom, a C,_3-alkyl, C5.7-cycloalkyl or phenyl group and Rr denotes a hydrogen atom or a C1_3-alkyl group, by a group which is negatively charged under physiological conditions is meant, for example, a tetrazol-5-yl, phenylcarbonylaminocarbonyl, trifluoromethylcarbonylaminocarbonyl, C1_6-alkylsulphonylamino, phenylsulphonylamino, benzylsulphonylamino, trifluoromethylsulphonylamino, C1_6-alkylsulphonylaminocarbonyl, phenylsulphonylaminocarbonyl, benzylsulphonylaminocarbonyl or perfluoro-C1.6-alkylsulphonylaminocarbonyl group and by a group which can be cleaved in vivo from an imino or amino group is meant, for example, a hydroxy group, an acyl group such as a phenylcarbonyl group optionally mono- or disubstituted by fluorine, chlorine, bromine or iodine atoms, by C1.3-alkyl or C1.3-alkoxy groups, while the substituents may be identical or different, a pyridinoyl group or a C1_16-alkanoyl group such as the formyl, acetyl, propionyl, butanoyl, pentanoyl or hexanoyl group, a 3,3,3-trichloropropionyl or allyloxycarbonyl group, a C1.16-alkoxycarbonyl or C1.16-alkylcarbonyloxy group, wherein hydrogen atoms may be wholly or partially replaced by fluorine or chlorine atoms such as the methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, tert.butoxycarbonyl, pentoxycarbonyl, hexoxycarbonyl, octyloxycarbonyl, nonyloxycarbonyl, decyloxycarbonyl, undecyloxycarbonyl, dodecyloxycarbonyl, hexadecyloxycarbonyl, methylcarbonyloxy, ethylcarbonyloxy, 2,2,2-trichloroethylcarbonyloxy, propylcarbonyloxy, isopropylcarbonyloxy, butylcarbonyloxy, tert.butylcarbonyloxy, pentylcarbonyloxy, hexylcarbonyloxy, octylcarbonyloxy, nonylcarbonyloxy, decylcarbonyloxy, undecylcarbonyloxy, dodecylcarbonyloxy or hexadecylcarbonyloxy group, a phenyl-C,.6-alkoxycarbonyl group such as the benzyloxycarbonyl, phenylethoxycarbonyl or phenylpropoxycarbonyl group, a 3-amino-propionyl group wherein the amino group may be mono- or disubstituted by C,_6-alkyl or C3.7-cycloalkyl groups and the substituents may be identical or different, a C1.3-alkylsulphonyl-C2.4-alkoxycarbonyi, C1.3-alkoxy-C2.4-alkoxy-C2-4-alkoxycarbonyl, Rp-CO-O-(RqCRr)-O-CO, C14-alkyl-CO-NH-(RSCRt)-O-CO- or C1.6-alkyl-CO-O-(R3CRt)-(RSCRt)-O-CO- group, wherein Rp to Rr are as hereinbefore defined, Ra and Rt, which may be identical or different, denote hydrogen atoms or C1.3-alkyl groups.

A first aspect of the invention relates to compounds of general formula (1) wherein R1 denotes a methyl group which is substituted by a dimethylaminocarbonyl, pyrrolidin-1-ylcarbonyl, piperidin-1-ylcarbonyl, tert.-butylcarbonyl or a cyclohexylcarbonyl group, a methyl group which is substituted by a naphthyl, methylnaphthyl, methoxynaphthyl, nitronaphthyl or (dimethylamino)-naphthyl group, a methyl group which is substituted by a 2-phenylethenyl or a biphenylyl group, a methyl group which is substituted by a phenyl-oxadiazolyl, 5-methyl-3-phenyl-isoxazolyl, phenyl-pyridinyl, indolyl, benzothiophenyl, quinolinyl, isoquinolinyl, methylisoquinolinyl, (methoxycarbonylmethylamino)-isoquinolinyl, cinnolinyl, quinazolinyl, methyiquinazolinyl, 1,2-dihydro-1-methyl-2-oxo-quinolinyl, 1,2-dihydro-2-methyl-1-oxo-isoquinolinyl, 3,4-dihydro-4-oxo-phthalazinyl, 3,4-dihydro-3-methyl-4-oxo-phthalazinyl, 3,4-dihydro-4-oxo-quinazolinyl, 3,4-dihydro-3-methyl-4-oxo-quinazolinyl or a 2-oxo-2H-chromenyl group, a 2-methoxyethyl, 2-phenyloxyethyl or 2-cyanoethyl group, a phenylcarbonylmethyl or a 1-(phenylcarbonyl)-ethyl group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by an amino, cyanomethylamino, methylcarbonylamino, ethylcarbonylamino, isopropylcarbonylamino, methoxycarbonylamino, (ethyloxycarbonylamino)-carbonylamino or a 2-oxo-imidazolidin-1-yl group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a carboxy, methoxycarbonyl, ethyloxycarbonyl, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl or morpholin-4-ylcarbonyl group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a methylsulphanyl, methylsulphinyl or methylsulphonyl group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a carboxymethoxy, ethyloxycarbonylmethoxy, isopropyloxycarbonylmethoxy, aminocarbonylmethoxy, methylaminocarbonylmethoxy, ethylaminocarbonylmethoxy, isopropylaminocarbonylmethoxy, dimethylaminocarbonylmethoxy, pyrrolidin-1-ylcarbonylmethoxy or morpholin-4-ylcarbonylmethoxy group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a 1-(methoxycarbonyl)-ethyloxy or a 1-(aminocarbonyl)-ethyloxy group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a methylsulphinylmethoxy group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by two methoxy groups or a phenylcarbonylmethyl group wherein in the phenyl moiety two adjacent hydrogen atoms are replaced by a -O-CH2-O, -O-CH2-CH2-O or a -N(CH3)-CO-O group, R2 denotes a methyl, isopropyl or phenyl group and R3 denotes a 2-methyl -2-propen-1-yl, 2-chloro-2-propen-1-yl or 3-bromo-2-propen-1-yl group a 2-buten-1-yl or 2,3-dimethyl-2-buten-1-yl group, a 2-butyn-1-yl group, a 1-cyclopenten-1 -ylmethyl group or a 2-furanylmethyl group, as well as the compounds 1-(2-cyano-ethyl)-3-methyl -7-(2-cyano-be nzyl)-8-(3-amino-pi peridin-1-yl)-xanthine, 1-(2-{2-[(ethoxycarbonyl )methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-I -yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-(2-{2-[(aminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-I -yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-(2-{3-[(methanesulphinyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-l-yl)-8-(3-amino-piperidin-l-yl)-xanthine, 1-(1-methyl-2-oxo-2-phenyl-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yi)-xanthine, 1 -(2-p h enoxy-ethyl)-3-methyl-7-(2-cyano-benzyl)-8-(3-am ino-pi pe rid i n-1 -yl)-xanthine, 1-(2-phenyl-2-oxo-ethyl)-7-(3-methyl-2-buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine, 1-(2-{3-[(ethoxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine, 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-l-yl)-8-(3-amino-piperidin-l-yl)-xanthine, 1-(2-{2-[(dimethylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine, 1-(2-methoxy-ethyl)-3-methyl-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-methyl-3-[(methoxycarbonyl)methyl]-7-(2-cyano-benzyl)-8-(3-amino-piperidin-l -yl)-xanthine, 1 -methyl-3-cyanomethyl-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1 -yl)-xanthine, 1-methyl-3-(2- propyn-1-yl)-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-{2-[3-(2-oxo-imidazolidin-1-yl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-methyl-3-(2-propen-1-yl)-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-(2-{2-[(ethylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-methyl-3-phenyl-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-((S)-3-amino-piperidin-1-yl)-xanthine, 1-(2-phenyl-2-oxo-ethyl)-3-cyanomethyl-7-(3-methyl-2-buten-1-yi)-8-(3-amino-piperidin-1-yl)-xanthine, 1-[(quinolin-2-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-[(2-oxo-2H-chromen-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-[(cinnolin-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-[(1-methyl-2-oxo-1,2-dihydro-quinolin-4-yl)methyl]-3-methyl -7-(3-methyl-2-buten-1-yi)-8-(3-amino-piperidin-1-yl)-xanthine, 1-[(4-oxo-3,4-dihydro-phthalazin-1-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-[(quinazolin-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-[(5-methyl-3-phenyl-isoxazol-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-l-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-[(isoquinolin-3-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-[(3-phenyl-[1,2,4]oxadiazol-5-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-[(4-phenyl-pyridin-2-yl)meth yl]-3-methyl -7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-[(5-phenyl-pyridin-2-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-[(3-methyl-4-oxo-3,4-dihydro-phthalazin-1 -yl)methyl]-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine, 1 - [2-(3- m ethyl s u I ph anyl-phenyl)-2-oxo-ethyl]-3-methyl -7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-[2-(3-methanesulphinyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl )-xanthine, 1-[2-(3-methanesulphonyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-[2-(3-carboxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-[2-(3-methoxycarbonyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-{2-[3-(methylaminocarbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-{2-[3-(dimethylaminocarbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-{2-[3-(morpholin-4-yl-carbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yi)-xanthine, 1-[2-(2-carboxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-[2-(2-ethoxycarbonyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-{2-[2-(d imethylaminocarbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-{2-[2-(mo rp hol i n-4-yl-ca rbo nyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yi)-xanthine, 1-[2-(2,6-dimethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-((E)-3-phenyl-alIyl)-3-methyl -7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-[(benzo[b]thiophen-3-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-[(1 H-indol-3-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yi)-xanthine, 1-[(biphenyl-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-(2-cyclohexyl-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-(3,3-dimethyl-2-oxo-butyl)-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine, 1-({5-[(methoxycarbonyl)methylamino]-isoquinolin-1-yl}methyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-(2-dimethylamino-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-(3-amino-piperidin-1 -yi)-xanthine, 1-[2-(piperidin-1-yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-[(2-methyl-1 -oxo-1,2-dihydro-isoquinolin-4-yl)methyl]-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-[2-(2,3-dimethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-[2-(pyrrolidin-1-yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-[2-(2,3-dihydro-benzo[1,4]dioxi n-5-yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yi)-8-(3-amino-piperidin-1-yl)-xanthine, 1-[2-(3-methyl -2-oxo-2,3-d ihyd ro-benzooxazol-7-yl)-2-oxo-ethyl] -3- m ethyl (3-methyl-2-buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine, 1-[2-(benzo[1, 3]dioxol-4-yl)-2-oxo-ethyl]-3-methyl -7-(3-methyl -2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-methyl-3-isopropyl-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-[2-(2-cyanomethylamino-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1 -[(isoquinolin-1 -yl)methyl]-3-[(methoxycarbonyl)methyl]-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-(2-{2-[(isopropyloxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-[2-(2-{[(ethoxycarbonylamino)carbonyl]amino}-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-[2-(2-acetylamino-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-((S)-3-amino-piperidin-1-yl)-xanthine, 1-(2-{2-[(methyl aminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-((S)-3-amino-piperid in-1-yl)-xanthine, 1-methyl-7-(2-cyano-benzyl)-8-(3-amino-pi perid i n- 1 -yl)-xanthine, 1-(2-{2-[(isopropyl carbon yl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-(2-{2-[(methoxycarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-I -yl)-8-(3-amino-piperid in-1-yl)-xanthine, 1-[2-(3-methyl-2-oxo-2, 3-d ihyd ro-benzooxazol-4-yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-[2-(2-nitro-3-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-pipe(din-l -yl)-xanthine, 1-[2-(2-amino-3-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-[2-(2-oxo-2,3-dihydro-benzooxazol-7-yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(3-methyl-1-buten-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine, 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-[2-(3-carboxymethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-l -yl)-8-(3-amino-piperidin-1-yl)-xanthine and 1-[2-(2-carboxymethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yi)-8-(3-amino-piperidin-1-yl)-xanthine, the tautomers, enantiomers, diastereomers, the mixtures thereof, the prodrugs thereof and the salts thereof.

A first preferred sub-group of the first aspect of the invention comprises compounds of general formula I wherein R' denotes a 4-methoxy-1-naphthylmethyl group, a 2-quinolinylmethyl, 4-quinolinylmethyl or a 6-quinolinylmethyl group, a 1-isoquinolinylmethyl, 3-methyl-1-isoquinolinylmethyl, 4-methyl-1-isoquinolinylmethyl or a 3-isoquinolinylmethyl group or 25771-1004(S) a 2-quinazolinylmethyl, 4-methyl-2-quinazolinylmethyl or a 4-quinazolinylmethyl group, R2 denotes a methyl group and R3 denotes a 2-buten-1-yl or a 2-butyn-1-yl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.

A further sub-group of the above embodiment comprises a compound of general formula I, wherein R1 denotes a 2-quinazolinylmethyl, 4-methyl-2-quinazolinylmethyl or 4-quinazolinylmethyl group, R2 denotes a methyl group and R3 denotes a 2-buten-1-yl or a 2-butyn-1-yl group, a tautomer, enantiomer, diastereomer, mixture thereof or salt thereof.

In the above embodiment, R3 as 2-butyn-1-yl is exemplary.

A second preferred sub-group of the first aspect of the invention comprises compounds of general formula I, wherein R1 denotes a [2-(methylcarbonylamino)-phenyl]-carbonylmethyl group, a [2-(ethylcarbonylamino)-phenyl]-carbonylmethyl group or a [2-(isopropylcarbonylamino)-phenyl]-carbonylmethyl group, R2 denotes a methyl group and 25771-1004(S) 16a R3 denotes a 2-buten-1-yl or a 2-butyn-1-yl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.

A third preferred sub-group of the first aspect of the invention comprises compounds of general formula 1, wherein R' denotes a [2-(aminocarbonylmethoxy)-phenyl]-carbonylmethyl group, [2-(methylaminocarbonylmethoxy)-phenyl]-carbonylmethyl group, a [2-(ethylaminocarbonylmethoxy)-phenyl]-carbonylmethyl group or a [2-(isopropylaminocarbonylmethoxy)-phenyl]-carbonylmethyi group, R2 denotes a methyl group and R3 denotes a 2-buten-1-yl group, a 2-butyn-1-yl group or a 1-cyclopenten-1-ylmethyl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.

A second aspect of the invention relates to compounds of general formula 1, wherein R1 denotes a methyl group which is substituted by a naphthyl, fluoronaphthyl, methyinaphthyl, methoxynaphthyl, (difluoromethoxy)-naphthyl, cyanonaphthyl, nitronaphthyl or (dimethylamino)-naphthyl group, a methyl group which is substituted by a phenanthrenyl group, a methyl group which is,substituted by a 2-phenylethenyl, 2-[(trifluoromethyl)-phenyl]-ethenyl, 2-(nitrophenyl)ethenyl, 2-(pentafluorophenyl)ethenyl or a biphenylyl group, a methyl group which is substituted by a phenyloxadiazolyl, phenylpyridinyl, indolyl, methylindolyl, dimethyl-6,7-dihydro-5H-[2]pyrindinyl, benzimidazolyl, methylbenzimidazolyl, (cyanoethyl)-benzimidazolyi, (methylamino-carbonylmethyl)benzimidazolyl, benzylbenzimidazolyl, benzofuranyl, acetylbenzofuranyl, cyanobenzofuranyl, benzoxazolyl, nitrobenzoxazolyl, benzothiophenyl, methylbenzothiazolyl, quinolinyl, methoxyquinolinyl, isoquinolinyl, methylisoquinolinyl, (difluoromethyl)-isoquinolinyl, (trifluoromethyl)-isoquinolinyl, dimethylisoquinolinyl, (1-cyano-1-methyl-ethyl)isoquinolinyl, phenylisoquinolinyl, methoxyisoquinolinyl, methoxy-chloro-isoquinolinyl, methoxy-bromo-isoquinolinyl, (methoxycarbonylmethylamino)-isoquinolinyl, dimethyl-5,6,7,8-tetrahydroisoquinolinyl, 1,2,3,4-tetrahydro-phenanthridinyl, cinnolinyl, quinazolinyl, methylquinazolinyl, isopropylquinazolinyl, cyclopropylquinazolinyl, phenylquinazolinyl, aminoquinazolinyl, (dimethylamino)-quinazolinyl, pyrrolidin-1-ylquinazolinyl, piperidin-1-ylquinazolinyl, piperazin-l-ylquinazolinyl, morpholin-4-ylquinazolinyl, ethoxyquinazolinyl, isopropyloxyquinazolinyl, phenyl-oxyquinazolinyl, imidazo[1,2-a]pyridinyl, methylimidazo[1,2-a]pyridinyl, phenyl-imidazo[1,2-a]pyridinyl, benzylimidazo[I,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, quinoxalinyl, methylquinoxalinyl, dimethylquinoxalinyl, trimethylquinoxalinyl, phenylquinoxalinyl, methylphthalazinyl, naphthyridinyl, 2,3-dihydro-benzo[1,4]-dioxinyl, 1,2-dihydro-2-oxo-quinolinyl, 1,2-dihydro-1-methyl-2-oxo-quinolinyl, 1,2-dihydro-2-methyl-1-oxo-isoquinolinyl, 3,4-dihydro-4-oxo-phthalazinyl, 3,4-dihydro-3-methyl-4-oxo-phthalazinyl, 3,4-dihydro-4-oxo-quinazolinyl, 3,4-dihydro-3-methyl-4-oxo-quinazolinyl or a 2-oxo-2H-chromenyl group, a phenylcarbonylmethyl group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by an amino, cyanomethylamino, (ethyloxycarbonylmethyl)amino, (methylaminocarbonyl)methylamino, methylcarbonylamino, ethylcarbonylamino, isopropylcarbonylamino, phenylcarbonylamino, methoxycarbonylamino, (ethyloxycarbonylamino)-carbonylamino or a 2-oxo-imidazolidin-1-yl group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a phenyl group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a carboxy, methoxycarbonyl, ethyloxycarbonyl, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl or morpholin-4-ylcarbonyl group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a methylsulphanyl, methylsuiphinyl or methylsulphonyl group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a methoxy, difluoromethoxy, trifluoromethoxy, ethyloxy, isopropyloxy or phenyloxy group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a methylsulphinylmethoxy, carboxymethoxy, ethyloxycarbonylmethoxy, isopropyloxycarbonylmethoxy, aminocarbonylmethoxy, methylaminocarbonylmethoxy, ethylaminocarbonylmethoxy, isopropylamino-carbonylmethoxy, dimethylaminocarbonylmethoxy, pyrrolidin-1-ylcarbonylmethoxy or morpholin-4-ylcarbonylmethoxy group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a 1 -(ethyl oxyca rbo nyl)- 1 -methyl-ethyloxy, 1 -(methoxycarbonyl)-ethyloxy or a 1-(aminocarbonyl)-ethyloxy group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by two methoxy groups, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a methoxy group and a nitro group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a methoxy group and an amino group, a phenylcarbonylmethyl group wherein in the phenyl moiety two adjacent hydrogen atoms are replaced by a -O-CH2-O, -O-CF2-O, -O-CH2-CH2-O, -NH-CO-NH, -N(CH3)-CO-NH, -N(CH3)-CO-N(CH3), -NH-CO-O- or a -N(CH3)-CO-O group, a (2-phenylethyl)carbonylmethyl group, a naphthylcarbonylmethyl, indolylcarbonylmethyl or quinolinylcarbonylmethyl group or a 2-cyanimino-2-phenyl-ethyl group, R2 denotes a methyl, isopropyl, cyclopropyl, phenyl or fluorophenyl group and R3 denotes a 2-methyl-2-propen-1-yl, 2-chloro-2-propen-1-yl or 3-bromo-2-propen-1-yl group a 1-buten-1-yl, 3-methyl-1-buten-1-yl, 2-buten-l-yl, 2-methyl-2-buten-1-yl-or 2,3-dimethyl-2-buten-1-yl group, a 2-butyn-1-yl group, a 1-cyclopenten-l-ylmethyl group or a 2-furanylmethyl group, the tautomers, enantiomers, diastereomers, the mixtures thereof, the prodrugs thereof and the salts thereof.

A preferred sub-group of the second aspect of the invention comprises compounds of general formula I wherein R1 and R2 are as hereinbefore defined and R3 denotes a 1-buten-1-yl, 2-buten-1-yl or 2-butyn-l-yl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.

A particularly preferred sub-group of the second aspect of the invention comprises compounds of general formula I wherein R1 denotes a methyl group which is substituted by a naphthyl, fluoronaphthyl, methylnaphthyl, methoxynaphthyl, (difluoromethoxy)-naphthyl, cyanonaphthyl or nitronaphthyl group, a methyl group which is substituted by a 2-(pentafluorophenyl)ethenyl group, a methyl group which is substituted by a benzofuranyl, methylbenzothiazolyl, quinolinyl, methoxyquinotinyl, isoquinolinyl, methylisoquinolinyl, (difluoromethyl)-isoquinolinyl, (trifluoromethyl)-isoquinolinyl, dimethylisoquinolinyl, (1-cyano-1-methyl-ethyl)isoquinolinyl, phenyl-isoquinolinyl, methoxyisoquinolinyl, 1,2,3,4-tetrahydrophenanthridinyl, quinazolinyl, methylquinazolinyl, isopropytquinazolinyl, cyclopropyl-quinazolinyl, phenyiquinazolinyl, aminoquinazolinyl, (dimethylamino)-quinazolinyl, pyrrolidin-1-ylquinazolinyl, piperidin-I-ylquinazolinyl, piperazin-1-ylquinazolinyl, morpholin-4-ylquinazolinyl, ethoxyquinazolinyl, isopropyloxyquinazolinyl, quinoxalinyl, methylquinoxalinyl, dimethylquinoxalinyl, trimethylquinoxalinyi, phenylquinoxalinyl, [I,5]naphthyridinyl, [I,6]naphthyridinyl, [I,8]naphthyridinyl or a 1,2-dihydro-methyl-2-oxo-quinolinyl group, a phenylcarbonylmethyl group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a phenyl group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a methoxy, difluoromethoxy, trifluoromethoxy, ethyloxy, isopropyloxy or phenyloxy group, a phenylcarbonylmethyl group wherein in the phenyl moiety two adjacent hydrogen atoms are replaced by a -0-CH2-O, -O-CF2-O, -O-CH2-CH2-O, -N(CH3)-CO-N(CH3) or a -N(CH3)-CO-O group, a naphthylcarbonylmethyl, indolylcarbonylmethyl or quinolinylcarbonylmethyl group or a 2-cyanimino-2-phenyl-ethyl group, R2 denotes a methyl, isopropyl, cyclopropyl, phenyl or 4-fluorophenyl group and R3 denotes a 1-buten-1-yl, 2-buten-1-yl or a 2-butyn-1-yl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.

A second preferred sub-group of the second aspect of the invention comprises compounds of general formula I, wherein R' and R2 are defined as immediately above and R3 denotes a 1-buten-1-yl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.

A third preferred sub-group of the second aspect of the invention comprises compounds of general formula I wherein R' and R2 are defined as immediately above and R3 denotes a 2-buten-1-yl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.

A fourth preferred sub-group of the second aspect of the invention comprises compounds of general formula I wherein R' and R2 are defined as immediately above and R3 denotes a 2-butyn-1-yl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.

A third aspect of the invention relates to compounds of general formula I
wherein R1 denotes a methyl group which is substituted by a naphthyl, fluoronaphthyl, methylnaphthyl, methoxynaphthyl, (difluoromethoxy)-naphthyl, cyanonaphthyl or nitronaphthyl- group, a methyl group which is substituted by a 2-(pentafluorophenyl)ethenyl group, or a methyl group which is substituted by a benzofuranyl, methylbenzothiazolyl, quinolinyl, methoxyquinolinyl, isoquinolinyl, methylisoquinolinyl, (difluoromethyl)-isoquinolinyl, (trifluoromethyl)-isoquinolinyl, dimethylisoquinolinyl, (1-cyano-1-methyl-ethyl)isoquinolinyl, phenyl-isoquinolinyl, methoxyisoquinolinyl, 1,2,3,4-tetrahydrophenanthridinyl, quinazolinyl, methylquinazolinyl, isopropylquinazolinyl, cyclopropyl-quinazolinyl, phenylquinazolinyl, aminoquinazolinyl, (dimethylamino)-quinazolinyl, pyrrolidin-l-ylquinazolinyl, piperidin-l-ylquinazolinyl, piperazin-l-ylquinazolinyl, morpholin-4-ylquinazolinyl, ethoxyquinazolinyl, isopropyloxyquinazolinyl, quinoxalinyl, methylquinoxalinyl, dimethylquinoxalinyl, trimethylquinoxalinyl, phenylquinoxalinyl, [1,5]naphthyridinyl, [1,6]naphthyridinyl, [1,8]naphthyridinyl or a 1,2-dihydro-methyl-2-oxo-quinolinyl group, R2 denotes a methyl, isopropyl, cyclopropyl or phenyl group and R3 denotes a 2-chlorobenzyl, 2-bromobenzyl, 2-ethynylbenzyl or 2-cyanobenzyl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.

A first preferred sub-group of the third aspect of the invention comprises compounds of general formula I wherein R1 denotes a (3-methyl-isoquinolin-1-yl)methyl group, R2 denotes a methyl group and R3 denotes a 2-chlorobenzyl, 2-bromobenzyl, 2-ethynylbenzyl or 2-cyanobenzyl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.

A second preferred sub-group of the third aspect of the invention comprises compounds of general formula I wherein R' and R2 are as hereinbefore defined and R3 denotes a 2-chlorobenzyl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.

A third preferred sub-group of the third aspect of the invention comprises compounds of general formula I wherein R' and R2 are as hereinbefore defined and R3 denotes a 2-bromobenzyl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.

A fourth preferred sub-group of the third aspect of the invention comprises compounds of general formula I wherein R' and R2 are as hereinbefore defined and R3 denotes a 2-ethynylbenzyl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.

A fifth preferred sub-group of the third aspect of the invention comprises compounds of general formula I wherein R' and R2 are as hereinbefore defined and R3 denotes a 2-cyanobenzyl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.

Most particularly preferred are the following compounds of general formula I:
(1) 1-[(quinazolin-2-yl)methyl]-3-methyl -7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine, (2) 1-(2-{2-[(ethylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine, (3) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-I -yl)-8-((R)-3-amino-piperidin-1 -yl)-xanthine, (4) 1-(2-phenyl-2-oxo-ethyl)-3-methyl -7-((E)-2-buten-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine, (5) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl -7-(2-butyn-1-yl)-8-((S)-3-amino-piperidin-1-yl)-xanthine, (6) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl -7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine, (7) 1-[(4-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((S)-3-amino-piperidin-1-yl)-xanthine, (8) 1-[(4-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine, (9) 1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, (10) 1-[(4-methoxy-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((S)-3-amino-piperidin-1-yl)-xanthine, (11) 1-[(4-methoxy-naphthalen-1-yl)methyl]-3-methyl -7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine, (12) 1-[2-(benzo[1,3]dioxol-4-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine, (13) 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, (14) 1-(2-{2-[(iso propylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-((S)-3-amino-piperidin-1-yl)-xanthine, (15) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine, (16) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-((S)-3-amino-piperidin-1-yl)-xanthine, (17) 1-(2-{2-[(isopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine, (18) 1-(2-{2-[(isopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine, (19) 1-[(4-cyano-naphthalen-1-yl)methyl]-3-methyl -7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine, (20) 1-[(4-phenyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yi)-8-((R)-3-amino-piperidin-1-yl)-xanthine, (21) 1-[(8-methyl-quinoxalin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine, (22) 1-[(4-fluoro-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine , (23) 1-((E)-3-pentafluorophenyl-allyl)-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine , (24) 1-[(3-trifluoromethyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-((R)-3-amino-piperidin-1-yl)-xanthine, (25) 1-[(3-difluoromethyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine, (26) 1-[2-(biphenyl-2-yl)-2-oxo-ethyl]-3-methyl -7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine, (27) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-cyclopropyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine, (28) 1-[2-(3-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine, (29) 1-[(3-methyl -isoquinolin-1-yl)methyl]-3-methyl-7-(2-chloro-benzyl)-8-((R)-3-amino-piperidin-1-yl)-xanthine and (30) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-bromo-benzyl)-8-((R)-3-amino-piperidin-1-yl)-xanthine as well as the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.

According to the invention the compounds of general formula I are obtained by methods known per se, for example by the following methods:

a) reacting a compound of general formula RI N

Z1 ~II)r O N N
I
Rs wherein R1 to R3 are as hereinbefore defined and Z' denotes a leaving group such as a halogen atom, a substituted hydroxy, mercapto, sulphinyl, sulphonyl or sulphonyloxy group such as a chlorine or bromine atom, a methanesulphonyl or methanesulphonyloxy group, with 3-aminopiperidine, the enantiomers thereof or the salts thereof.
The reaction is expediently carried out in a solvent such as isopropanol, butanol, tetrahydrofuran, dioxane, dimethylformamide, dimethylsulphoxide, ethyleneglycol monomethylether, ethyleneglycol diethylether or sulpholane, optionally in the presence of an inorganic or tertiary organic base, e.g.
sodium carbonate, potassium carbonate or potassium hydroxide, a tertiary organic base, e.g. triethylamine, or in the presence of N-ethyl-diisopropylamine (Hunig base), while these organic bases may simultaneously also serve as solvent, and optionally in the presence of a reaction accelerator such as an alkali metal halide or a palladium-based catalyst at temperatures between -20 and 180 C, but preferably at temperatures between -10 and 120 C. The reaction may, however, also be carried out without a solvent or in an excess of the 3-aminopiperidine.

b) deprotecting a compound of general formula O R3 N H Ox \\

'~'~ J N>- (III), O N
I

wherein R1, R2 and R3 are as hereinbefore defined.

The tert.-butyloxycarbonyl group is preferably cleaved by treatment with an acid such as trifluoroacetic acid or hydrochloric acid or by treatment with bromotrimethylsilane or iodotrimethylsilane, optionally using a solvent such as methylene chloride, ethyl acetate, dioxane, methanol, isopropanol or diethyl ether at temperatures between 0 and 80 C.

c) In order to prepare a compound of general formula I wherein R1 according to the definition provided hereinbefore contains a carboxy group:
deprotecting a compound of general formula R1~N N
N (IV), O N
I

wherein R2 and R3 are as hereinbefore defined and R"contains a carboxy group protected by a C1_4-alkyl group.

The protecting group is cleaved by hydrolysis, for example, using an acid such as hydrochloric acid or sulphuric acid or an alkali metal hydroxide such as lithium hydroxide, sodium hydroxide or potassium hydroxide in a solvent such as methanol, ethanol, isopropanol, tetrahydrofuran or dioxane in the presence of water.

In the reactions described hereinbefore, any reactive groups present such as carboxy, amino, alkylamino or imino groups may be protected during the reaction by conventional protecting groups which are cleaved again after the reaction.

For example, a protecting group for a carboxy group may be a trimethylsilyl, methyl, ethyl, tert.butyl, benzyl or tetrahydropyranyl group and protecting groups for an amino, alkylamino or imino group may be a formyl, acetyl, trifluoroacetyl, ethoxycarbonyl, tert.butoxycarbonyl, benzyloxycarbonyl, benzyl, methoxybenzyl or 2,4-dimethoxybenzyl group and additionally, for the amino group, a phthalyl group.

Any protecting group used is optionally subsequently cleaved for example by hydrolysis in an aqueous solvent, e.g. in water, isopropanol/water, acetic acid/water, tetrahydrofuran/water or dioxane/water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid or sulphuric acid or in the presence of an alkali metal base such as sodium hydroxide or potassium hydroxide or aprotically, e.g. in the presence of iodotrimethylsilane, at temperatures between 0 and 120 C, preferably at temperatures between 10 and 100 C.

However, a benzyl, methoxybenzyl or benzyloxycarbonyl group is cleaved, for example, hydrogenolytically, e.g. with hydrogen in the presence of a catalyst such as palladium/charcoal in a suitable solvent such as methanol, ethanol, ethyl acetate or glacial acetic acid, optionally with the addition of an acid such as hydrochloric acid at temperatures between 0 and 100 C, but preferably at temperatures between 20 and 60 C, and at a hydrogen pressure of 1 to 7 bar, but preferably 3 to 5 bar. A 2,4-dimethoxybenzyl group, however, is preferably cleaved in trifluoroacetic acid in the presence of anisol.
A tert.butyl or tert.butyloxycarbonyl group is preferably cleaved by treating with an acid such as trifluoroacetic acid or hydrochloric acid or by treating with iodotrimethylsilane, optionally using a solvent such as methylene chloride, dioxan, methanol or diethylether.

A trifluoroacetyl group is preferably cleaved by treating with an acid such as hydrochloric acid, optionally in the presence of a solvent such as acetic acid at temperatures between 50 and 120 C, or by treating with sodium hydroxide solution, optionally in the presence of a solvent such as tetrahydrofuran at temperatures between 0 and 50 C.

A phthalyl group is preferably cleaved in the presence of hydrazine or a primary amine such as methylamine, ethylamine or n-butylamine in a solvent such as methanol, ethanol, isopropanol, toluene/water or dioxan at temperatures between 20 and 50 C.

Moreover, the compounds of general formula I obtained may be resolved into their enantiomers and/or diastereomers, as mentioned hereinbefore. Thus, for example, cis/trans mixtures may be resolved into their cis and trans isomers, and compounds with at least one optically active carbon atom may be separated into their enantiomers.

Thus, for example, the cis/trans mixtures may be resolved by chromatography into the cis and trans isomers thereof, the compounds of general formula I
obtained which occur as racemates may be separated by methods known per se (cf. Allinger N. L. and Eliel E. L. in "Topics in Stereochemistry", Vol. 6, Wiley Interscience, 1971) into their optical antipodes and compounds of general formula I with at least 2 asymmetric carbon atoms may be resolved into their diastereomers on the basis of their physical-chemical differences using methods known per se, e.g. by chromatography and/or fractional crystallisation, and, if these compounds are obtained in racemic form, they may subsequently be resolved into the enantiomers as mentioned above.
The enantiomers are preferably separated by column separation on chiral phases or by recrystallisation from an optically active solvent or by reacting with an optically active substance which forms salts or derivatives such as e.g.
esters or amides with the racemic compound, particularly acids and the activated derivatives or alcohols thereof, and separating the diastereomeric mixture of salts or derivatives thus obtained, e.g. on the basis of their differences in solubility, whilst the free antipodes may be released from the pure diastereomeric salts or derivatives by the action of suitable agents.
Optically active acids in common use are e.g. the D- and L-forms of tartaric acid or dibenzoyltartaric acid, di-o-tolyltartaric acid, malic acid, mandelic acid, camphorsulphonic acid, glutamic acid, aspartic acid or quinic acid. An optically active alcohol may be for example (+) or (-)-menthol and an optically active acyl group in amides, for example, may be a (+)-or (-)-menthyloxycarbonyl.
Furthermore, the compounds of formula I may be converted into the salts thereof, particularly for pharmaceutical use into the physiologically acceptable salts with inorganic or organic acids. Acids which may be used for this purpose include for example hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or maleic acid.

Moreover, if the new compounds of formula I thus obtained contain a carboxy group, they may subsequently, if desired, be converted into the salts thereof with inorganic or organic bases, particularly for pharmaceutical use into the physiologically acceptable salts thereof. Suitable bases for this purpose include for example sodium hydroxide, potassium hydroxide, arginine, cyclohexylamine, ethanolamine, diethanolamine and triethanolamine.

The compounds of general formulae II to IV used as starting materials are either known from the literature or may be obtained by methods known from the literature (cf. Examples I to LXXI).

As already mentioned hereinbefore, the compounds of general formula I
according to the invention and the physiologically acceptable salts thereof have valuable pharmacological properties, particularly an inhibiting effect on the enzyme DPP-IV.

The biological properties of the new compounds were investigated as follows:
The ability of the substances and their corresponding salts to inhibit the DPP-IV activity can be demonstrated in a test set-up in which an extract of human colon carcinoma cell line Caco-2 is used as the DPP-IV source. The differentiation of the cells in order to induce the DPP-IV expression was carried out as described by Reiher et al. in an article entitled "Increased expression of intestinal cell line Caco-2", which appeared in Proc: Natl.
Acad.
Sci. Vol. 90, pages 5757-5761 (1993). The cell extract was obtained from cells solubilised in a buffer (10mM Tris HCI, 0.15 M NaCl, 0.04 t.i.u.
aprotinin, TN
0.5% Nonidet-P40, pH 8.0) by centrifuging at 35,000 g of for 30 minutes at 4 C (to remove cell debris).

The DPP-IV assay was carried out as follows:

50 pl substrate solution (AFC; AFC is amido-4-trifluoromethylcoumarin), final concentration 100 NM, were placed in black microtitre plates. 20 NI of assay buffer (final concentrations 50 mM Tris HCI pH 7.8, 50 mM NaCl, 1 % DMSO) was pipetted in. The reaction was started by adding 30 NI of solubilised Caco-2 protein (final concentration 0.14 pg of protein per well). The test substances .to be investigated were typically added prediluted in 20 ill, and the volume of assay buffer was then reduced accordingly. The reaction was carried out at ambient temperature, incubating for 60 minutes. Then the fluorescence was measured in a Victor 1420 Multilabel Counter, the excitation wavelength being 405 nm and the emission wavelength being 535 nm. Blank readings (corresponding to 0 % activity) were obtained in mixtures without any Caco-2 protein (volume replaced by assay buffer), control values (corresponding to 100 % activity) were obtained in mixtures with no substance added. The potency of the test substances in question, expressed as IC50 values, was calculated from dosage/activity curves consisting of 11 measuring points in each case. The following results were obtained:
Compound DPP-IV inhibition (Example no.) IC5o [nMJ
2(3) 2160 2(9) 264 2(12) 16 2(17) 32 2(20) 12 2(25) 4 2(27) 9 2(35) 5 2(37) 5 2(43) 6 2(51) 6 2(52) 9 2(59) 250 2(66) 22 2(80) 1 2(86) 2 2(96) 2 2(99) 1 2(100) 3 2(108) 3 2(129) 3 2(130) 3 2(131) 3 2(132) 1 2(135) 3 2(137) 13 2(138) 8 2(139) 4 2(142) 1 2(145) 4 2(148) 1 2(150) 1 2(151) 3 2(152) 4 2(185) 3 2(217) 4 2(247) 2 2(251) 12 2(256) 8 2(260) 13 2(264) 6 2(277) 6 2(280) 5 2(285) 3 2(287) 11 2(288) 14 The compounds prepared according to the invention are well tolerated, as for example when 10 mg/kg of the compound of Example 2(80) were administered to rats by oral route no changes in the animals' behaviour could be detected.

In view of their ability to inhibit DPP-IV activity, the compounds of general formula I according to the invention and the corresponding pharmaceutically acceptable salts thereof are suitable for treating all those conditions or illnesses which can be influenced by the inhibition of the DPP-IV activity. It is therefore to be expected that the compounds according to the invention will be suitable for the prevention or treatment of diseases or conditions such as type 1 and type 2 diabetes mellitus, diabetic complications (such as e.g.
retinopathy, nephropathy or neuropathies), metabolic acidosis or ketosis, reactive hypoglycaemia, insulin resistance, metabolic syndrome, dyslipidaemias of various origins, arthritis, atherosclerosis and related diseases, obesity, allograft transplantation and calcitonin-induced osteoporosis. In addition these substances are capable of preventing B-cell degeneration such as e.g. apoptosis or necrosis of pancreatic B-cells. The substances are also suitable for improving or restoring the function of pancreatic cells and also increasing the number and size of pancreatic B-cells. Additionally, and on the basis of the role of the Glucagon-Like Peptides, such as e.g. GLP-1 and GLP-2 and their link with DPP-IV inhibition, it is likely that the compounds according to the invention are suitable for achieving, inter alia, a sedative or anxiety-relieving effect and also for favourably affecting catabolic states after operations or hormonal stress responses or reducing mortality or morbidity after myocardial infarct. They are also suitable for treating all conditions which are connected with the above mentioned effects and which are mediated by GLP-1 or GLP-2. The compounds according to the invention may also be used as diuretics or antihypertensives and are suitable for preventing and treating acute renal failure. Furthermore, the compounds according to the invention may be used to treat inflammatory diseases of the respiratory tract. They are also suitable for the prevention and treatment of chronic inflammatory intestinal diseases such as e.g. irritable bowel syndrome (IBS), Crohn's disease or ulcerative colitis and also pancreatitis. It is also likely that they can be used for all kinds of damage to or impairment of the gastrointestinal tract such as colitis and enteritis, for example. It is also expected that DPP-IV inhibitors and hence also the compounds according to the invention may be used to treat infertility or to improve fertility in humans or mammals, particularly when the infertility is connected with insulin resistance or polycystic ovary syndrome. On the other hand these substances are suitable for affecting sperm motility and can thus be used as male contraceptives. The substances are also suitable for treating deficiencies of growth hormone which are associated with reduced stature, and may also be used to advantage in any indications in which growth hormone may be used.
The compounds according to the invention are also suitable, on the basis of their inhibitory effect on DPP-IV, for treating various autoimmune diseases such as e.g. rheumatoid arthritis, multiple sclerosis, thyroiditis and Basedow's disease, etc. They may also be used to treat viral diseases and also, for example, in HIV infections, for stimulating blood production, in benign prostatic hyperplasia, gingivitis, as well as for the treatment of neuronal defects and neurodegenerative diseases such as Alzheimer's disease, for example. The compounds described may also be used for the treatment of tumours, particularly for modifying tumour invasion and also metastasisation;
examples here are their use in treating T-cell lymphomas, acute lymphoblastic leukaemia, cell-based pancreatic carcinomas, basal cell carcinomas or breast cancers. Other indications are stroke, ischaemia of various origins, Parkin-son's disease and migraine. In addition, further indications include follicular and epidermal hyperkeratoses, increased keratinocyte proliferation, psoriasis, encephalomyelitis, glomerulonephritis, lipodystrophies, as well as psycho-somatic, depressive and neuropsychiatric diseases of all kinds.

The compounds according to the invention may also be used in conjunction with other active substances. Therapeutic agents which are suitable for such combinations include, for example, antidiabetics, such as metformin, sulphonylureas (e.g. glibenclamide, tolbutamide, glimepiride), nateglinide, repaglinide, thiazolidinedione (e.g. rosiglitazone, pioglitazone), PPAR-gamma agonists (e.g. GI 262570) and antagonists, PPAR-gamma/alpha modulators (e.g. KRP 297), alpha-glucosidase inhibitors (e.g. acarbose, voglibose), other DPPIV inhibitors, alpha2 antagonists, insulin and insulin analogues, GLP-1 and GLP-1 analogues (e.g. exendin-4) or amylin. Also, SGLT2 inhibitors such as T-1095, inhibitors of protein tyrosine phosphatase 1, substances which influence deregulated glucose production in the liver, such as e.g. inhibitors of glucose-6-phosphatase, or fructose-l,6-bisphosphatase, glycogen phosphorylase, glucagon receptor antagonists and inhibitors of phosphoenol -pyruvate carboxykinase, glycogen synthase kinase or pyruvate dehydrokinase, lipid lowering agents, such as HMG-CoA-reductase inhibitors (e.g. simvastatin, atorvastatin), fibrates (e.g. bezafibrate, fenofibrate), nicotinic acid and its derivatives, PPAR-alpha agonists, PPAR-delta agonists, ACAT
inhibitors (e.g. avasimibe) or cholesterol resorption inhibitors such as for example ezetimibe, bile acid-binding substances such as for example cholestyramine, inhibitors of ileac bile acid transport, HDL-raising compounds such as for example inhibitors of CETP or regulators of ABC1 or active substances for the treatment of obesity, such as e.g. sibutramine or tetrahydrolipostatin, dexfenfluramine, axokine, antagonists of the cannabinoidl receptor, MCH-1 receptor antagonists, MC4 receptor agonists, NPY5 or NPY2 antagonists or R3-agonists such as SB-418790 or AD-9677 as well as agonists of the 5HT2c receptor.

It is also possible to combine the compounds with drugs for treating high blood pressure such as e.g. All antagonists or ACE inhibitors, diuretics, 13-blockers, Ca-antagonists, etc., or combinations thereof.

The dosage required to achieve such an effect is expediently, by intravenous route, 1 to 100 mg, preferably 1 to 30 mg, and by oral route 1 to 1000 mg, preferably 1 to 100 mg, in each case 1 to 4 times a day. For this purpose, the compounds of formula I prepared according to the invention, optionally combined with other active substances, may be incorporated together with one or more inert conventional carriers and/or diluents, e.g. with corn starch, lactose, glucose, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethylene glycol, propylene glycol, cetylstearyl alcohol, carboxymethyl ce I lu lose or fatty substances such as hard fat or suitable mixtures thereof into conventional galenic preparations such as plain or coated tablets, capsules, powders, suspensions or suppositories.
The Examples that follow are intended to illustrate the invention:

Preparation of the starting compounds:
Example I
1 , 3-d i methyl-7-(2,6-dicyano-benzyl)-8-bromo-xanthine A mixture of 555 mg of 8-bromotheophyllin and 0.39 ml of Hunig base in 9 ml N,N-dimethylformamide is combined with 600 mg of 2-bromomethyl-isophthalonitrile and stirred overnight at ambient temperature. For working up the reaction mixture is poured onto water. The precipitate formed is suction filtered, washed with water and dried.
Yield: 686 mg (83 % of theory) Rf value: 0.56 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 399, 401 [M+H]+

The following compounds are obtained analogously to Example I:
(1) 3-methyl-7-(3-methyl-2-buten-1-yl)-8-chloro-(anthine Mass spectrum (ESI+): m/z = 269, 271 [M+H]+

(2) 3-methyl-7-(2-cyano-benzyl)-8-chloro-xanthine Mass spectrum (ESI+): m/z = 316, 318 [M+H]+

(3) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-bromo-xanthine Mass spectrum (ESI+): m/z = 415, 417 [M+H]+

(4) 3-methyl-7-[(2-trimethylsilanyl-ethoxy)methyl]-8-bromo-xanthine (Carried out in the presence of potassium carbonate) Mass spectrum (ESI+): m/z = 375, 377 [M+H]+

(5) 3-methyl-7-(3-methyl-2-buten-1-yl)-8-bromo-xanthine Mass spectrum (ESI+): m/z = 313, 315 [M+H]+

(6) 3-methyl-7-(2,3-d imethyl-2-buten-1-yl)-8-bromo-xanthine Rf value: 0.43 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 327, 329 [M+H]+

(7) 3-methyl-7-(2-butyn- 1 -yl)-8- bro m o-xa nth ine Rf value: 0.72 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 297/299 [M+H]+

(8) 3-methyl-7-((E)-2-buten-1-yl)-8-bromo-xanthine (The product is contaminated with approx. 10-20 % of Z compound) Rf value: 0.55 (silica gel, cyclohexane/ethyl acetate/methanol = 6:3:1) Mass spectrum (ESI+): m/z = 299, 301 [M+H]+

(9) 3-methyl-7-[(1-cyclopenten-1-yl)methyl]-8-bromo-xanthine Mass spectrum (ESI+): m/z = 325, 327 [M+H]+

(10) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-[(1-cyclopenten-l-yl)methyl]-8-bromo-xanthine Mass spectrum (ESI+): m/z = 443, 445 [M+H]+

(11) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-bromo-xanthine (product contains approx. 25 % of Z isomer) Mass spectrum (ESI+): m/z = 417, 419 [M+H]+

(12) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-(2-methyl-al lyl)-8-bromo-xanthine Rf value: 0.71 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 417, 419 [M+H]+

(13) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-(3-bromo-allyl)-8-bromo-xanthine Rf value: 0.68 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 481, 483, 485 [M+H]+

(14) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-[(furan-2-yl)methyl]-8-bromo-xanthine Rf value: 0.60 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 443, 445 [M+H]+

(15) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-(2-chloro-allyl)-8-bromo-xanthine Rf value: 0.77 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 437, 439, 441 [M+H]+

(16) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-((Z)-2-methyl-2-buten-1-yl)-8-bromo-xanthine Rf value: 0.77 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 431, 433 [M+H]+

(17) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-((E)-2-methyl-2-buten-1-yl)-8-bromo-xanthine Rf value: 0.77 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 431, 433 [M+H]+

(18) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-(1-phenylsulphanyl-butyl)-8-bromo-xanthine Rf value: 0.83 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 527, 529 [M+H]+

(19) 3-methyl-7-(3-methyl-1-phenylsulphanyl-butyl)-8-bromo-xanthine (The [(1-chloro-3-methyl-butyl)sulphanyl]-benzene used as starting material for the reaction is obtained by chlorination of [(3-methyl-butyl)sulphanyl]-benzene with N-chloro-succinimide in carbon tetrachloride) Rf value: 0.38 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 423, 425 [M+H]+

(20) 1,3-dimethyl-7-(2-bromo-benzyl)-8-chloro-xanthine Rf value: 0.50 (silica gel, cyclohexane/ethyl acetate = 1:1) (21) 1,3-dimethyl-7-(2-chloro-benzyl)-8-chloro-xanthine Rf value: 0.50 (silica gel, cyclohexane/ethyl acetate = 1:1) (22) 3-cyclopropyl-7-(2-butyn-1-yl)-8-bromo-xanthine Rf value: 0.45 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 223/225 [M+H]+
Example II
1-(2-{2-[(ethoxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-vl)-8-[3-(tert.-butvloxvcarbonvlami no)-piperidin-1-vll-xanth ine 63 mg of ethyl bromoacetate are added to a mixture of 200 mg of 1-[2-(2-hyd roxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-bute n-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine and 63 mg of potassium carbonate in 3 ml N,N-dimethylformamide. The reaction mixture is stirred for five hours at ambient temperature. For working up it is combined with water and the precipitate formed is suction filtered, washed with water and dried for three hours at 80 C in the drying cupboard.
Yield: 216 mg (94 % of theory) Mass spectrum (ESI+): m/z = 653 [M+H]+

The following compounds are obtained analogously to Example II:

(1) 1-(2-{2-[(aminocarbo nyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yi]-xanthine Mass spectrum (ESI+): m/z = 624 [M+H]+

(2) 1-(2-{3-[(methylsulphanyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.20 (silica gel, cyclohexane/ethyl acetate = 6:4) Mass spectrum (ESI+): m/z = 627 [M+H]+

(3) 1-(2-{3-[(ethoxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-l-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-l -yl]-xanthine Rf value: 0.50 (silica gel, cyclohexane/ethyl acetate = 3:7) ............. .

(4) 1-(2-{2-[(methylaminocarbonyl)meth oxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-l -yl]-xanthine Mass spectrum (ESI+): m/z = 638 [M+H]+

(5) 1-(2-{2-[(dimethylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylami no)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 652 [M+H]+

(6) 1-(2-{3-[(methoxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin- l -yl]-xanthine Mass spectrum (ESI+): m/z = 639 [M+H]+

(7) 1-(2-{2-[(ethylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 636 [M+H]+

(8) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-[(1-cyclopenten-1-yl)methyl]-8-[3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine Mass spectrum (ESI+): m/z = 650 [M+H]+

(9) 1-(2-{2-[(methyl am inocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 622 [M+H]+

(10) 1-(2-{2-[(aminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine Mass spectrum (ESI+): m/z = 608 [M+H]+

(11) 1-(2-{2-[(methoxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 623 [M+H]+

(12) 1-(2-{2-[(isopropyloxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 667 [M+H]+

(13) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 622 [M+H]+

(14) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine (product contains some Z isomer) Rf value: 0.35 (silica gel, cyclohexane/ethyl acetate/methanol = 5:4:1) Mass spectrum (ESI+): m/z = 624 [M+H]+

(15) 1-(2-{2-[(ethylaminocarbonyl)meth oxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 636 [M+H]+

(16) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 622 [M+H]+

(17) 1-(2-{2-[(meth oxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 639 [M+H]+

(18) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[(S)-3-(tert.-butyloxycarbonylami no)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 638 [M+H]+
(19) 2-(2-acetyl-phenoxy)-N-ethyl-acetamide Mass spectrum (ESI+): m/z = 222 [M+H]+

(20) 1-{2-[2-(1-methoxycarbonyl-ethoxy)-phenyl]-2-oxo-ethyl}-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 637 [M+H]+

(21) 1-{2-[2-(1-aminocarbonyl-ethoxy)-phenyl]-2-oxo-ethyl}-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylami no)-piperidin-l-yl]-xanthine Mass spectrum (ESI+): m/z = 622 [M+H]+

(22) 2-(2-acetyl-phenoxy)-N-methyl-acetamide Mass spectrum (ESI+): m/z = 208 [M+H]+

(23) 1-{2-[2-(2-oxo-propoxy)-phenyl]-2-oxo-ethyl}-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 607 [M+H]+

(24) 1-{2-[2-(1-ethoxycarbonyl-1-methyl-ethoxy)-phenyl]-2-oxo-ethyl}-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 665 [M+H]+

(25) 1-{2-[2-cyanomethoxy-phenyl]-2-oxo-ethyl}-3-methyl-7-(2-butyn-l-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 590 [M+H]+

(26) 1-(2-{2-[(methylsulphanyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 611 [M+H]+

(27) 1-{[2-(tert.-butylcarbonyl)-benzofuran-3-yl]methyl}-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine (Formed as main product when 1-[2-(2-hydroxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tent.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine is reacted with 1-chloro-3,3-dimethyl-butan-2-one) Mass spectrum (ESI+): m/z = 631 [M+H]+
Example III
1-[2-(2-hydroxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3:
(tert.-butyloxycarbonvlam ino)-piperidin-1-yll-xanthine 1.30 g of 3-tert.-butyloxycarbonylamino-piperidine are added to a mixture of 2.51 g of 1-[2-(2-hydroxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-chloro-xanthine and 880 mg of sodium carbonate in 8 ml of dimethylsulphoxide. The reaction mixture is stirred for 18 hours at 60 C. For working up it is combined with water and the precipitate formed is suction filtered. The solid crude product is dissolved in ethyl acetate, the solution is dried over magnesium sulphate and evaporated down. The flask residue is chromatographed through a silica gel column with cyclohexane/ethyl acetate (10:1 to 1:1) as eluant.
Yield: 2.56 g (91 % of theory) Mass spectrum (ESI+): m/z = 567 [M+H]+

The following compounds are obtained analogously to Example III:

(1) 3-methyl-7-(3-methyl-2-buten-l-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine Mass spectrum (ESI+): m/z = 433 [M+H]+

(2) 1-(1-methyl-2-oxo-2-phenyl-ethyl)-3-methyl-7-(3-methyl-2-buten-l-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine Mass spectrum (ESI+): m/z = 565 [M+H]+

(3) 3-methyl-7-(2-cyano-benzyl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.90 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI"): m/z = 478 [M-H]"

(4) 1-methyl-3-[(methoxycarbonyl)methyl]-7-(2-cyano-benzyl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine Mass spectrum (ESI+): m/z = 552 [M+H]+

(5) 1-methyl-3-cyanomethyl-7-(2-cyano-benzyl)-8-[3-(tert.-butyloxycarbonyl-amino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 519 [M+H]+

(6) 1-methyl-3-(2-propyn-1-yl)-7-(2-cyano-benzyl)-8-[3-(tert.-butyloxycarbonyl-amino)-piperidin-l-yl]-xanthine Mass spectrum (ESI+): m/z = 518 [M+H]+

(7) 1-[2-(3-nitro-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.25 (silica gel, cyclohexane/ethyl acetate/methanol = 7:2:1) Mass spectrum (ESI+): m/z = 596 [M+H]+

(8) 1-methyl-3-(2-propen-1-yl)-7-(2-cyano-benzyl)-8-[3-(tert.-butyloxycarbonyl-amino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 520 [M+H]+

(9) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine Mass spectrum (ESI+): m/z = 535 [M+H]+

(10) 1-[2-(2-nitro-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.52 (silica gel, cyclohexane/ethyl acetate = 3:7) Mass spectrum (ESI+): m/z = 596 [M+H]+

(11) 1-methyl-3-phenyl-7-(2-cyano-benzyl)-8-[3-(tert.-butyloxycarbonylamino)-p i peri d i n-1-yl]-xanth i n e Mass spectrum (ESI+): m/z = 556 [M+H]+

(12) 1-[2-(2-nitro-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-l-yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 596 [M+H]+

(13) 1-[(cinnolin-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine mixed with 1 -[(1,4-dihydro-cinnolin-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.62 (silica gel, ethyl acetate) (14) 1-({4-oxo-3-[(2-trimethylsilanyl-ethoxy)methyl]-3,4-dihydro-phthalazin-1-yl}methyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine (Carried out with potassium carbonate in the presence of Hunig base) Rf value: 0.27 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 720 [M+H]+

(15) 1-[(isoquinolin-3-yl)methyl]-3-methyl-7-(3-methyl-2-buten-l-yl)-8-[3-(tert.-butyloxycarbonylami no)-piperidin-l-yl]-xanthine Rf value: 0.31 (silica gel, ethyl acetate/petroleum ether = 7:3) Mass spectrum (ESI+): m/z = 574 [M+H]+

(16) 1-[(3-methyl-4-oxo-3,4-dihydro-phthalazin-1-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.45 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5) Mass spectrum (ESI+): m/z = 605 [M+H]+

(17) 3-methyl-7-(2,3-dimethyl-2-buten-l-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperid in-1-yl]-xanthine (Carried out with potassium carbonate) Rf value: 0.42 (silica gel, methylene chloride/methanol = 20:1) Mass spectrum (ESI+): m/z = 447 [M+H]+

(18) 3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine (Carried out with potassium carbonate) Melting point: 235-237 C
Mass spectrum (ESI+): m/z = 417 [M+H]+

(19) 1-[(quinolin-4-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylami no)-piperidin-l-yl]-xanthine (Carried out with potassium carbonate) Rf value: 0.36 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 558 [M+H]+

(20) 1-[(isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine (Carried out with potassium carbonate) Rf value: 0.71 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 558 [M+H]+

(21) 1-[(isoquinolin-l-yl)methyl]-3-methyl-7-((E)-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine (Carried out with potassium carbonate; the product contains approx. 20 % of Z isomer) Rf value: 0.24 (silica gel, ethyl acetate/petroleum ether = 1:1) Mass spectrum (ESI+): m/z = 560 [M+H]+

(22) 3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine (Carried out with potassium carbonate) Rf value: 0.64 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 417 [M+H]+

(23) 3-methyl-7-(2-butyn-1-yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine (Carried out with potassium carbonate) Rf value: 0.64 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 417 [M+H]+

(24) 3-methyl-7-((E)-2-buten-1-yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine (product contains approx. 15 % of Z isomer) Rf value: 0.35 (silica gel, cyclohexane/ ethyl acetate = 3:7) Mass spectrum (ESI+): m/z = 419 [M+H]+

(25) 3-methyl-7-((E)-2-buten-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine (product contains approx. 15 % of Z isomer) Rf value: 0.35 (silica gel, cyclohexane/ ethyl acetate = 3:7) Mass spectrum (ESI+): m/z = 419 [M+H]+

(26) 1-[2-(2-hydroxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-l-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 551 [M+H]+

(27) 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-[(1-cyclopenten-1-yl)methyl]-8-[3-(tert.-butyloxycarbonylamino)-piperidin-l-yi]-xanthine Mass spectrum (ESI+): m/z = 578 [M+H]+

(28) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-[(1-cyclopenten-l-yl)methyl]-8-[3-(tent.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine Mass spectrum (ESI+): m/z = 563 [M+H]+

(29) 1-[2-(2-hydroxy-phenyl)-2-oxo-ethyl]-3-methyl -7-[(1-cyclopenten-1-yl)methyl]-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 579 [M+H]+

(30) 1-methyl-3-isopropyl-7-(2-cyano-benzyl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine Mass spectrum (ESI+): m/z = 522 [M+H]+

(31) 1-[2-(2-hydroxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 551 [M+H]+

(32) 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl -7-((E)-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine (product contains approx. 10 % of Z isomer) Rf value: 0.20 (silica gel, cyclohexane/ethyl acetate =1:1) Mass spectrum (ESI+): m/z = 552 [M+H]+

(33) 1-(2-phenyl-2-oxo-ethyl)-3-methyl -7-((E)-2-buten- 1-yl)-8-[3-(tert.-butyl oxy-carbonylamino)-piperidin-l-yl]-xanthine (product contains approx. 25 % of Z isomer) Mass spectrum (ESI+): m/z = 537 [M+H]+

(34) 1-[2-(2-hydroxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-l-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine (35) 1-[2-(2-hydroxy-phenyl)-2-oxo-ethyl]-3-methyl-7-((E)-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperid in-l-yl]-xanthine (product contains some Z isomer) Rf value: 0.30 (silica gel, cyclohexane/ethyl acetate = 4:6) Mass spectrum (ESI+): m/z = 553 [M+H]+
(36) 1-[2-(2-hydroxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 551 [M+H]+
(37) 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-l-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.50 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 550 [M+H]+
(38) 1-[2-(2-hydroxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 567 [M+H]+
(39) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-(2-butyn-l-yl)-8-[(R)-3-(tert.-butyloxy-carbonylamino)-piperidin-l-yl]-xanthine Mass spectrum (ESI+): m/z = 535 [M+H]+
(40) 1-methyl-3-[(2-trimethylsilanyl-ethoxy)methyl]-7-(2-cyano-benzyl)-8-[3-(tert: butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 610 [M+H]+
(41) 3-methyl-7-(2-butyn-1-yl)-8-[(S)- 3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanth ine (Carried out with potassium carbonate) Rf value: 0.52 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 417 [M+H]+
(42) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-(2-methyl-al lyl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.46 (silica gel, methylene chloride/methanol = 95:5) (43) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-(3-bromo-allyl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.22 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 601, 603 [M+H]+
(44) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-[(furan-2-yl)methyl]-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.41 (silica gel, methylene chloride/methanol = 95:5) (45) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-(2-chloro-allyl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.49 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 557, 559 [M+H]+
(46) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-[(S)-3-(tert.-butyloxy-carbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 535 [M+H]+
(47) 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-((E)-2-buten-1-yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine Rf value: 0.40 (silica gel, cyclohexane/ethyl acetate = 4:6) Mass spectrum (ESI+): m/z = 552 [M+H]+
(48) 1-[2-(2-nitro-phenyl)-2-oxo-ethyl]-3-methyl-7-((E)-2-buten-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylam ino)-pi peridin-1-yl]-xanthine Rf value: 0.50 (silica gel, cyclohexane/ethyl acetate = 1:2) (49) 1-[2-(2-nitro-phenyl)-2-oxo-ethyl]-3-methyl-7-((E)-2-buten-1-yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 582 [M+H]+
(50) 1-[2-(2-nitro-3-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-l-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 626 [M+H]+
(51) 1-(2-{2-oxo-3-[(2-trimethylsilanyl-ethoxy)methyl]-2,3-dihydro-benzooxazol-7-yl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-l-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 738 [M+H]+
(52) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-((Z)-2-methyl-2-buten-l-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.48 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 551 [M+H]+
(53) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-((E)-2-methyl-2-buten-l-yl)-8-[3-(tert.-butyloxycarbonylamino)-pi peridin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 551 [M+H]+
(54) 1-(2-{2-oxo-3-[(2-trimethylsilanyl-ethoxy)methyl]-2,3-dihydro-benzooxazo l-4-yl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.40 (silica gel, petroleum ether/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 722 [M+H]+
(55) 1-[2-(2,2-difluoro-benzo[I,3]dioxol-4-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 615 [M+H]+
(56) 1-[2-(2,2-difluoro-benzo[1,3]dioxol-4-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 615 [M+H]+
(57) 1-[(1-methyl-1H-indol-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxy-carbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.80 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 560 [M+H]+
(58) 1-[(quinolin-3-yl)methyl]-3-methyl-7-(2-butyn-l-yl)-8-[3-(tert.-butyloxycarbonyl-amino)-piperidin-1-yl]-xanthine Rf value: 0.50 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 558 [M+H]+
(59) 1-{[1-(tert.-butyloxycarbonylamino)-1H-indol-2-yl]methyl}-3-methyl-7-(2-butyn-l-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rfvalue: 0.40 (silica gel, petroleum ether/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 646 [M+H]+
(60) 1-[(2-methyl-1-[(2-trimethylsilanyl-ethoxy)methyl]-1 H-benzoimidazol-5-yI)methyl]-3-methyl-7-(2-butyn- l -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin- 1-yl]-xanthine (mixed with 1-[(2-methyl-3-[(2-trimethylsilanyl-ethoxy)methyl]-3H-benzoimidazol-5-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine) Rf value: 0.15 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 691 [M+H]+
(61) 1-[2-(quinolin-8-yl-]-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxy-carbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.35 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 586 [M+H]+
(62) 1-[(1-[(2-trimethylsilanyl-ethoxy)methyl]-1 H-benzoimidazol-5-yl)methyl]-methyl-7-(2-butyn-l -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine (mixed with 1-[(3-[(2-trimethylsilanyl-ethoxy)methyl]-3H-benzoi midazol-5-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine) Rf value: 0.23 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 677 [M+H]+
(63) 1-[(pyrazolo[1,5-a]pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert:butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.46 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 547 [M+H]+
(64) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-((E)-1-buten-l-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine Rf value: 0.48 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 537 [M+H]+
(65) 1-{2-[1-(tert.-butyloxycarbonyl)-1H-indol-7-yl]-2-oxo-ethyl}-3-methyl-7-(2-butyn-l-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.38 (silica gel, petroleum ether/ethyl acetate = 1:1) (66) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(3-methyl-1-buten-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.40 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 588 [M+H]+
(67) 1,3-dimethyl-7-(2-bromo-benzyl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.40 (silica gel, cyclohexane/ethyl acetate = 1:1) (68) 1,3-dimethyl-7-(2-chloro-benzyl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin- 1-yl]-xanthine Rf value: 0.42 (silica gel, cyclohexane/ethyl acetate = 1:1) (69) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-cyano-benzyl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 635 [M+H]+
Rf value: 0.40 (silica gel, cyclohexane/ethyl acetate = 3:7) (70) 3-cyclopropyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 443 [M+H]+
Rf value: 0.70 (silica gel, ethyl acetate) (71) 3-cyclopropyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.35 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 443 [M+H]+
(72) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-chloro-benzyl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine Mass spectrum (ESI+): m/z = 644, 646 [M+H]+
Rf value: 0.39 (silica gel, cyclohexane/ethyl acetate = 1:1) (73) 1-[(3-methyl-isoquinolin-l-yl)methyl]-3-methyl-7-(2-bromo-benzyl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidi n-1-yl]-xanthine Mass spectrum (ESI+): m/z = 644, 646 [M+H]+
(74) 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-chloro-benzyl)-8-[(R)-3-(tert.-butyloxycarbonylami no)- pi perid i n- 1 -yl]-xa nth i ne Prepared by reacting (4-methyl-quinazolin-2-yl)-methylchloride and 3-methyl-7-(2-chlorobenzyl)-8-bromo-xanthine and subsequently reacting with (R)-3-(tert.-butyloxycarbonylamino)-piperidine Mass spectrum (ESI+): m/z = 645, 647 [M+H]+
(75) 1-[(4-phenyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-chloro-benzyl)-8-[(R)-3-(tert.-butyloxycarbonylami no)-piperidin-1-yl]-xanthine Prepared by reacting (4-phenyl-quinazolin-2-yl)-methylchloride and 3-methyl-7-(2-chlorobenzyl)-8-bromo-xanthine and subsequently reacting with (R)-3-(tert.-butyloxycarbonylamino)-piperidine Mass spectrum (ESI+): m/z = 707, 709 [M+H]+

Example IV
1-[2-(2-hydroxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-chloro-xanthine Prepared by treating 1-[2-(2-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-chloro-xanthine with boron tribromide in methylene chloride. The desired product is contaminated with approx. 20 % 1-[2-(2-hydroxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-bromo-3-methyl-butyl)-8-chloro-xanthine.
Mass spectrum (ESI+): m/z = 403, 405 [M+H]+

The following compounds are obtained analogously to Example IV:

(1) 1-[2-(2-hydroxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-bromo-xanthine (product is contaminated with approx. 20 % 1-[2-(2-hydroxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-bromo-2-buten-1-yl)-8-bromo-xanthine) Mass spectrum (ESI+): mlz = 431, 433 [M+H]+

(2) 1-[2-(2-hydroxy-phenyl)-2-oxo-ethyl]-3-methyl-7-[(1-cyclopenten-1-yl)methyl]-8-bromo-xanthine Mass spectrum (ESI+): m/z = 459, 461 [M+H]+

(3) 1-[2-(2-hydroxy-phenyl)-2-oxo-ethyl]-3-methyl-7-((E)-2-buten-l-yl)-8-bromo-xanthine (product contains some Z isomer) Rf value: 0.60 (silica gel, cyclohexane/ethyl acetate = 4:6) Mass spectrum (ESI+): m/z = 433, 435 [M+H]+

(4) 1-[2-(2-hydroxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-bromo-xanthine Mass spectrum (ESI+): m/z = 447, 449 [M+H]+
Example V
1-[2-(2-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-chloro-xanthine 1.71 g of 2-bromo-1-(2-methoxy-phenyl)-ethanone are added to a mixture of 2.00 g of 3-methyl-7-(3-methyl-2-buten-1-yl)-8-chloro-xanthine and 1.38 mg of potassium carbonate in 15 ml of N,N-dimethylformamide. The reaction mixture is stirred for eight hours at ambient temperature. After aqueous working up the crude product is purified by chromatography through a silica gel column with cyclohexane/ethyl acetate (8:1 to 8:1) as eluant.
Yield: 2.61 g (84 % of theory) Mass spectrum (ESI+): m/z = 417, 419 [M+H]+

The following compounds are obtained analogously to Example V:

(1) 1-[2-(3-hydroxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine (The reaction is carried out with 2-bromo-1-[3-(tert.-butyldimethylsilanyloxy)-phenyl]-ethanone) Rf value: 0.40 (silica gel, cyclohexane/ethyl acetate = 3:7) Mass spectrum (ESI+): m/z = 567 [M+H]+

(2) 1-(1-methyl-2-oxo-2-phenyl-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-chloro-xanthine Mass spectrum (ESI+): m/z = 401, 403 [M+H]+

(3) 1-(2-cyano-ethyl)-3-methyl-7-(2-cyano-benzyl)-8-chloro-xanthine Mass spectrum (ESI+): m/z = 391, 393 [M+Na]+

(4) 1-(2-phenoxy-ethyl)-3-methyl-7-(2-cyano-benzyl)-8-[3-(tert.-butyloxycarbonylami no)-pi peridin-1-yl]-xanthine Rf value: 0.90 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 600 [M+H]+

(5) 1-(2-phenyl-2-oxo-ethyl)-3-[(2-trimethylsilanyl-ethoxy)methyl]-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine Mass spectrum (ESI+): m/z = 667 [M+H]+

(6) 1-(2-methoxy-ethyl)-3-methyl-7-(2-cyano-benzyl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.90 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 538 [M+H]+

(7) 1-methyl-3-[(2-trimethylsilanyl-ethoxy)methyl]-7-(2-cyano-benzyl)-xanthine Rf value: 0.60 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 412 [M+H]+

(8) 1-[2-(3-nitro-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-l-yl)-8-chloro-xanthine Rf value: 0.40 (silica gel, cyclohexane/ethyl acetate/methanol = 7:2:1) Mass spectrum (ESI+): m/z = 432, 434 [M+H]+

(9) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-[(2-trimethylsi lanyl-ethoxy)methyl]-8-bromo-xanthine Mass spectrum (ESI+): m/z = 493, 495 [M+H]+

(10) 1-[2-(2-nitro-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-chloro-xanthine Rf value: 0.64 (silica gel, cyclohexane/ethyl acetate = 3:7) Mass spectrum (ESI+): m/z = 432, 434 [M+H]+

(11) 1-[2-(2-nitro-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-bromo-xanthine Mass spectrum (ESI+): m/z = 476, 478 [M+HJ+

(12) 1-[(quinolin-2-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.45 (silica gel, ethyl acetate/petroleum ether = 7:3) Mass spectrum (ESI+): m/z = 574 [M+H]+

(13) 1-[(2-oxo-2H-chromen-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylami no)-piperidin-1-yl]-xanthine (The starting material 4-bromomethyl-chromen-2-one is prepared analogously to Kimura et al., Chem. Pharm. Bull. 1982, 30, 552-558.) Rf value: 0.52 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 591 [M+H]+

(14) 1-[(1-methyl-2-oxo-1,2-dihydro-quinolin-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-l-yl)-8-[3-(tert.-butyloxycarbonylami no)-piperidin-1-yl]-xanthine Rf value: 0.54 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 604 [M+H]+

(15) 1-[(quinazolin-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-l-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine Melting point: 195-197 C
Mass spectrum (ESI+): m/z = 575 [M+H]+

(16) 1-[(5-methyl-3-phenyl-isoxazol-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylam ino)-piperidin-1-yl]-xanthine Rf value: 0.40 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 604 [M+H]+

(17) 1-[(3-phenyl-[1,2,4]oxadiazol-5-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yI)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.18 (silica gel, petroleum ether/ethyl acetate = 2:1) Mass spectrum (ESI+): m/z = 591 [M+H]+

(18) 1-[(4-phenyl-pyridin-2-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylami no)-piperidin-1-yl]-xanthine Rf value: 0.53 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 600 [M+H]+

(19) 1-[(5-phenyl-pyridin-2-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.73 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 600 [M+H]+

(20) 1-[2-(3-methylsulphanyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.43 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 597 [M+H]+

(21) 1-[2-(3-methoxycarbonyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine (Carried out in N-methylpyrrolidin-2-one at 60 C) Rf value: 0.27 (silica gel, methylene chloride/methanol = 20:1) Mass spectrum (ESI+): m/z = 609 [M+H]+

(22) 1-[2-(2- ethoxycarbonyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine (Carried out in N-methylpyrrolidin-2-one at 60 C) Rf value: 0.35 (silica gel, methylene chloride/methanol = 20:1) Mass spectrum (ESI+): m/z = 623 [M+H]+

(23) 1-[2-(2,6-d imethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbo nylami no)-pi peridin-1-yl]-xanthine (Carried out in N-methylpyrrolidin-2-one at 60 C) Rf value: 0.53 (silica gel, methylene chloride/methanol = 20:1) Mass spectrum (ESI+): m/z = 611 [M+H]+

(24) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-(2,3-dimethyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine (Carried out in N-methylpyrrolidin-2-one at 60 C) Rf value: 0.38 (silica gel, methylene chloride/methanol = 20:1) Mass spectrum (ESI+): m/z = 565 [M+H]+

(25) 1-((E)-3-phenyl-al lyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.54 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) Mass spectrum (ESI+): m/z = 549 [M+H]+

(26) 1-[(1-benzo[b]thiophen-3-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.75 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 579 [M+H]+

(27) 1-{[1-(tert.-butyloxycarbonyl)-indol-3-yl]methyl}-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonyaam ino)-piperidin-1-yl]-xanthine Rf value: 0.61 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 662 [M+H]+

(28) 1-[(biphenyl-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-l-yl)-8-[3-(tert.-butyloxycarbonylami no)-piperidin-1-yl]-xanthine Rf value: 0.68 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 599 [M+H]+

(29) 1-[(1-naphthyl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylami no)-piperidin-l-yl]-xanthine Rf value: 0.83 (silica gel, ethyl acetate/petroleum ether = 4:1) Mass spectrum (ESI+): m/z = 557 [M+H]+

(30) 1-[(1-methyl-2-oxo-l,2-dihydro-quinolin-4-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.25 (silica gel, ethyl acetate/petroleum ether = 4:1) Mass spectrum (ESI+): m/z = 588 [M+H]+

(31) 1-(2-cyclohexyl-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Melting point: 163-165 C
Mass spectrum (ESI+): m/z = 557 [M+H]+

(32) 1-(3,3-dimethyl-2-oxo-butyl)-3-methyl-7-(3-methyl-2-buten-l-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.95 (silica gel, ethyl acetate/petroleum ether = 4:1) Mass spectrum (ESI+): m/z = 531 [M+H]+

(33) 1-[(quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.40 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 559 [M+H]+

(34) 1-[(2-methyl-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine Rf value: 0.80 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 571 [M+H]+

(35) 1-[(5-nitro-isoquinolin-1-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.54 (silica gel, methylene chloride/methanol = 95:5) (36) 1-(2-dimethylamino-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.23 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 518 [M+H]+

(37) 1-[2-(piperidin-1-yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.44 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 558 [M+H]+

(38) 1-[(2-methyl-1-oxo-l,2-dihydro-isoquinolin-4-yl)methyl]-7-(2-butyn-1-yl)-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.25 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 588 [M+H]+

(39) 1-[(2-methyl-1-oxo-l,2-dihydro-isoquinolin-4-yl)methyl]-7-(3-methyl-2-buten-l-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine Rf value: 0.30 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 604 [M+H]+

(40) 1-[(2-methoxy-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine Rf value: 0.75 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 587 [M+H]+

(41) 1-[(4-methoxy-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.80 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 587 [M+H]+

(42) 1-[(3-methyl-isoquinolin-l-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.56 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 572 [M+H]+

(43) 1-[2-(2,3-dimethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.83 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 611 [M+H]+

(44) 1-[(5-nitro-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.78 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 602 [M+H]+

(45) 1-[2-(pyrrolidin-1-yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.39 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 544 [M+H]+

(46) 1-[(4-methyl-isoquinolin-l-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine Rf value: 0.56 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 572 [M+H]+

(47) 1-[(2-naphthyl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.78 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 557 [M+H]+

(48) 1-cyanomethyl-3-methyl-7-(2-butyn-l-yl)-8-[3-(tert.-butyloxycarbonyl-amino)-piperidin-1-yl]-xanthine Rf value: 0.80 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 456 [M+H]+

(49) 1-[(quinolin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.40 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 558 [M+H]+

(50) 1-[(3-methoxy-naphthalen-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.83 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 587 [M+H]+

(51) 1-[2-(2,3-dihydro-benzo[ 1,4]dioxin-5-yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylami no)-piperidin-1-yl]-xanthine Rf value: 0.38 (silica gel, ethyl acetate/petroleum ether = 1:1) Mass spectrum (ESI+): m/z = 609 [M+H]+

(52) 1-[2-(3-methyl-2-oxo-2,3-dihydro-benzooxazol-7-yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine (Carried out with potassium-tert. butoxide in dimethylsulphoxide) Rf value: 0.48 (silica gel, ethyl acetate/petroleum ether = 2:1) Mass spectrum (ESI+): m/z = 622 [M+H]+

(53) 1-[2-(benzo[ 1, 3]dioxol-4-yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 595 [M+H]+

(54) 1-[(quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yi)-8-[(R)-3-(tert.-butyloxycarbonylami no)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 559 [M+H]+

(55) 1-[(quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 559 [M+H]+

(56) 1-[(quinazolin-2-yl)methyl]-3-methyl-7-((E)-2-buten-1-yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine (product contains approx. 15 % of Z isomer) Rf value: 0.30 (silica gel, ethyl acetate/cyclohexane = 8:2) Mass spectrum (ESI+): m/z = 561 [M+H]+

(57) 1-[(quinazolin-2-yl)methyl]-3-methyl-7-((E)-2-buten-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine (product contains approx. 15 % of Z isomer) Rf value: 0.30 (silica gel, ethyl acetate/cyclohexane = 8:2) Mass spectrum (ESI+): m/z = 561 [M+H]+

(58) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-((E)-2-buten-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine (product contains approx. 17 % of Z isomer) Rf value: 0.58 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 574 [M+H]+

(59) 1-[(3-methyl-isoquinolin-l-yl)methyl]-3-methyl-7-((E)-2-buten-1-yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine (product contains approx. 17 % of Z isomer) Rf value: 0.58 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 574 [M+H]+

(60) 1-[2-(2-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn- l -yl)-8-bromo-xanthine Mass spectrum (ESI+): m/z = 445, 447 [M+H]+

(61) 1-[2-(2-nitro-phenyl)-2-oxo-ethyl]-3-methyl-7-[(1-cyclopenten-1-yl)methyl]-8-bromo-xanthine Mass spectrum (ESI+): m/z = 488, 490 [M+H]+

(62) 1-[2-(2-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-[(1-cyclopenten-1-yl)methyl]-8-bromo-xanthine Mass spectrum (ESI+): m/z = 473, 475 [M+H]+

(63) 1-[(isoquinolin-1-yl)methyl]-3-[(methoxycarbonyl)methyl]-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.35 (silica gel, methylene chloride/methanol = 95:5) (64) 1-[2-(2-nitro-phenyl)-2-oxo-ethyl]-3-methyl-7-((E)-2-buten-1-yl)-8-bromo-xanthine (product contains approx. 10 % of Z isomer) Rf value: 0.60 (silica gel, cyclohexane/ethyl acetate = 4:6) Mass spectrum (ESI+): m/z = 462, 464 [M+H]+

(65) 1-[2-(2-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-((E)-2-buten-1-yl)-8-bromo-xanthine (product contains some Z isomer) Rf value: 0.30 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 447, 449 [M+H]+

(66) 1-[2-(2-nitro-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-bromo-xanthine Rf value: 0.77 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 460, 462 [M+H]+

(67) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylami no)-piperid in-1-yl]-xanthine (product contains approx. 20 % of Z isomer) Mass spectrum (ESI+): m/z = 537 [M+H]+

(68) 1-[2-(2-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-bromo-xanthine Mass spectrum (ESI+): m/z = 461, 463 [M+H]+

(69) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-bromo-xanthine Rf value: 0.61 (silica gel, cyclohexane/ethyl acetate = 4:6) (70) 1-(2-{2-[(ethylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine (product contains approx. 17 % of Z isomer) Mass spectrum (ESI+): m/z = 638 [M+H]+

(71) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine (product contains approx. 18 % of Z isomer) Rf value: 0.35 (silica gel, cyclohexane/ethyl acetate = 6:4) Mass spectrum (ESI+): m/z = 537 [M+H]+

(72) 1-[2-(2-nitro-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.60 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 580 [M+H]+

(73) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(S)-3-(tert.-butyloxycarbonylami no)-piperidin-1-yl]-xanthine Rf value: 0.52 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 572 [M+H]+

(74) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine Mass spectrum (ESI+): m/z = 572 [M+H]+

(75) 1-[(4-methyl-isoquinolin-l-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 572 [M+H]+
(76) 1-[(4-methyl-isoquinolin-l-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yi]-xanthine Mass spectrum (ESI+): m/z = 572 [M+H]+
(77) 1-[(4-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-((E)-2-buten-1-yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine Rf value: 0.52 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 574 [M+H]+
(78) 1-[(4-methyl-isoquinolin-l-yl)methyl]-3-methyl-7-((E)-2-buten-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.52 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 574 [M+H]+
(79) 1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine Rf value: 0.18 (silica gel, ethyl acetate/petroleum ether = 1:1) Mass spectrum (ESI+): m/z = 593 [M+H]+
(80) 1-[2-(2,3-dihydro-benzo[I ,4]dioxin-5-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[(S)-3-(tert.-butyloxycarbonylami no)- pi perid i n- 1 -yl]-xa nth ine Mass spectrum (ESI+): m/z = 593 [M+H]+
(81) 1-[(4-methoxy-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine Rf value: 0.56 (silica gel, petroleum ether/ethyl acetate = 1:2) Mass spectrum (ESI+): m/z = 587 [M+H]+
(82) 1-[(4-methoxy-naphthalen-l-yl)methyl]-3-methyl-7-(2-butyn-l-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 587 [M+H]+
(83) 1-[2-(benzo[1,3]dioxol-4-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.86 (silica gel, ethyl acetate/petroleum ether = 4:1) Mass spectrum (ESI+): m/z = 579 [M+H]+
(84) 1-[2-(benzo[1,3]dioxol-4-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-l-yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidi n- 1 -yl]-xa nth i ne Rf value: 0.86 (silica gel, ethyl acetate/petroleum ether = 4:1) Mass spectrum (ESI+): m/z = 579 [M+H]+
(85) 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine Rf value: 0.48 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 573 [M+H]+
(86) 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-l-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine Rf value: 0.48 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 573 [M+H]+
(87) 1-[2-(3-methyl-2-oxo-2,3-dihydro-benzooxazol-4-yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.50 (silica gel, petroleum ether/ethyl acetate = 1:2) Mass spectrum (ESI+): m/z = 622 [M+H]+
(88) 1-(2-{2-[(ethylaminocarbonyl)meth oxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-l -yl)-8-[(S)-3-(tert.-butyloxycarbonylami no)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 638 [M+H]+
(89) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 624 [M+H]+
(90) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 624 [M+H]+
(91) 1-[2-(2-nitro-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.60 (silica gel, methylene chloride/methanol = 95:5) (92) 1-[2-(2-nitro-3-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-bromo-xanthine Mass spectrum (ESI+): m/z = 506, 508 [M+H]+
(93) 1-[(4-dimethylamino-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylami no)-piperidin-1-yl]-xanthine (Carried out in the presence of caesium carbonate) Rf value: 0.40 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 602 [M+H]+
(94) 1-(2-{2-oxo-3-[(2-trimethylsilanyl-ethoxy)methyl]-2,3-dihydro-benzooxazol-7-yl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-l-yl)-8-bromo-xanthine Rf value: 0.75 (silica gel, ethyl acetate/petroleum ether = 1:1) Mass spectrum (ESI+): m/z = 618, 620 [M+H]+
(95) 1-[(imidazo[1,2-a]pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.44 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 547 [M+H]+
(96) 1-[(quinoxalin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonyl-amino)-piperidin-1-yl]-xanthine Rf value: 0.50 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 559 [M+H]+
(97) 1-[2-(1,3-dimethyl-2-oxo-2,3-dihydro-1 H-benzoimidazol-4-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine Rf value: 0.50 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 619 [M+H]+
(98) 1-[(quinoxalin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.35 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 559 [M+H]+
(99) 1-(2-{2-oxo-3-[(2-trimethylsilanyl-ethoxy)methyl]-2,3-dihydro-benzooxazol-4-yl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-bromo-xanth ine Rf value: 0.30 (silica gel, petroleum ether/ethyl acetate = 2:1) Mass spectrum (ESI-): m/z = 600, 602 [M-H]-(100) 1-[(3-methyl-quinoxalin-2-yl)methyl]-3-methyl-7-(2-butyn-l-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperid in-1-yl]-xanthine Rf value: 0.44 (silica gel, petroleum ether/ethyl acetate = 1:2) Mass spectrum (ESI+): m/z = 573 [M+H]+
(101) 1-[(3-phenyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylam ino)-piperidin-1-yl]-xanthine Rf value: 0.85 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 634 [M+H]+
(102) 1-[(3,4-dimethyl-isoquinolin-l-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.60 (silica gel, ethyl acetate/methanol = 3:1) Mass spectrum (ESI+): m/z = 586 [M+H]+
(103) 1-[(benzofuran-2-yl)methyl]-3-methyl-7-(2-butyn-l-yl)-[(R)-3-(tert.-butyl-oxycarbonylamino)-piperidin-l-yl]-xanthine Mass spectrum (ESI+): m/z = 547 [M+H]+
(104) 1-{[4-(morpholin-4-yl)-quinazolin-2-yl]methyl}-3-methyl-7-(2-butyn-l-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine (Carried out in the presence of caesium carbonate) Rf value: 0.28 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 644 [M+H]+
(105) 1-{[4-(piperidin-1-yl)-quinazolin-2-yl]methyl}-3-methyl-7-(2-butyn-l-yl)-[3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine (Carried out in the presence of caesium carbonate) Rf value: 0.35 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 642 [M+H]+
(106) 1-({4-[4-(tert.-butyloxycarbonyl)-piperazin-l-yl]-quinazolin-2-yl}methyl)-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-pi peridin-l-yl]-xanthine (Carried out in the presence of caesium carbonate) Rf value: 0.50 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 743 [M+H]+
(107) 1-{[4-(pyrrolidin-l-yl)-quinazolin-2-yl]methyl}-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine (Carried out in the presence of caesium carbonate) Rf value: 0.59 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
95:5:0.1) Mass spectrum (ESI+): m/z = 628 [M+H]+
(108) 1-[2-(1-ethoxycarbonyl-3-methyl-2-oxo-2,3-dihydro- 1 H-benzoimidazol-4-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-l-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.25 (silica gel, petroleum ether/ethyl acetate = 1:2) Mass spectrum (ESI+): m/z = 677 [M+H]+
(109) 1-[(4-cyano-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.77 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 582 [M+H]+
(110) 1-[(imidazo[1,2-a]pyridine-3-yl)methyl]-3-methyl-7-(2-butyn-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin- l-yl]-xanthine Mass spectrum (ESI+): m/z = 547 [M+H]+
(111) 1-[(8-methyl-imidazo[1,2-a]pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-l-yl)-8-[3-(tent.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine Rf value: 0.25 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 561 [M+H]+
(112) 1-[(8-methoxy-quinolin-5-yl)methyl]-3-methyl-7-(2-butyn-l-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine Rf value: 0.60 (silica gel, ethyl acetate/methanol = 9:1) Mass spectrum (ESI+): m/z = 588 [M+H]+
(113) 1-[(5-methoxy-quinolin-8-yl)methyl]-3-methyl-7-(2-butyn-l-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperid in-l-yl]-xanthine Rf value: 0.40 (silica gel, methylene chloride/methanol = 20:1) Mass spectrum (ESI+): m/z = 588 [M+H]+
(114) 1-[(4-phenyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-l-yl)-8-[3-(tert.-butyloxycarbonylami no)-piperidin-l-yl]-xanthine Mass spectrum (ESI+): m/z = 635 [M+H]+
(115) 1-[(7-methyl-imidazo[1,2-a]pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperid i n- 1 -yl]-xa nth i ne Rf value: 0.50 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 561 [M+H]+
(116) 1-(2-oxo-4-phenyl-butyl)-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 563 [M+H]+
(117) 1-(2-{2-oxo-1,3-bis-[(2-trimethylsilanyl-ethoxy)methyl]-2,3-dihydro-1 H-benzoimidazol-4-yl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxy-carbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.50 (silica gel, ethyl acetate/petroleum ether = 1:1) Mass spectrum (ESI+): m/z = 851 [M+H]+
(118) 1-[(3-difluoromethyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-l-yl)-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine (By-product of the reaction of 3-methyl-7-(2-butyn-l-yl)-8-[3-(tert.-butyloxy-carbonylamino)-piperidin-1-yl]-xanthine with 1-chloromethyl-3-trifluoromethyl-3,4-dihydro-isoquinoline) Rf value: 0.75 (aluminium oxide, petroleum ether/ethyl acetate = 1:2) Mass spectrum (ESI+): m/z = 608 [M+H]+
(119) 1-[2-(2,2-difluoro-benzo[1, 3]dioxol-4-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-bromo-xanthine Mass spectrum (ESI+): m/z = 495, 497 [M+H]+
(120) 1-[(3-methyl-imidazo[1,2-a]pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.50 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 561 [M+H]+
(121) 1-[(5-methyl-imidazo[1,2-a]pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.50 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 561 [M+H]+
(122) 1-[(6-methyl-imidazo[I ,2-a]pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.10 (silica gel, ethyl acetate/methanol = 98:2) Mass spectrum (ESI+): m/z = 561 [M+H]+
(123) 1-[(3-benzyl-imidazo[1,2-a]pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.60 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 637 [M+H]+
(124) 1-[(4-isopropyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.50 (silica gel, ethyl acetate/petroleum ether = 8:2) Mass spectrum (ESI+): m/z = 601 [M+H]+
(125) 1-[(2,3-dihydro-benzo[1,4]dioxin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.53 (silica gel, ethyl acetate/petroleum ether = 3:2) (126) 1-[(3-phenyl-imidazo[1,2-a]pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.50 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 623 [M+H]+
(127) 1-[2-(naphthalen-1-yl]-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.54 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 585 [M+H]+
(128) 1-[(5-methoxy-isoquinolin-8-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.50 (silica gel, ethyl acetate/methanol = 24:1) Mass spectrum (ESI+): m/z = 588 [M+H]+
(129) 1-[(3-difluoromethyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine (By-product of the reaction of 3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxy-carbonylamino)-piperidin-1-yl]-xanthine with 1-chloromethyl-3-trifluoromethyl-3,4-dihydro-isoquinoline) Rf value: 0.75 (aluminium oxide, petroleum ether/ethyl acetate = 1:2) Mass spectrum (ESI+): m/z = 608 [M+H]+
(130) 1-{[1-(1-cyano-1-methyl-ethyl)-isoquinolin-3-yl]methyl}-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert. -butyl oxyca rbonyl am i no)-pi perid i n-1-yl]-xa nth i ne Rf value: 0.75 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 625 [M+H]+

(132) 1-methoxycarbonylmethyl-3-methyl-7-(2-butyn-l-yl)-8-[3-(tert.-butyloxycarbonyl-amino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 489 [M+H]+

(133) 1-[(4-phenyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 635 [M+H]+

(134) 1-[(2,3-dimethyl-quinoxalin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin- l-yl]-xanthine (Carried out in the presence of caesium carbonate) Rf value: 0.40 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 587 [M+H]+

(135) 1-[(4-phenyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-l-yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.55 (silica gel, ethyl acetate/petroleum ether = 8:2) Mass spectrum (ESI+): m/z = 635 [M+H]+

(136) 1-[2-(quinol in-8-yl-]-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-bromo-xanthine Rf value: 0.55 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 466, 468 [M+H]+

(137) 1-[(3,4-dimethyl-6,7-dihydro-5H-[2]pyrindin-l-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.65 (aluminium oxide, ethyl acetate/petroleum ether = 3:1) Mass spectrum (ESI+): m/z = 576 [M+H]+

(138) 1-[(3,4-dimethyl-5,6,7,8-tetrahydro-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.40 (aluminium oxide, methylene chloride/methanol = 20:1) Mass spectrum (ESI+): m/z = 590 [M+H]+

(139) 1-{2-[1-(tert.-butyloxycarbonyl)-1 H-indol-4-yl]-2-oxo-ethyl}-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine Rf value: 0.55 (silica gel, petroleum ether/ethyl acetate = 1:2) Mass spectrum (ESI+): m/z = 674 [M+H]+

(140) 1-[(1-methyl-2-oxo-l,2-dihydro-quinolin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (El): m/z = 587 [M]+

(141) 1-({1-[(2-trimethylsilanyl-ethoxy)methyl]-2-oxo-1,2-dihydro-quinolin-6-yl}methyl)-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin- 1-yl]-xanthine Mass spectrum (ESI+): m/z = 704 [M+H]+

(142) 1-[(2,3,8-trimethyl-quinoxalin-6-yl)methyl]-3-methyl-7-(2-butyn-l-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 601 [M+H]+

(143) 1-[(8-methyl-quinoxalin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 573 [M+H]+

(144) 1-[(4-methyl-phthalazin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.65 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 573 [M+H]+

(145) 1-[(4-bromo-3-methoxy-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.65 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 666, 668 [M+H]+

(146) 1-[(4-difluoromethoxy-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.80 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 623 [M+H]+

(147) 1-{2-[1-(tert.-butyloxycarbonyl)-1H-indol-7-yl]-2-oxo-ethyl}-3-methyl-7-(2-butyn-1-yl)-8-bromo-xanthine Rf value: 0.83 (silica gel, methylene chloride/methanol = 95:5) (148) 1-[(E)-3-(2-nitro-phenyl)-2-propen-l-yl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine Mass spectrum (ESI+): m/z = 578 [M+H]+

(149) 1 -((E)-3- pentafl uorophenyl-2-propen- 1-yl)-3-methyl-7-(2-butyn-1-yl)-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 623 [M+H]+

(150) 1-[(4-nitro-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylami no)- pi peri di n- 1 -yl]-xa nth i ne Rf value: 0.41 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 602 [M+H]+

(151) 1-[(benzooxazol-2-y)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbo-nylamino)-piperidin-1-yl]-xanthine Rf value: 0.40 (silica gel, cyclohexane/ethyl acetate = 3:7) Mass spectrum (ESI+): m/z = 548 [M+H]+

(152) 1-[(5-nitro-benzooxazol-2-y)methyl]-3-methyl-7-(2-butyn-l-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.50 (silica gel, cyclohexane/ethyl acetate/methanol = 5:4:1) Mass spectrum (ESI+): m/z = 593 [M+H]+

(153) 1-[(3-methyl-isoquinolin-l-yl)methyl]-3-methyl-7-(3-methyl-1-buten-1-yl)-8-bromo-xanthine Rf value: 0.65 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 468, 470 [M+H]+

(154) 1-[(quinolin-7-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonyl-amino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 558 [M+H]+

(155) 1-[([1,5]naphthyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 559 [M+H]+

(156) 1-[(8-methyl-quinoxalin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.45 (silica gel, methylene chloride/methanol = 19:1) Mass spectrum (ESI+): m/z = 573 [M+H]+

(157) 1-[(2,3,8-trimethyl-quinoxalin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.32 (silica gel, methylene chloride/methanol = 96:4) Mass spectrum (ESI+): m/z = 601 [M+H]+

(158) 1-[([1,6]naphthyridin-5-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.20 (silica gel, ethyl acetate/methanol = 98:2) Mass spectrum (ESI+): m/z = 559 [M+H]+

(159) 1-[([1,8]naphthyridin-2-yl)methyl]-3-methyl-7-(2-butyn-l-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.12 (silica gel, ethyl acetate/methanol = 98:2) Mass spectrum (ESI+): m/z = 559 [M+H]+

(160) 1-[(4-fluoro-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-l-yl)-8-[(R)-3-(tert.-butyloxycarbonyl a mi no)-pi peri di n- 1 -yl]-xa nth i ne Rf value: 0.47 (silica gel, petroleum ether/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 575 [M+H]+

(161) 1-[([1,5]naphthyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.39 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 559 [M+H]+

(162) 1-[2-(3-methyl-2-oxo-2,3-dihydro-benzooxazol-4-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.-butyloxycarbonyla mino)-piperidin-1-yl]-xanthine Rf value: 0.60 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 606 [M+H]+

(163) 1-[(8-phenyl-quinoxalin-6-yl)methyl]-3-methyl-7-(2-butyn-l -yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.48 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 356 [M+H]+

(164) 1-[([1,5]naphthyridin-4-yl)methyl]-3-methyl-7-(2-butyn-l-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine Rf value: 0.25 (silica gel, ethyl acetate/petroleum ether = 4:1) Mass spectrum (ESI+): m/z = 559 [M+H]+

(165) 1-((E)-3-pentafluorophenyl-allyl)-3-methyl-7-(2-butyn-l-yl)-8-[(R)-3-(tert.-butyloxycarbonylami no)- pi perid i n- 1 -yl]-xa nth i ne Mass spectrum (ESI+): m/z = 623 [M+H]+

(166) 1-[(E)-3-(2-trifluoromethyl-phenyl)-allyl]-3-methyl-7-(2-butyn-l-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 601 [M+H]+

(167) 1-[(E)-3-(3-trifluoromethyl-phenyl)-allyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 601 [M+H]+

(168) 1-[(E)-3-(4-trifluoromethyl-phenyl)-aIIyI]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylam ino)-piperidin-l-yl]-xanthine Mass spectrum (ESI+): m/z = 601 [M+H]+

(169) 1-[(3-trifluoromethyl-isoquinolin-l-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine Rf value: 0.68 (silica gel, cyclohexane/ethyl acetate = 3:7) Mass spectrum (ESI+): m/z = 626 [M+H]+

(170) 1-[(3-methyl-isoquinolin-l-yl)methyl]-3-methyl-7-(2-cyano-benzyl)-8-chloro-xanthine (171) 1-[(3-difluoromethyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine Rf value: 0.38 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 608 [M+H]+

(172) 1-[(4-chloro-3-methoxy-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine Rf value: 0.65 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 622, 624 [M+H]+

(173) 1-[(4-ethoxy-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.25 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 603 [M+H]+

(174) 1-[(4-isopropyloxy-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.40 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 617 [M+H]+

(175) 1-[(2-methyl-benzothiazol-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.56 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 578 [M+H]+

(176) 1-[(3-phenyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-l-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.75 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 634 [M+H]+

(177) 1-[(4-phenyloxy-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.35 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 651 [M+H]+

(178) 1-[(4-phenyl-quinazolin-2-yl)methyl]-3-cyclopropyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.45 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 661 [M+H]+

(179) 1-[(3-methyl-isoquinolin-l-yl)methyl]-3-cyclopropyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.50 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 598 [M+H]+

(180) 1-[2-(3-difluoromethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylami no)-piperidin-1-yl]-xanthine Rf value: 0.77 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 601 [M+H]+

(181) 1-[(2-phenyl-quinazolin-4-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine Rf value: 0.65 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 635 [M+H]+

(182) 1-[2-(2-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.57 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 565 [M+H]+

(183) 1-[2-(3-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidi n-1-yl]-xanthine Rf value: 0.63 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 565 [M+H]+

(184) 1-[2-(3-trifluoromethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.64 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 619 [M+H]+

(185) 1-[2-(biphenyl-2-yl)-2-oxo-ethyl]-3-methyl -7-(2-butyn-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.70 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 611 [M+H]+

(186) 1-[2-(biphenyl-3-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperid in-l-yl]-xanthine Rf value: 0.75 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 611 [M+H]+

(187) 1-[2-(3-isopropyloxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-l-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.66 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 593 [M+H]+

(188) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-cyclopropyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylam ino)-piperidin-1-yl]-xanthine Rf value: 0.50 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 598 [M+H]+

(189) 1-[(4-phenyl-quinazolin-2-yl)methyl]-3-cyclopropyl-7-(2-butyn-l-yl)-8-[(R)-3-(tert.-butyloxycarbonylam ino)-piperidin-l-yl]-xanthine Rf value: 0.50 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 661 [M+H]+

(190) 1-[(4-cyano-naphthalen-l-yl)methyl]-3-cyclopropyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine Rf value: 0.75 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 608 [M+H]+

(191) 1-[2-(2-phenyloxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-l -yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.85 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 627 [M+H]+

(192) 1-[2-(3-ethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.72 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 579 [M+H]+

(193) 1-[2-(3-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.67 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 565 [M+H]+

(194) 1-[2-(2-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-l-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-pi peridin-1-yl)-xanthine Rf value: 0.57 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 565 [M+H]+

(195) 1-[(3-methyl-isoquinolin-l-yl)methyl]-3-methyl-7-(2-chloro-benzyl)-8-bromo-xanthine (196) 1-[(3-methyl-isoquinolin-l-yl)methyl]-3-methyl-7-(2-bromo-benzyl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine (197) 1-[(1,2,3,4-tetrahydro-phenanthridin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.55 (silica gel, ethyl acetate/ petroleum ether = 2:1) Mass spectrum (ESI+): mlz = 612 [M+H]+
Example VI
1-(2-{3-[(methanesulphi nyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methvl-2-buten-1-yl)-8-[3-(tert.-butyloxyca rbonvlami no)-piperid in-1-yll-xanthine To a solution of 402 mg of 1-(2-{3-[(methylsulphanyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-l-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine in 10 ml hexafluoroisopropanol are added 0.15 ml of a 35 % hydrogen peroxide solution. The reaction mixture is stirred for half an hour at ambient temperature.Then 5 ml of a 10 % sodium thiosulphate solution are added. The aqueous phase is extracted twice with 5 ml of methylene chloride. The combined extracts are dried over sodium sulphate and evaporated down. The yellow residue is purified by chromatography through a silica gel column with cyclohexane/ ethyl acetate/methanol (5:4:1) as eluant.
Yield: 299 mg (73 % of theory) Rf value: 0.28 (silica gel, cyclohexane/ethyl acetate/methanol = 5:4:1) Mass spectrum (ESI+): m/z = 643 [M+H]+

The following compounds are obtained analogously to Example VI:

(1) 1-[2-(3-methanesulphinyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.05 (silica gel, ethyl acetate/cyclohexane = 3:1) Mass spectrum (ESI+): m/z = 613 [M+H]+

(2) 1-(2-{2-[(methanesu[phi nyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 627 [M+H]+

Example VII
3-[(2-trimethylsilanyl-ethoxy)methyl]-7-(3-methyl-2-buten-l-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yll-xanthine 236 pl of 1,8-diazabicyclo[5.4.0]undec-7-ene are added dropwise to 630 mg of 7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine in 11 ml of acetonitrile. The solution is stirred for two hours at ambient temperature, then the acetonitrile is distilled off in vacuo. The flask residue is taken up in 11 ml of N,N-dimethylformamide and combined with 258 mg of (2-trimethylsilanyl-ethoxy)methyl chloride. The reaction mixture is stirred for three hours at 120 C. For working up water is added, the precipitate formed is filtered off and taken up in ethyl acetate. The solution is dried over magnesium sulphate, evaporated down and chromatographed through a silica gel column with cyclohexane/ethyl acetate/methanol (6:1:0 to 0:5:1) as eluant.
Yield: 435 mg (53 % of theory) Mass spectrum (ESI+): m/z = 549 [M+H]+

The following compounds are obtained analogously to Example VII:
(1) 3-[(2-tri methylsi lanyl-ethoxy) m ethyl]-7-(2-cyano- benzyl)-xa nth i ne Mass spectrum (ESI"): m/z = 396 [M-H]-(2) 3-[(methoxycarbonyl)methyl]-7-(3-methyl-2-buten-l-yl)-8-[3-(tert.-butyloxy-carbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.31 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 491 [M+H]+
Example VIII
7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylami no)-piperidin-1-yll-xanthine 510 mg of potassium-tert. butoxide are added to 2.32 g of 2-[3-(tert.-butyloxycarbonylami no)-piperidin-1-yl]-3-(3-methyl-2-buten-1-yl)-4-ethoxycarbonyl-5-{[(ethoxycarbonylamino)carbonyl]amino}-3H-imidazole in 35 ml of ethanol. The yellow solution is refluxed for five hours. After cooling to ambient temperature it is diluted with methylene chloride. The organic phase is washed with saturated ammonium chloride solution and saturated sodium chloride solution, dried over magnesium sulphate and evaporated down. The crude product is purified by chromatography through a silica gel column with methylene chloride/methanol/conc. methanolic ammonia (95:5:1 to 90:10:1) as eluant.
Yield: 630 mg (35 % of theory) Rf value: 0.24 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 419 [M+H]+
Example IX
2-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(3-methyl-2-buten-1-yl)-4-ethoxycarbonyl-5-{f(ethoxycarbonylamino)carbonyllamino}-3H-imidazole 2.97 ml of ethyl isocanatoformate are added to 4.00 g of 2-[3-(tert.-butyloxycarbonylami no)-piperidin-1-yl]-3-(3-methyl-2-buten-1-yl)-4-ethoxycarbonyl-5-amino-3H-imidazole in 90 ml of 1,2-dimethoxyethane and the light brown solution is heated overnight at 120 C in an oil bath. Then a further 0.6 ml of ethyl isocyanatoformate is added and heating is continued for a further four hours. For working up the reaction mixture is combined with saturated potassium carbonate solution and extracted with ethyl acetate. The organic phase is dried over magnesium sulphate, evaporated down and purified through a silica gel column with methylene chloride/methanol/conc.
methanolic ammonia (98:2:1 to 90:10:1) as eluant.
Yield: 2.27 g (45 % of theory) Rf value: 0.29 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 537 [M+H]+
Example X
2-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(3-methyl-2-buten-1-yl)-4-ethoxycarbonvl-5-amino-3H-imidazole Prepared by refluxing cyanimino-[N-(3-methyl-2-buten-1-yl)-N-(ethoxy-carbonylmethyl)-amino]-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-methane with sodium in ethanol.
Rf value: 0.26 (aluminium oxide, ethyl acetate/petroleum ether = 8:2) Mass spectrum (ESI+): m/z = 422 [M+H]+

Example XI
Cyanimino-[N-(3-methyl-2-buten-1-yl)-N-(ethoxycarbonylmethyl)-amino]-[3-(tert.-butyloxycarbonylamino)-piperidin-1-vll-methane Prepared by reacting cyanimino-[N-(3-methyl-2-buten-1-yl)-N-(ethoxy-carbonylmethyl)-amino]-phenyloxy-methane with 3-(tert.-butyloxycarbonylamino)-piperidine in the presence of potassium carbonate in N,N-dimethylformamide at ambient temperature.
Rf value: 0.10 (silica gel, petroleum ether/ethyl acetate = 6:4) Mass spectrum (ESI+): m/z = 422 [M+H]+

Example XII
cyan imino-[N-(3-methyl-2-buten-1-yl)-N-(ethoxycarbonylmethyl)-amino]-phenyloxy-methane Prepared by reacting cyanimino-[(ethoxycarbonylmethyl)amino]-phenyloxy-methane with 1-bromo-3-methyl-2-butene in the presence of potassium carbonate in acetone at ambient temperature.
Rf value: 0.70 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 316 [M+H]+

Example XIII
cyanimino-t(ethoxycarbonylmethyl)ami nol-phenyloxy-methan Prepared by reacting diphenylcyanocarbonimidate with ethyl aminoacetate-hydrochloride in the presence of triethylamine in isopropanol at ambient temperature (analogously to R. Besse et al., Tetrahedron 1990, 46, 7803-7812).
Rf value: 0.73 (silica gel, petroleum ether/ethyl acetate = 8:2) Mass spectrum (ESI+): m/z = 248 [M+H]+

Example XIV
1-methyl-3-[(methoxycarbonyl)methyll-7-(2-cyano-benzvl)-8-chloro-xanthine Prepared by reacting 1 -methyl-7-(2-cya n o-benzyl)-8-ch lo ro-xa nth i ne with methyl bromoacetate in the presence of potassium carbonate in N,N-dimethylformamide at ambient temperature.

Rf value: 0.80 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 388, 390 [M+H]+

The following compounds are obtained analogously to Example XIV:
(1) 1-methyl-3-cyanomethyl-7-(2-cyano-benzyl)-8-chloro-xanthine Mass spectrum (ESI+): mlz = 355, 357 [M+H]+

(2) 1-methyl-3-(2-propyn-1-yl)-7-(2-cyano-benzyl)-8-chloro-xanthine Rf value: 0.80 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 354, 356 [M+H]+

(3) 1 -methyl-3-(2- propen- 1 -yl)-7-(2-cya no-benzyl)-8-ch loro-xa nth i ne Rf value: 0.90 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 356, 358 [M+H]+

(4) 1-(2-phenyl-2-oxo-ethyl)-3-cyanomethyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylami no)-piperidin-1-yl]-xanthine Rf value: 0.78 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 576 [M+H]+

(5) 1-methyl-3-isopropyl-7-(2-cyano-benzyl)-8-chloro-xanthine Mass spectrum (ESI+): m/z = 358, 360 [M+H]+

Example XV
1-methyl-7-(2-cyano-benzyl)-8-chloro-xanthine Prepared by treating 1-methyl-3-[(2-trimethylsilanyl-ethoxy)methyl]-7-(2-cyano-benzyl)-8-chloro-xanthine with trifluoroacetic acid in methylene chloride at ambient temperature.
Rf value: 0.50 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 316, 318 [M+H]+

The following compounds are obtained analogously to Example XV:
(1) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-8-bromo-xanthine Rf value: 0.26 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI"): m/z = 361, 363 [M-H]-(2) 1-[(4-oxo-3,4-dihydro-phthalazin-l-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (As the compound still contains impurities which cannot be removed by chromatography, the material is again converted into the BOC-protected derivative and then purified by chromatography, cf. Ex. XXV(1).) Mass spectrum (ESI+): m/z = 491 [M+H]+
Example XVI
1-methyl-3-f(2-trimethylsilanyl-ethoxy)methyll-7-(2-cvano-benzyl)-8-chloro-xanthine Prepared by chlorination of 1-methyl-3-[(2-trimethyl siIanyl-ethoxy)methyl]-7-(2-cyano-benzyl)-xanthine with N-chlorosuccinimide in dichloroethane while refluxing.
Mass spectrum (El): m/z = 445, 447 [M]+
Example XVII
7-(2-cvano-benzyl)-xanthine Prepared by treating 16.68 g of 2-amino-7-(2-cyano-benzyl)-1,7-dihydro-purin-6-one with 17.00 g of sodium nitrite in a mixture of 375 ml of conc. acetic acid, 84 ml of water and 5.2 ml of conc. hydrochloric acid at 50 C.
Yield: 8.46 g (50 % of theory) Mass spectrum (ESI+): m/z = 268 [M+H]+
Example XVIII
2-amino-7-(2-cvano-benzyl)-1,7-dihydro-purin-6-one Prepared by reacting 20.00 g of guanosine-hydrate with 22.54 g of 2-cyano-benzylbromide in dimethylsulphoxide at 60 C and subsequent treatment with 57 ml of conc. hydrochloric acid.

Yield: 18.00 g (97% of theory) Mass spectrum (ESI+): m/z = 267 [M+H]+
Example XIX
1 -{2-[3-(2-oxo-imidazolidin-1-yl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl-2-buten-1-vl)-8-f3-(tert.-butyloxycarbonylamino)-piperidin-1-vll-xanthine Prepared by treating 1-[2-(3-{[(2-chloro-ethylamino)carbonyl]amino}-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxy-carbonylamino)-piperidin-1-yl]-xanthine with potassium-tert. butoxide in N,N-dimethylformamide at ambient temperature.
Rf value: 0.50 (silica gel, methylene chloride/methanol = 9:1) Example XX
1-[2-(3-{[(2-chloro-ethylamino)carbonyl]amino}-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-vl)-8-f3-(tert.-butyloxvcarbonylamino)-piperidin-l-vll-xanthine Prepared by reacting 221 mg of 1-[2-(3-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine with 60 pl of 2-chloroethyl isocyanate in 3 ml methylene chloride at ambient temperature.
Yield: 163 mg (64 % of theory) Rf value: 0.20 (silica gel, cyclohexane/ethyl acetate/methanol = 6:3:1) Mass spectrum (ESI+): m/z = 671, 673 [M+H]+

The following compounds are obtained analogously to Example XX:

(1) 1-[2-(2-{[(ethoxycarbonylamino)carbonyl]amino}-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine (Carried out in N,N-dimethylformamide at 30 C) Rf value: 0.26 (silica gel, cyclohexane/ethyl acetate = 4:6) Mass spectrum (ESI+): m/z = 681 [M+H]+

Example XXI

1-[2-(3-am i no-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3_ (tert.-butvloxycarbonvlamino)-piperidin-1-vll-xanthine Prepared by treating 1-[2-(3-nitro-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine with iron powder in a mixture of ethanol, water and glacial acetic acid (80:25:10) at 100 C.
Rf value: 0.55 (silica gel, cyclohexane/ethyl acetate/methanol/conc. aqueous ammonia = 50:30:20:1) Mass spectrum (ESI+): m/z = 566 [M+H]+

The following compounds are obtained analogously to Example XXI:

(1) 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 566 [M+H]+

(2) 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[(S)-3-(tert.-butyloxycarbonylami no)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 566 [M+H]+

(3) 1-[(5-amino-isoquinolin-1-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonyl ami no)-piperidin-1-yl]-xanthine Rf value: 0.22 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 589 [M+H]+

(4) 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-[(1-cyclopenten-1-yl)methyl]-8-bromo-xanthine Mass spectrum (ESI+): m/z = 458, 460 [M+H]+

(5) 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-((E)-2-buten-l-yl)-8-bromo-xanthine (product contains approx. 10 % of Z isomer) Rf value: 0.55 (silica gel, cyclohexane/ethyl acetate = 4:6) Mass spectrum (ESI+): m/z = 432, 434 [M+H]+

(6) 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-bromo-xanthine Rf value: 0.50 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 430, 432 [M+H]+

(7) 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-((E)-2-buten-l-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 552 [M+H]+

(8) 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-((E)-2-buten-1-yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 552 [M+H]+

(9) 1-[2-(2-amino-3-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.82 (silica gel, ethyl acetate/petroleum ether = 4:1) Mass spectrum (ESI+): m/z = 596 [M+H]+
Example XXII
1-(2-{2-[(ethylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylam ino)-Piperid in-1-yll-xanthine Prepared by reacting 248 mg of 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine with 40 pi of propionic acid chloride in the presence of 60 pl of pyridine in N,N-dimethylformamide at 80 C.
Yield: 168 mg (62 % of theory) Rf value: 0.55 (silica gel, cyclohexane/ethyl acetate = 3:7) Mass spectrum (ESI+): m/z = 622 [M+H]+

The following compounds are obtained analogously to Example XXII:

(1) 1-({5-[(methoxycarbonyl)methylamino]-isoquinolin-1-yl}methyl)-3-methyl-7-(3-methyl-2-buten-l-yl)-8-[3-(tert.-butyloxycarbonylami no)-piperidin-l-yl]-xanthine (Carried out with methyl bromoacetate and potassium carbonate) Rf value: 0.42 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 661 [M+H]+

(2) 1-[2-(2-acetylamino-phenyl)-2-oxo-ethyl]-3-methyl-7-((E)-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylami no)-piperidin-1-yl]-xanthine (product contains approx. 10 % of Z isomer) Mass spectrum (ESI+): m/z = 594 [M+H]+

(3) 1-(2-{2-[(isopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine (product contains approx. 10 % of Z isomer) Mass spectrum (ESI+): m/z = 622 [M+H]+

(4) 1-[2-(2-acetylamino-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[(S)- 3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.50 (silica gel, cyclohexane/ethyl acetate = 3:7) Mass spectrum (ESI+): m/z = 608 [M+H]+

(5) 1-[2-(2-acetylamino-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-l-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.34 (silica gel, cyclohexane/ethyl acetate = 3:7) Mass spectrum (ESI+): m/z = 592 [M+H]+

(6) 1-(2-{2-[(isopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.25 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 636 [M+H]+

(7) 1-(2-{2-[(isopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylami no)-piperidin-1-yl]-xanthine Rf value: 0.44 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 620 [M+H]+

(8) 1-[2-(2-acetylamino-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-l-yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.34 (silica gel, cyclohexane/ethyl acetate = 3:7) Mass spectrum (ESI+): m/z = 592 [M+H]+

(9) 1-(2-{2-[(isopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.44 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 620 [M+H]+

(10) 1-(2-{2-[(methoxycarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin- l -yl]-xanthine (Carried out in acetonitrile at 55 C) Rf value: 0.25 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 624 [M+H]+

(11) 1-(2-{2-[(isopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine (Carried out in acetonitrile at 65 C) Rf value: 0.50 (silica gel, cyclohexane/ethyl acetate/isopropanol = 14:3:3) Mass spectrum (ESI+): m/z = 622 [M+H]+

(12) 1-(2-{2-[(ethylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 608 [M+H]+

(13) 1-[2-(2-acetylamino-phenyl)-2-oxo-ethyl]-3-methyl-7-((E)-2-buten-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperid i n-1-yl]-xanthine Mass spectrum (ESI+): m/z = 594 [M+H]+

(14) 1-[2-(2-acetyl amino-phenyl)-2-oxo-ethyl]-3-methyl-7-((E)-2-buten-1-yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.28 (silica gel, cyclohexane/ethyl acetate/isopropanol = 8:1:1) Mass spectrum (ESI+): mlz = 594 [M+H]+

(15) 1-(2-{2-[(isopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine Rf value: 0.90 (silica gel, methylene chloride/methanol = 9:1) (16) 1-(2-{2-[(isopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl])-xanthine (Carried out in 1,2-dichloroethane at 45 C) Rf value: 0.30 (silica gel, cyclohexane/ethyl acetate/isopropanol = 8:1:1) Mass spectrum (ESI+): m/z = 622 [M+H]+

(17) 1-(2-{2-[(ethylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-pi peridi n-1-yl]-xanthine Rf value: 0.48 (silica gel, cyclohexane/ethyl acetate/isopropanol = 14:3:3) Mass spectrum (ESI+): m/z = 608 [M+H]+

(18) 1-(2-{2-[(ethylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine Mass spectrum (ESI+): m/z = 606 [M+H]+

(19) 1-(2-{2-[(ethylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.22 (silica gel, methylene chloride/methanol = 95:5) (20) 1-(2-{2-[(phenylcarbonyl)aminoj-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.55 (silica gel, cyclohexane/ethyl acetate/isopropanol = 14:3:3) Mass spectrum (ESI+): m/z = 656 [M+H]+

(21) 1-(2-{2-[(cyclopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-[(1-cyclopenten-1-yl)methyl]-8-[3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine (Carried out with Hunig base and 4-dimethylamino-pyridine in methylene chloride) Rf value: 0.60 (silica gel, methylene chloride/methanol = 18:1) Example XXI II
1-(2-{3-[(methoxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2- buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine Prepared by treating 1-(2-{3-[(methoxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-j3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine with trifluoroacetic acid in methylene chloride at ambient temperature.
Mass spectrum (ESI+): m/z = 539 [M+H]+

The following compounds are obtained analogously to Example XXIII:

(1) 1-(2-{2-[(methoxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine Mass spectrum (ESI+): m/z = 539 [M+H]+

Example XXIV
1 -methyl-3-phenyl-7-(2-cyano-benzyl)-8-chloro-xanthine A mixture of 829 mg of 1-methyl-7-(2-cyano-benzyl)-8-chloro-xanthine, 640 mg of phenylboric acid, 509 mg of anhydrous copper acetate and 0.43 ml of pyridine in 20 ml methylene chloride is stirred for four days at ambient temperature in the presence of 100 mg of 4A molecular sieves.Then another 320 mg of phenylboric acid are added and the reaction mixture is stirred for another day at ambient temperature. For working up the mixture is filtered through talc and washed with ethyl acetate. The filtrate is evaporated down and chromatographed through a silica gel column with cyclohexane/ethyl acetate (7:3 to 1:1) as eluant.

Yield: 142 mg (14 % of theory) Mass spectrum (ESI+): m/z = 392, 394 [M+H]+
Example XXV
1-(2-phenyl-2-oxo-ethyl)-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonyl-amino)-piperidin-1-vll-xanthine Prepared by reacting 1-(2-phenyl-2-oxo-ethyl)-7-(3-methyl-2-buten-l-yl)-8-(3-amino-piperidin-1-yl)-xanthine with di-tert.butyl pyrocarbonate in the presence of HUnig base in methylene chloride at ambient temperature.
Rf value: 0.27 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) The following compounds are obtained analogously to Example XXV:
(1) 1-[(4-oxo-3,4-dihydro-phthalazin-1-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonyl-amino)-piperidin-1-yl]-xanthine Rf value: 0.27 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 591 [M+H]+

(2) 7-acetyl-1-(tert.-butyloxycarbonyl)-1H-indole Rf value: 0.82 (silica gel, methylene chloride/petroleum ether/ethyl acetate=
5:4:1) Mass spectrum (ESI+): m/z = 260 [M+H]+
Example XXVI
1-[(cinnolin-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-chloro-xanthine and 1-1(1,4-dihydro-cinnolin-4-vl)methyll-3-methyl-7-(3-methyl-2-buten-l-vl)-8-chloro-xanthine 510 mg of a mixture of (cinnolin-4-yl)-methanol and (1,4-dihydro-cinnolin-4-yl)-methanol (see Ex. XXVII) are added to 830 mg of 3-methyl-7-(3-methyl-2-buten-l-yl)-8-chloro-xanthine and 1.25 g of triphenylphosphine in 25 ml of tetrahydrofuran. The reaction mixture is combined with 0.92 ml diethyl azodicarboxylate and stirred overnight at ambient temperature.Then it is evaporated down and chromatographed through a silica gel column with ethyl acetate/petroleum ether (7:3 to 0:1) as eluant. A mixture of cinnoline and 1,4-dihydro-cinnoline compound is obtained.
Yield: 660 mg (52 % of theory) Rf value: 0.60 (silica gel, ethyl acetate/petroleum ether = 7:3) The following compounds are obtained analogously to Example XXVI:

(1) 1-({4-oxo-3-[(2-trimethylsilanyl-ethoxy)methyl]-3,4-dihydro-phthalazin-1-yl}methyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-chloro-xanthine Rf value: 0.85 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 557, 559 [M+H]+

(2) 1-[(isoquinolin-3-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-chloro-xanthine Melting point: 194-195 C
Mass spectrum (ESI+): m/z = 410, 412 [M+H]+

(3) 1-[(3-methyl -4-oxo-3,4-dihydro-phthalazin-1-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-chloro-xanthine Rf value: 0.66 (silica gel, ethyl acetate) Mass spectrum (ESI`): m/z = 441, 443 [M+H]+

(4) 1 -[(q u ino I in-4-yl)methyl]-3-methyl-7-(2-buty n- 1 -yl)-8-bromo-xa nth i ne (Carried out with potassium carbonate) Rf value: 0.45 (silica gel, ethyl acetate) Mass spectrum (ESI+): mlz = 438, 440 [M+H]+

(5) 1-[(isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-bromo-xanthine Rf value: 0.78 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 438, 440 [M+H]+

(6) 1-[(4-dimethyl amino-naphtha len-1-yl)methyl]-3-methyl-7-(2-butyn-1-yI)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.80 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 600 [M+H]+

(7) 1-[(isoquinolin-1-yl)methyl]-3-methyl-7-((E)-2-buten-1-yl)-8-bromo-xanthine (The product contains approx. 20 % of Z isomer) Rf value: 0.71 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 440, 442 [M+H]+

(8) 1-[(1-methyl-1 H-indol-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-bromo-xanthine Rf value: 0.95 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 440, 442 [M+H]+

(9) 1-[(quinolin-3-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-bromo-xanthine Rf value: 0.55 (silica gel, ethyl acetate/petroleum ether = 8:2) Mass spectrum (ESI+): m/z = 438, 440 [M+H]+

(10) 1-{[1-(tert.-butyloxycarbonylamino)-1H-indol-2-yl]methyl}-3-methyl-7-(2-butyn-l-yl)-8-bromo-xanthine Rf value: 0.74 (silica gel, petroleum ether/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 526, 528 [M+H]+

(11) 1-({2-methyl-1-[(2-trimethyl silanyl-ethoxy)methyl]-1 H- benzoi m i dazol-yl}methyl)-3-methyl-7-(2- butyn- 1 -yl)-8- bro mo-xa nth i ne (mixed with 1-({2-methyl-3-[(2-trimethylsilanyl-ethoxy)methyl]-3H-benzoimidazol-5-yl}methyl)-3-methyl-7-(2-butyn-l-yl)-8-bromo-xanthine) Mass spectrum (ESI+): m/z = 571, 573 [M+H]+

(12) 1-[(1-[(2-trimethylsilanyl-ethoxy)methyl]-1 H-benzoimidazol-5-yl)methyl]-methyl-7-(2-butyn-1-yl)-8-bromo-xanthine (mixed with 1-[(3-[(2-trimethylsila nyl-ethoxy)methyl]-3H-benzoimidazol-5-yl) methyl]-3-methyl-7-(2-butyn-1-yl)-8-bromo-xanthine) Rf value: 0.50 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 557, 559 [M+H]+

(13) 1-[(pyrazolo[1,5-a]pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-bromo-xanthine Rf value: 0.35 (silica gel, petroleum ether/ethyl acetate = 1:2) Mass spectrum (ESI+): m/z = 427, 429 [M+H]+

Example XXVII
(cinnolin-4-vl)-methanol and (1,4-dihydro-cinnolin-4-vl)-methanol A solution of 1.00 g of methyl cinnolin-4-carboxylate in 15 ml diethyl ether is added dropwise at 0 C to a suspension of 222 mg of lithium aluminium hydride in 5 ml of diethyl ether. After 1.5 hours water is carefully added dropwise to the reaction mixture, this is stirred with methylene chloride and suction filtered through a glass fibre filter. The aqueous phase is extracted with methylene chloride and the combined organic phases are dried over magnesium sulphate and evaporated down. According to 'H-NMR a mixture of cinnoline and 1,4-dihydro-cinnoline compound is obtained as a yellow oil which is reacted further without any more purification.
Yield: 530 mg (62 % of theory) Rf value: 0.63 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 161 [M1+H]+ and 163 [M2+H]+

The following compounds are obtained analogously to Example XXVII:

(1) {2-methyl-1-[(2-trimethylsilanyl-ethoxy)methyl]-1 H-benzoimidazol-5-yl}-methanol (mixed with {2-methyl-3-[(2-trimethylsilanyl-ethoxy)methyl]-3H-benzoimidazol-5-yi}-methanol) Mass spectrum (ESI+): m/z = 293 [M+H]+

(2) (2,3,8-trimethyl-quinoxalin-6-yl)-methanol Rf value: 0.45 (silica gel, petroleum ether/ethyl acetate = 1:2) Mass spectrum (ESI+): m/z = 203 [M+H]+

(3) (8-methyl-quinoxalin-6-yl)-methanol Rf value: 0.18 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 175 [M+H]+
(4) (E)-3-pentafluorophenyl-2-propen-1-ol (Carried out with diisobutylaluminium hydride in toluene) Mass spectrum (El): m/z = 224 [M]+

(5) (E)-3-(2-trifl uoromethyl-phenyl)-2- pro pen- 1 -ol (Carried out with diisobutylaluminium hydride in toluene) (6) (E)-3-(3-trifluoromethyl-phenyl)-2-propen-1-ol (Carried out with diisobutylaluminium hydride in toluene) Mass spectrum (El): m/z = 202 [M]+

(7) (E)-3-(4-trifluoromethyl-phenyl)-2-propen-1-ol (Carried out with diisobutylaluminium hydride in toluene) Example XXVII I
4-hvdroxvmethvl-2-f(2-trimethylsilanyl-ethoxy)methyll-2H-phthalazin-l-one Prepared by treating methyl 4-oxo-3-[(2-trimethylsilanyl-ethoxy)methyl]-3,4-dihydro-phthalazin-1-carboxylate with sodium borohydride in tetrahydrofuran at 40 C.
Rfvalue: 0.55 (silica gel, cyclohexane/ethyl acetate 1:1) Mass spectrum (ESI+): m/z = 307 [M+H]+

The following compounds are obtained analogously to Example XXVIII:
(1) (3,4-dimethyl-isoquinolin-1-yl)-methanol (Carried out with lithium borohydride in tetrahydrofuran) Rf value: 0.35 (silica gel, petroleum ether/ethyl acetate = 2:1) Mass spectrum (ESI+): m/z = 188 [M+H]+

(2) (3-methyl-imidazo[1,2-a]pyridin-2-yl)-methanol (Carried out with lithium borohydride in tetrahydrofuran) Rf value: 0.48 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 163 [M+H]+

(3) (3,4-dimethyl-6,7-dihydro-5H-[2]pyrindin-1-yl)-methanol (Carried out with lithium borohydride in tetrahydrofuran) Rf value: 0.40 (aluminium oxide, petroleum ether/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 178 [M+H]+

(4) (3,4-dimethyl-5,6,7,8-tetrahydro-isoquinolin-1-yl)-methanol (Carried out with lithium borohydride in tetrahydrofuran) Rf value: 0.45 (aluminium oxide, petroleum ether/ethyl acetate = 3:1) Mass spectrum (ESI+): m/z = 192 [M+H]+

(5) 6-hydroxymethyl-1,2,3,4-tetrahydro-phenanthridine (Carried out with lithium borohydride in tetrahydrofuran at ambient temperature) Rf value: 0.40 (silica gel, petroleum ether/ethyl acetate = 2:1) Mass spectrum (ESI+): m/z = 214 [M+H]+

Example XXIX
Methyl 4-oxo-3-[(2-trimethylsilanyl-ethoxy)methyl]-3,4-dihydro-phthalazin-1-carboxylate Prepared by reacting methyl 4-oxo-3,4-dihydro-phthalazin-1-carboxylate with (2-trimethyl silanyl-ethoxy)meth ylchIoride in the presence of Hunig base in methylene chloride at ambient temperature.
Rf value: 0.75 (silica gel, cyclohexane/ethyl acetate 6:4) Mass spectrum (ESI+): m/z = 335 [M+H]+

The following compounds are obtained analogously to Example XXIX:
(1) 7-acetyl-3-[(2-trimethylsilanyl-ethoxy)methyl]-3H-benzooxazol-2-one Mass spectrum (ESI+): m/z = 308 [M+H]+

(2) 4-acetyl-3-[(2-trimethylsilanyl-ethoxy)methyl]-3H-benzooxazol-2-one Rf value: 0.87 (silica gel, methylene chloride/methanol = 99:1) (3) 4-acetyl-1,3-bis-[(2-trimethylsilanyl-ethoxy)methyl]-1,3-dihydro-benzoimidazol-2-one (Carried out with potassium-tert. butoxide in N,N-dimethylformamide) Rf value: 0.90 (silica gel, petroleum ether/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 437 [M+H]+

(4) 6-methyl- 1-[(2-trimethylsilanyl-ethoxy)methyl]-1 H-quinolin-2-one Rf value: 0.78 (silica gel, petroleum ether/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 290 [M+H]+

(5) methyl {2-methyl-1-[(2-trimethylsilanyl-ethoxy)methyl]-1 H-benzoimidazol-5-yl}-carboxylate (mixed with methyl {2-methyl-3-[(2-trimethylsilanyl-ethoxy)methyl]-3H-benzoimidazol-5-yl}-carboxylate) Mass spectrum (ESI+): m/z = 321 [M+H]+

Example XXX
1-[2-(3-methanesulphonyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-YI)-8-f 3-(tert.-butyloxycarbonylamino)-piperidin-1-vll-xanthi ne 0.22 ml of a 35 % hydrogen peroxide solution and 20 mg of sodium tungstate are added to 500 mg of 1-[2-(3-methylsulphanyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine in 5 ml methylene chloride. The reaction mixture is stirred overnight at ambient temperature, then 1 ml of methanol is added. After another 48 hours a further 1.5 ml of 35 % hydrogen peroxide solution, a spatula tip of sodium tungstate and two drops of water are added. The next morning, the oxidation is complete according to thin layer chromatography and the reaction mixture is diluted with 50 ml methylene chloride and washed twice with 30 ml of 10 % sodium thiosulphate solution. The organic phase is dried over magnesium sulphate and evaporated down, leaving a viscous resin which is reacted further without any more purification.
Yield: 530 mg (100 % of theory) Rf value: 0.72 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 629 [M+H]+
Example XXXI
1-[2-(3-carboxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3_ (tert.-butyloxycarbonvlamino)-piperidin-1-yll-xanthine Prepared by treating 1-[2-(3-methoxycarbonyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylami no)-piperidin-l -yl]-xanthine with 3 M sodium hydroxide solution in methanol at ambient temperature:
Rf value: 0.34 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 595 [M+H]+

The following compounds are obtained analogously to Example XXXI:

(1) 1-[2-(2-carboxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylami no)-piperidin-1-yi]-xanthine Rf value: 0.49 (silica gel, methylene chloride/methanol = 9:1) (2) 1-[2-(2-carboxymethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-l-yl)-8-[3-(tert.-butyloxycarbonylami no)-pi peridin-1-yl]-xanthine (Carried out with 4 M potassiuim hydroxide solution in tetrahydrofuran) Mass spectrum (ESI+): m/z = 609 [M+H]+

(3) 1-[2-(2-carboxymethylamino-phenyl)-2-oxo-ethyl]-3-methyl-7-((E)-2-buten-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine (Carried out with 4 M potassium hydroxide solution in tetrahydrofuran) Rf value: 0.65 (silica gel, cyclohexane/ethyl acetate = 3:7) Mass spectrum (ESI+): m/z = 610 [M+H]+

(4) 1-carboxymethyl-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI+): m/z = 475 [M+H]+

Example XXXII
1-{2-[3-(methylaminocarbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl-2-buten-1-vl)-8-[3-(tert.-butyloxycarbonvlamino)-piperidin-1-yll-xanthine A mixture of 190 mg of 1-[2-(3-carboxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tent.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine, 43 pl of a 40 % aqueous methylamine solution, 103 mg of 0-(benzotriazol- 1 -yl)-N, N, N',N'-tetramethyl uronium tetrafluoroborate, 43 mg of N-hydroxybenzotriazole and 45 pl of triethylamine in 3 ml of tetrahydrofuran is stirred for eight hours at ambient temperature. For working up the reaction mixture is diluted with ethyl acetate and washed with water, 10 % citric acid solution, 10 % potassium carbonate solution and saturated sodium chloride solution. The organic phase is evaporated down and chromatographed through a silica gel column with methylene chloride/methanol (98:2 to 80:20) as eluant.
Yield: 173 mg (89 % of theory) Rf value: 0.30 (silica gel, methylene chloride/methanol = 20:1) Mass spectrum (ESI+): m/z = 608 [M+H]+

The following compounds are obtained analogously to Example XXXII:
(1) 1-{2-[3-(dimethylaminocarbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylami no)-piperidin-1-yl]-xanthine Rfvalue: 0.28 (silica gel, methylene chloride/methanol = 20:1) Mass spectrum (ESI+): m/z = 622 [M+H]+

(2) 1-{2-[3-(morpholin-4-yl-carbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl-2-buten- l -yl)-8-[3-(tent.-butyloxycarbonylami no)-piperidin-1-yl]-xanthine Rf value: 0.30 (silica gel, methylene chloride/methanol = 20:1) Mass spectrum (ESI+): m/z = 664 [M+H]+

(3) 1-{2-[2-(dim ethyl aminocarbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.30 (silica gel, methylene chloride/methanol = 20:1) Mass spectrum (ESI+): m/z = 622 [M+H]+

(4) 1-{2-[2-(morpholin-4-yl-carbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl-2-buten-l-yi)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.30 (silica gel, methylene chloride/methanol = 20:1) Mass spectrum (ESI+): m/z = 664 [M+H]+

(5) 1-(2-{2-[(isopropylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonyl amino)-piperidin-1-yl]-xanthine (Carried out with Hunig base in N,N-dimethylformamide) Mass spectrum (ESI+): m/z = 650 [M+H]+

(6) 1-(2-{2-[(ethylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine (Carried out with Honig base in N,N-dimethylformamide) Mass spectrum (ESI+): m/z = 636 [M+H]+

(7) 1-(2-{2-[2-oxo-2-(pyrrolidin-1-yl)-ethoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine (Carried out with Hunig base in N,N-dimethylformamide) Mass spectrum (ESI+): m/z = 662 [M+H]+

(8) 1-(2-{2-[2-(morpholin-4-yl)-2-oxo-ethoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine (Carried out with Hunig base in N,N-dimethylformamide) Mass spectrum (ESI+): m/z = 678 [M+H]+

(9) 1-(2-{2-[(methylaminocarbonyl)methylamino]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-l -yl]-xanthine Rf value: 0.40 (silica gel, cyclohexane/ethyl acetate/methanol = 5:4:1) Mass spectrum (ESI+): m/z = 623 [M+H]+

(10) 1-[(2-amino-phenylaminocarbonyl)methyl]-3-methyl-7-(2-butyn-l-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.40 (silica gel, cyclohexane/ethyl acetate/methanol = 5:4:1) Mass spectrum (ESI+): m/z = 565 [M+H]+
Example XXXIII
1-chloromethyl-4-methyl-isoguinoline-hydrochloride Prepared by treating (4-methyl-isoquinolin-1-yl)-methanol with thionyl chloride in methylene chloride.
Rf value: 0.76 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) Mass spectrum (ESI+): m/z = 192, 194 [M+H]+

The following compounds are obtained analogously to Example XXXIII:
(1) 1-chloromethyl-3,4-dimethyl-isoquinoline-hydrochloride Rf value: 0.65 (silica gel, petroleum ether/ethyl acetate = 2:1) Mass spectrum (ESI+): mlz = 206, 208 [M+H]+

(2) 5-chloromethyl-8-methoxy-quinoline-hydrochloride Mass spectrum (ESI+): m/z = 208, 210 [M+H]+

(3) 8-chloromethyl-5-methoxy-quinoline-hydrochloride Mass spectrum (El): m/z = 207, 209 [M]+

(4) 2-chloromethyl-3-methyl-imidazo[I,2-a]pyridine-hydrochloride Rf value: 0.55 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): mlz = 181, 183 [M+H]+

(5) 8-chloromethyl-5-methoxy-isoquinoline-hydrochloride Mass spectrum (ESI+): m/z = 208, 210 [M+H]+

(6) 1-chloromethyl-3,4-dimethyl-6,7-dihydro-5H-[2]pyridine-hydrochloride Rf value: 0.50 (aluminium oxide, petroleum ether/ethyl acetate = 10:1) Mass spectrum (ESI+): m/z = 196, 198 [M+H]+

(7) 1-chloromethyl-3,4-dimethyl-5,6,7,8-tetrahydro-isoquinoline-hydrochloride Rf value: 0.50 (aluminium oxide, petroleum ether/ethyl acetate = 10:1) Mass spectrum (ESI+): m/z = 210, 212 [M+H]+

(8) 6-chloromethyl-2,3,8-trimethyl-quinoxaline-hydrochloride Mass spectrum (ESI+): m/z = 221, 223 [M+H]+

(9) 6-chloromethyl-8-methyl-quinoxaline-hydrochloride Mass spectrum (ESI+): m/z = 193,195 [M+H]+

(10) 6-chloromethyl-1,2,3,4-tetrahydro-phenanth ridine-hydrochloride Rf value: 0.50 (silica gel, petroleum ether/ethyl acetate = 5:1) Mass spectrum (ESI+): m/z = 232, 234 [M+H]+
Example XXXIV
1-[(4-oxo-3,4-dihydro-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3_ (tert.-butyloxycarbonylamino)-piperidin-1-yll-xanthine 0.5 ml of a 1 M sodium methoxide solution in methanol is added dropwise to a solution of 428 mg of 1-cyanomethyl-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine in 3 ml of methanol at ambient temperature. After about 20 minutes the thick suspension formed is heated gently in a water bath and diluted with 2 ml of methanol. As soon as the reaction to form the iminoester is complete according to thin layer chromatography, the reaction mixture is neutralised with 0.5 ml 1 M glacial acetic acid solution in methanol and combined with a solution of 130 mg of anthranilic acid in 2 ml of methanol. Gentle heating produces a clear solution, which is stirred for 2.5 hours at ambient temperature. Then the reaction mixture is gently refluxed for about 3.5 hours. After standing overnight at ambient temperature the methanol is distilled off and the residue is stirred with cold water, suction filtered and dried. The crude product is suspended in 5 ml of methanol, gently heated and after cooling suction filtered, washed with methanol and dried in the desiccator.
Yield: 302 mg (56 % of theory) Rf value: 0.55 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 575 [M+H]+

The following compounds are obtained analogously to Example XXXV:
(1) (4-difluoromethoxy-naphthalen-1-yl)-methanol Rf value: 0.33 (silica gel, cyclohexane/ethyl acetate = 6:4) Mass spectrum (ESI"): m/z = 223 [M-H]-Example XXXV
(4-dimethylamino-naphthalen-1-yl)-methanol prepared by reduction of 4-dimethylamino-naphthalene-1-carbaldehyde with sodium borohydride in aqueous tetrahydrofuran.
Rf value: 0.67 (silica gel, cyclohexane/ethyl acetate = 1:1) Example XXXVI
2-bromo-1-(2,3-dihydro-benzo[1,41dioxin-5-vl)-ethanone prepared by bromination of 1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-ethanone in methylene chloride while cooling gently with an ice bath. The dibromo compound formed as a by-product is separated off by column chromatography.
Mass spectrum (ESI+): m/z = 257, 259 [M+H]+
Rf value: 0.92 (silica gel, methylene chloride) The following compounds are obtained analogously to Example XXXVI:

(1) 7-(2-bromo-acetyl)-3-methyl-3H-benzooxazol-2-one (bromination is carried out in dioxane at 40 C; the product is contaminated with approx. 20 % dibromo compound) Rf value: 0.44 (silica gel, petroleum ether/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 270, 272 [M+H]+

(2) 1-benzo[1,3]dioxol-4-yl-2-bromo-ethanone Mass spectrum (ESI+): m/z = 243, 245 [M+H]+
Rf value: 0.94 (silica gel, methylene chloride) (3) 2-[2-(2-bromo-acetyl)-phenoxy]-N-ethyl-acetamide (bromination is carried out with copper(II)bromide in dioxane) Mass spectrum (ESI+): m/z = 300, 302 [M+H]+

(4) 4-(2-bromo-acetyl)-3-methyl-3H-benzooxazol-2-one Rfvalue: 0.67 (silica gel, methylene chloride/methanol = 99:1) Mass spectrum (ESI+): m/z = 270, 272 [M+H]+

(5) 2-[2-(2-bromo-acetyl)-phenoxy]-N-methyl-acetamide Mass spectrum (ESI+): m/z = 386, 388 [M+H]+

(6) 7-(2-bromo-acetyl)-3-[(2-trimethylsilanyl-ethoxy)methyl]-3H-benzooxazol-2-one Rfvalue: 0.84 (silica gel, methylene chloride/methanol = 99:1) Mass spectrum (ESI+): m/z = 384, 386 [M+H]+

(7) 4-(2-bromo-acetyl)-1,3-dimethyl-1,3-dihydro-benzoimidazol-2-one Rf value: 0.38 (silica gel, ethyl acetate/petroleum ether = 1:1) Mass spectrum (ESI+): m/z = 283, 285 [M+H]+

(8) 4-(2-bromo-acetyl)-3-[(2-trimethylsilanyl-ethoxy)methyl]-3H-benzooxazol-2-one Rf value: 0.82 (silica gel, methylene chloride/methanol = 99:1) (9) 4-(2-bromo-acetyl)-1-ethoxycarbonyl-3-methyl-l,3-dihydro-benzoimidazol-2-one Rf value: 0.39 (silica gel, petroleum ether/ethyl acetate = 2:1) Mass spectrum (ESI+): m/z = 341, 343 [M+H]+

(10) 2-bromo-1-(2,2-difluoro-benzo[1,3]dioxol-4-yl)-ethanone Mass spectrum (ESI"): m/z = 277, 279 [M-H]-Example XXXVII
(2 3-dihydro-benzof 1,41dioxin-5-vl)-ethanone Prepared by reacting 1-(2,3-dihydroxy-phenyl)-ethanone with 1,2-dibromoethane in the presence of potassium carbonate in N,N-dimethylformamide at 100 C.
Rf value: 0.43 (silica gel, ethyl acetate/petroleum ether = 1:4) Mass spectrum (ESI+): m/z = 179 [M+H]+

Example XXXVIII
1-[(3-methyl-4-oxo-3,4-dihydro-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-f3-(tert.-butyloxycarbonylami no)-piperidin-1-yll-xanthine Prepared by reacting 1-[(4-oxo-3,4-dihydro-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yi)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine with methyl iodide in the presence of potassium carbonate in N,N-dimethylformamide at ambient temperature.
Rf value: 0.50 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 589 [M+H]+

The following compounds are obtained analogously to Example XXXVIII:
(1) 7-acetyl-3-methyl-3H-benzooxazol-2-one (The methylation is carried out in the presence of sodium carbonate in methanol) Rf value: 0.46 (silica gel, petroleum ether/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 192 [M+H]+

(2) 4-acetyl-3-methyl-3H-benzooxazol-2-one (The methylation is carried out in the presence of sodium carbonate in methanol while refluxing) Rf value: 0.67 (silica gel, methylene chloride/methanol = 99:1) Mass spectrum (ESI+): m/z = 192 [M+H]+

(3) 4-acetyl-1,3-dimethyl-1,3-dihydro-benzoimidazol-2-one (Carried out in the presence of potassium-tert. butoxide) Rfvalue: 0.40 (silica gel, ethyl acetate/petroleum ether = 2:1) Mass spectrum (ESI+): m/z = 205 [M+H]+

(4) 4-acetyl-1-ethoxycarbonyl-3-methyl-1,3-dihydro-benzoimidazol-2-one Rfvalue: 0.23 (silica gel, petroleum ether/ethyl acetate = 2:1) Mass spectrum (ESI+): m/z = 263 [M+H]+

(5) 1-[(1-methyl-1 H-benzoimidazol-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine Mass spectrum (ESI+): m/z = 561 [M+H]+

(6) 1-{[1-(2-cyano-ethyl)-1 H-benzoimidazol-2-yl]methyl}-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.50 (silica gel, cyclohexane/ethyl acetate/methanol = 5:4:1) Mass spectrum (ESI+): m/z = 600 [M+H]+

(7) 1-({1-[(methylaminocarbonyl)methyl]-1 H-benzoimidazol-2-yl}methyl)-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine Rf value: 0.45 (silica gel, cyclohexane/ethyl acetate/methanol = 5:4:1) Mass spectrum (ESI+): m/z = 618 [M+H]+

(8) 1-[(1-benzyl-1 H-benzoimidazol-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.50 (silica gel, cyclohexane/ethyl acetate/methanol = 5:4:1) Mass spectrum (ESI+): m/z = 637 [M+H]+

Example XXXIX
1-[2-(2-cyanomethylamino-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yI'-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yil-xanthine Prepared by reacting 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylami no)-piperidin- l -yl]-xanthine with paraformaldehyde and potassium cyanide in the presence of zinc chloride in glacial acetic acid at 40 C.
Rf value: 0.45 (silica gel, cyclohexane/ethyl acetate = 3:7) Mass spectrum (ESI+): m/z = 605 [M+H]+

Example XL
1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[(S)- 3-(tert.-butyloxycarbonylamino)-piperidin-1 -vll-xanthine prepared by reduction of 1-[2-(2-nitro-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-l-yl)-8-[(S)- 3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine with sodium dithionite in a mixture of methylglycol and water (2:1) at 100 C.
Rf value: 0.34 (silica gel, methylene chloride/methanol = 95:5) The following compounds are obtained analogously to Example XL:

(1) 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yi)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-l-yl]-xanthine Rf value: 0.50 (silica gel, cyclohexane/ethyl acetate = 4:6) Example XLI
2-ch l oro methyl-4-methyl-g u i nazol i n e prepared by treatment of 2.95 g of 2-chloromethyl-4-methyl-quinazoline-3-oxide with 6 ml phosphorus trichloride in 150 ml chloroform while refluxing.
Yield: 1.75 g (57 % of theory) Rf value: 0.81 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 193, 195 [M+H]+

Example XLII

2-chloromethyl-4-dimethylamino-quinazoline A freshly prepared solution of 202 mg of dimethylamine in 3.2 ml of tetrahydrofuran is added dropwise to 500 mg of 4-chloro-2-chloromethyl-quinazoline in 5 ml of tetrahydrofuran while cooling with an ice bath. Then the reaction mixture is stirred for another 3.5 hours while cooling with an ice bath and then for a further 30 minutes at ambient temperature.
The solvent is then gently distilled off using a rotary evaporator and the residue is taken up in methylene chloride. The solution is washed with saturated sodium hydrogen carbonate solution and with water, dried over magnesium sulphate and evaporated down. The solid residue is stirred with a little tert.-butylmethylether, suction filtered, washed with petroleum ether and dried in vacuo.
Yield: 323 mg (62 % of theory) Rf value: 0.60 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 222, 224 [M+H]+

The following compounds are obtained analogously to Example XLII:
(1) 2-chloromethyl-4-(morpholine-4-yl)-quinazoline Rf value: 0.50 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 264, 266 [M+H]+

(2) 2-chloromethyl-4-(piperidin-1-yl)-quinazoline Rf value: 0.70 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 262, 264 [M+H]+

(3) 4-[4-(tert.-butyloxycarbonyl)-piperazin-l-yl]-2-chloromethyl-quinazoline Rf value: 0.57 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 363, 365 [M+H]+
(4) 2-chloromethyl-4-(pyrrolidin-1-yl)-quinazoline Rf value: 0.50 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 248, 250 [M+H]+

(5) 2-chloromethyl-4-ethoxy-quinazoline (The reaction is carried out with sodium ethoxide in ethanol at ambient temperature.) Rf value: 0.50 (silica gel, cyclohexanelethyl acetate = 3:1) Mass spectrum (ESi+): m/z = 223, 225 [M+H]+

(6) 2-chloromethyl-4-isopropyloxy-quinazoline (The reaction is carried out with sodium isopropoxide in isopropanol at ambient temperature.) Rf value: 0.70 (silica gel, cyclohexane/ethyl acetate = 3:1) Mass spectrum (ESI+): m/z = 237, 239 [M+H]+

(7) 2-chloromethyl-4-phenyloxy-quinazoline (The reaction is carried out with sodium hydride and phenol in tetrahydrofuran at ambient temperature.) Rf value: 0.65 (silica gel, cyclohexane/ethyl acetate = 3:1) Mass spectrum (ESI+): m/z = 271, 273 [M+H]+

.Example XLIII
1-(2-{2-[(ethoxycarbonyl)methylam ino]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1-vl)-8-I3-(tert.-butyloxycarbonvlamino)-piperidin-l-yll-xanthine A solution of 110 pL of ethyl diazoacetate in 0.5 ml of toluene is added dropwise to 531 mg of 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-((E)-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-pipendin-1-yl]-xanthine and 10 mg of methyltrioxorhenium in 4.5 ml of toluene at ambient temperature under an argon atmosphere. The reaction mixture is stirred for 15 hours at ambient temperature.Then approx. another 5 mg of methyltrioxorhenium and 20 pL
ethyl diazoacetate are added and the reaction mixture is heated to 50 C for two hours. After cooling to ambient temperature another 5 mg of methyltrioxorhenium and 20 pL ethyl diazoacetate are added. After another 16 hours at ambient temperature the reaction mixture is combined with 5 ml of TM
conc. aqueous ammonia, shaken thoroughly and added to an Extrelut pack.
After 15 min it is rinsed with 200 ml methylene chloride. The methylene chloride solution is evaporated down and chromatographed through a silica gel column with cyclohexane/ethyl acetate/isopropanol (8:2:0 to 8:1:1) as eluant.
Yield: 220 mg (36 % of theory) Rf value: 0.40 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 638 [M+H]+

Example XLIV
1-[(2-cyano-benzofuran-3-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yll-xanthine A mixture of 215 mg of 1-{2-[2-cyanomethoxy-phenyl]-2-oxo-ethyl}-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine and 244 mg of caesium carbonate in 4 ml of N,N-dimethylformamide is stirred for two hours at 50 C, then a further three hours at 70 C. For working up the reaction mixture is combined with water and the precipitate formed is suction filtered and dried.
Yield: 130 mg (62 % of theory) Mass spectrum (ESI+): m/z = 572 [M+H]+
Example XLV
1 -[2-(3-methyl-2-oxo-2,3-d ihyd ro-1 H-benzoimidazol-4-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-f 3-(tert.-butyloxycarbonyla mino)-piperidin-1-yll-xanthine Prepared by treating 1-[2-(1-ethoxycarbonyl-3-methyl-2-oxo-2,3-dihydro-1H-benzoim idazol-4-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-l-yl)-8-[3-(tert.-butyloxy-carbonylamino)-piperidin-l-yl]-xanthine with 1 N sodium hydroxide solution in methanol at ambient temperature.
Rf value: 0.36 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 605 [M+H]+
Example XLVI
4-acetyl-1-ethoxycarbonyl-1,3-dihydro-benzoimidazol-2-one 5.29 g of diethyldicarbonat and 611 mg of dimethylaminopyridine are added to 1.50 g of 1-(2,3-diamino-phenyl)-ethanone in 75 ml methylene chloride. The reaction mixture is stirred for three hours at ambient temperature, then another 100 mg of dimethylaminopyridine and 1 ml of diethyldicarbonate are added and the mixture is stirred for a further 20 hours at ambient temperature.
For working up the reaction mixture is diluted with methylene chloride, washed with 2 N citric acid solution as well as saturated sodium hydrogen carbonate solution and saturated sodium chloride solution, dried over magnesium sulphate and evaporated down. The residue is chromatographed through a silica gel column with petroleum etherlethyl acetate (3:1 to 1:2) as eluant. The desired product is stirred with a little tert.-butylmethylether, suction filtered, nachwashed with a little ethyl acetate and tert.-butylmethylether and dried.
Yield: 900 mg (36 % of theory) Rf value: 0.15 (silica gel, petroleum ether/ethyl acetate = 2:1) Mass spectrum (ESI+): m/z = 249 [M+H]+

Example XLVII
I -[(4-amino-quinazol in-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperid in-1 -yl]-xanthine 501 mg of 1-cyanomethyl-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine are added to a mixture of 17 mg of potassium-tert. butoxide in 10 ml of methanol. After brief heating with stirring a clear solution is formed and after about 20 minutes the nitrile has largely reacted to form the iminoester according to thin layer chromatography.
206 mg of 2-amino-benzamidine-hydrochloride are then added and the reaction mixture is refluxed for four hours. After cooling to ambient temperature the precipitate formed is suction filtered, washed with methanol and dried.
Yield: 143 mg (23 % of theory) Rf value: 0.15 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 574 [M+H]+
Example XLVIII
1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-((Z)-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl-xanthine 150 mg of 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine are hydrogenated in a mixture of 5 ml of tetrahydrofuran and 5 ml of methanol in the presence of 30 mg of 5 %m palladium on activated charcoal (contaminated with quinoline) at ambient temperature, until the calculated amount of hydrogen has been taken up.
Then a spatula tip of activated charcoal is added and the mixture is suction filtered. The filtrate is evaporated down and the crude product is purified by chromatography over a silica gel column with cyclohexane/ethyl acetate (7:3 to 4:6).
Yield: 120 mg (85 % of theory) Rf value: 0.40 (silica gel, cyclohexane/ethyl acetate = 4:6) Mass spectrum (ESI+): m/z = 537 [M+H]+

Example XLIX
8- hvd roxvmeth v l-5-meth oxy-a u i n o l i n e 148 mg of sodium hydride (approx. 60 % in mineral oil) are added batchwise to a solution of 640 mg of 8-hydroxymethyl-quinolin-5-ol in N,N-dimethylformamide while cooling with an ice bath and the reaction mixture is slowly heated to ambient temperature. After the development of gas has ended, 230 pI methyl iodide are added dropwise while cooling with an ice bath, then the reaction mixture is stirred for approx. another two hours at ambient temperature. For working up it is poured onto ice water, saturated with sodium chloride and extracted with a mixture of diethyl ether and ethyl acetate. The combined extracts are washed with saturated sodium chloride solution, dried over magnesium sulphate and evaporated down. The flask residue is triturated with petroleum ether and the supernatant is decanted.
The crude product is purified through a silica gel column with ethyl acetate as eluant.
Yield: 470 mg (68 % of theory) Rf value: 0.70 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 190 [M+H]+

The following compounds are obtained analogously to Example XLIX:

(1) 8-hydroxymethyl-5-methoxy-isoquinoline Rf value: 0.40 (silica gel, methylene chloride/methanol = 10:1) Mass spectrum (ESI+): m/z = 190 [M+H]+

Example L
8-hydroxymethyl-quinolin-5-ol 3.40 g of quinolin-5-ol is combined with 8 ml of conc. hydrochloric acid and 8 ml of 37 % formalin solution while cooling with an ice bath. Then hydrogen chloride gas is piped through the reaction mixture for about two hours, while the temperature slowly rises. The reaction mixture is stirred first overnight while cooling with an ice bath, then at ambient temperature and then evaporated down in vacuo. The flask residue is taken up in water, covered with a layer of diethyl ether and adjusted to pH 10 while cooling with an ice bath and vigorously stirring with dilute ammonia solution. After another two hours' vigorous stirring at ambient temperature the organic phase is separated off and the aqueous phase is extracted with diethyl ether. The combined organic phases are washed with water and saturated sodium chloride solution, dried over magnesium sulphate and evaporated down. The flask residue is chromatographed through a silica gel column with methylene chloride/methanol (20:1) as eluant.
Yield: 660 mg (16 % of theory) Mass spectrum (ESI+): m/z = 176 [M+H]+

The following compounds are obtained analogously to Example L:
(1) 8-hydroxymethyl-isoquinolin-5-ol Rf value: 0.50 (silica gel, methylene chloride/methanol = 5:1) Mass spectrum (ESI+): m/z = 176 [M+H]+

Example LI
1-[(2-cyclopropyl-quinazolin-4-yl)methyl]-3-methyl-7-[(1-cyclopenten-1-yl)meth yll-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yll-xanthine A mixture of 250 mg of 1-(2-{2-[(cyclopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-[(1-cyclopenten-1-yl)methyl]-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine and 7.5 ml of ethanolic ammonia solution (6 M) is heated to 150 C for seven hours in a bomb. For working up the reaction mixture is evaporated down and chromatographed through a silica gel column with methylene chloride/methanol (100:0 to 70:30) as eluant. The contaminated product fraction is evaporated down and again purified through a reversed phase HPLC column with water/
acetonitrile/trifluoroacetic acid (65:15:0.08 to 0:100:0.1) as eluant. The product fractions are evaporated down, made alkaline with dilute sodium hydroxide solution and extracted with methylene chloride. The combined extracts are dried over magnesium sulphate and evaporated down.
Yield: 40 mg (14 % of theory) Rf value: 0.40 (silica gel, methylene chloride /ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 627 [M+H]+

Example LII
4-(2-bromo-acetyl)-1,3-bis-[(2-trimethylsilanyl-ethoxy)methyl]-1,3-dihydro-benzoimidazol-2-one 520 mg of 2-pyrrolidinone-hydrotribromide and 89 mg of 2-pyrrolidinone are added to 420 mg of 4-acetyl-1,3-bis-[(2-trimethylsilanyl-ethoxy)methyl]-1,3-dihydro-benzoimidazol-2-one in 5 ml of tetrahydrofuran under an argon atmosphere. The reaction mixture is refluxed for two hours and then suction filtered while still warm. The filter cake is washed with tetrahydrofuran and the filtrate is evaporated down, leaving 660 mg of a yelllowish-brown solid. This is stirred with a little methanol, suction filtered, washed with some methanol and dried. The crude product is reacted further without any more purification.
Yield: 430 mg (87 % of theory) Rf value: 0.23 (silica gel, petroleum ether/ethyl acetate = 9:1) Mass spectrum (El): m/z = 514, 516 [M]+

The following compounds are obtained analogously to Example LII:
(1) 7-(2-bromo-acetyl)-1-(tert.-butyloxycarbonyl)-1 H-indole Rf value: 0.33 (silica gel, petroleum ether/ethyl acetate = 9:1) Mass spectrum (ESI+): m/z = 338, 340 [M+H]+

(2) 2-bromo-1-(3-isopropyloxy-phenyl)-ethanone (Carried out with phenyltrimethylammonium tribromide in methylene chloride) Rf value: 0.39 (silica gel, cyclohexane/ethyl acetate = 9:1) (3) 2-bromo-1-(3-difluoromethoxy-phenyl)-ethanone (Carried out with phenyltrimethylammonium tribromide in methylene chloride) Rf value: 0.24 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Example LIII
methyl 3-methyl-imidazof 1.2-alpyridine-2-carboxylate A mixture of 1.91 g of 2-aminopyridine and 4.40 g of methyl 3-bromo-2-oxo-butyrate in 40 ml of ethanol is refluxed for 6 hours and then left to stand for 2 days at ambient temperature. The solvent is distilled off using the rotary evaporator and the crude product is purified by chromatography over a silica gel column with methylene chloride/methanol/methanolic ammonia solution (95:4:1 to 90:9:1) as eluant. 560 mg of the ethyl ester are isolated as the by-product.
Yield: 2.09 g (54 % of theory) Rf value: 0.20 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 191 [M+H]+

Example LIV
2-chloromethyl-4-isopropyl-auinazoline Dry hydrogen chloride gas is piped through a solution of 2.86 g of 1-(2-amino-phenyl)-2-methyl-propan-1-one and 1.33 ml of chloroacetonitrile in 14 ml dioxane with stirring at ambient temperature for approx. five hours. Then the dioxane is largely distilled off in a water jet vacuum. The honey-like residue is combined with ice water and the resulting suspension is made alkaline with saturated potassium carbonate solution while cooling with an ice bath. The precipitate is suction filtered, washed with water and dried. The crude product is purified by chromatography over a silica gel column with petroleum ether/methylene chloride (8:2 to 0:1) as eluant.

Yield: 1.80 g (58 % of theory) Rf value: 0.30 (silica gel, methylene chloride/petroleum ether = 1:1) Mass spectrum (ESI+): m/z = 221, 223 [M+H]+

Example LV
1-chloromethyl-3-trifluoromethyl-3,4-dihydro-isopuinoline 530 mg of N-(1-benzyl-2,2,2-trifluoro-ethyl)-2-chloro-acetamide (prepared by reacting 1-benzyl-2,2,2-trifluoro-ethylamine with chloroacetyl chloride in the presence of triethylamine) and 0.74 ml of phosphorus oxychloride are added to 4.00 g of polyphosphoric acid. The viscous mixture is stirred for 1.5 hours at 130 C. For working up the reaction mixture is cooled and combined with ice water, stirred vigorously for ten minutes and suction filtered. The filter cake is dissolved in ethyl acetate and the solution is dried over magnesium sulphate and evaporated down, leaving a white solid.
Yield: 415 mg (84 % of theory) Rf value: 0.55 (aluminium oxide, petroleum ether/ethyl acetate = 10:1) Mass spectrum (ESI+): m/z = 248, 250 [M+H]+

The following compound is obtained analogously to Example LV:
(1) 1-methyl-3-trifluoromethyl-3,4-dihydro-isoquinoline (The starting material N-(1-benzyl-2,2,2-trifluoro-ethyl)-acetamide is obtained by reacting 1-benzyl-2,2,2-trifluoro-ethylamine with acetic anhydride.) Example LVI
3-bromomethyl-1-(1-cyano-1-methyl-ethyl)-isopuinoline A mixture of 375 mg of 1-(1-cyano-1-methyl-ethyl)-3-methyl-isoquinoline and 321 mg of N-bromosuccinimide in 5 ml carbon tetrachloride is combined with a spatula tip of 2,2-azoisobutyric acid dinitrile and refluxed for about six hours. The cooled reaction mixture is filtered and evaporated down. The flask residue is reacted further without any more purification.
Rf value: 0.70 (silica gel, cyclohexane/ethyl acetate = 3:1) The following compounds are obtained analogously to Example LVI:

(1) 6-bromomethyl-1-[(2-trimethylsilanyl-ethoxy)methyl]-1 H-quinolin-2-one (2) 1-bromomethyl-4-bromo-3-methoxy-isoquinoline (3) 2-bromomethyl-[1,5]naphthyridine Mass spectrum (ESI+): m/z = 223, 225 [M+H]+
(4) 5-bromomethyl-[1,6]naphthyridine Rf value: 0.48 (silica gel, ethyl acetate/methanol = 98:2) (5) 7-bromomethyl-5-phenyl-quinoxaline Rf value: 0.85 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 299, 301 [M+H]+

(6) 4-bromomethyl-[1,5]naphthyridine Rf value: 0.56 (silica gel, methylene chloride/ethyl acetate = 7:3) Mass spectrum (ESI+): m/z = 223, 225 [M+H]+

(7) 1-bromomethyl-3-trifluoromethyl-isoquinoline Mass spectrum (ESI+): m/z = 290, 292 [M+H]+
(8) 1-bromomethyl-3-difuoromethyl-isoquinoline Mass spectrum (ESI+): m/z = 272, 274 [M+H]+

(9) 1-bromomethyl-4-chloro-3-methoxy-isoquinoline Example LVII
1-(1-cyano-1-methyl-ethyl)-3-methyl-isoq uinoline 3.30 g of 2,2-azoisobutyric acid dinitrile are added to 1.60 g of 3-methyl-isoquinoline-N-oxide in 30 ml of toluene. The reaction mixture is stirred for six hours at 85 C and then left to stand for two days at ambient temperature. For working up the reaction mixture is extracted with 20% hydrochloric acid. The combined aqueous phases are diluted with methylene chloride, made alkaline with saturated potassium carbonate solution while cooling with an ice bath and extracted with methylene chloride. The combined methylene chloride extracts are dried over magnesium sulphate and evaporated down. The residue is chromatographed through a silica gel column with cyclohexane as eluant.
Yield: 375 mg (18 % of theory) Mass spectrum (ESI+): m/z = 211 [M+H]+
Rf value: 0.75 (silica gel, cyclohexane/ethyl acetate = 3:1) Example LVIII
1-(2-cyanoimino-2-phenyl-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butvloxvcarbonvlamino)-piperidin-1-yll-xanthine (E/Z-mixture) 0.48 ml of a 1 M solution of titaniium tetrachloride in methylene chloride are added dropwise to 244 mg of 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-6-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine in 7 ml of methylene chloride. Then 88 pl of 1,3-bis(trimethylsilyl)carbodiimide are added and the mixture is stirred for four hours at ambient temperature. For working up the reaction mixture is diluted with methylene chloride and poured onto ice water. The organic phase is washed with 0.5 N citric acid, dried over magnesium sulphate and evaporated down. The crude product is purified by chromatography over a silica gel column with methylene chloride/methanol (98:2 to 95:5) as eluant.
Yield: 206 mg (97 % of theory) Mass spectrum (ESI-): m/z = 557 [M-H]-Rf value: 0.16 (silica gel, cyclohexane/ethyl acetate = 1:1) Example LIX
1-[(1 H-benzoimidazol-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxvcarbonvlamino)-piperidin-1-yll-xanthine 350 mg of 1-[(2-amino-phenylaminocarbonyl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine are refluxed in 3 ml glacial acetic acid for two hours. Then the reaction mixture is evaporated down, the flask residue is combined with 5 ml of 1 M sodium hydroxide solution and washed with methylene chloride. Then the aqueous phase is acidified with 1 M hydrochloric acid and extracted with methylene chloride.
The combined extracts are evaporated down and chromatographed through a silica gel column with cyclohexane/ethyl acetate/methanol (6:4:0 to 5:4:1) as eluant.
Yield: 250 mg of (74 % of theory) Mass spectrum (ESI+): m/z = 547 [M+H]+
Example LX
Ethyl 3,4-dimethyl-6,7-dihydro-5H42lpyrindin-1-carboxylate Prepared by treating 1.16 g of ethyl 3,4-dimethyl-4a-(pyrrolidin-1-yl)-5,6,7,7a-tetrahydro-4aH-[2]pyrindin- 1-carboxylate with 1.08 g of 70 % 3-chloro-perbenzoic acid in 50 ml methylene chloride at ambient temperature.
Yield: 850 mg (97 % of theory) Rf value: 0.30 (aluminium oxide, petroleum ether/ethyl acetate = 5:1) Mass spectrum (ESI+): m/z = 220 [M+H]+

The following compounds are obtained analogously to Example LX:
(1) ethyl 3,4-dimethyl-5,6,7,8-tetrahydro-isoquinoline-1-carboxyl ate Rf value: 0.35 (aluminium oxide, petroleum ether/ethyl acetate = 5:1) Mass spectrum (ESI+): m/z = 234 [M+H]+

Example LXI
Ethyl 3,4-dimethyl-4a-(pyrrolidin-1-yl)-5,6,7,7a-tetrahydro-4aH-[2]pyrindin-l -carboxylate Prepared by reacting 2.50 g of ethyl 5,6-di methyl-[1,2,4]triazin-3-carboxylate with 2.74 g of 1-(cyclopenten-1-yl)-pyrrolidine in 25 ml chloroform at ambient temperature.
Yield: 3.00 g (75 % of theory) Rf value: 0.60 (aluminium oxide, petroleum ether/ethyl acetate = 5:1) Mass spectrum (ESI+): m/z = 291 [M+H]+

The following compounds are obtained analogously to Example LXI:

(1) ethyl 3,4-dimethyl-4a-(pyrrolidin-l-yl)-4a,5,6,7,8,8a-hexahydro-isoquinoline-1-carboxylate Rf value: 0.60 (aluminium oxide, petroleum ether/ethyl acetate = 5:1) Mass spectrum (ESI+): mlz = 305 [M+H]+

Example LXII
Methyl 2 , 3, 8-trimethyl-quinoxalin-6-carboxylate Prepared by reacting 1.60 g of methyl 3,4-diamino-5-methyl-benzoate with 0.86 ml diacetyl in a mixture of water and ethanol while refluxing.
Yield: 1.53 g (80 % of theory) Rf value: 0.63 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 231 [M+H]+

The following compounds are obtained analogously to Example LXII:
(1) methyl 8-methyl-quinoxalin-6-carboxylate (reaction is carried out with glyoxal in water.) Rf value: 0.55 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 203 [M+H]+

(2) 5-bromo-7-methyl-quinoxaline (reaction is carried out with glyoxal in a water/ethanol mixture.) Rf value: 0.75 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 223, 225 [M+H]+

Example LXIII
Methyl 3,4-diamino-5-methyl-benzoate Prepared by reduction of methyl 3-nitro-4-amino-5-methyl-benzoate at a partial hydrogen pressure of 50 psi in the presence of Raney nickel in methanol at ambient temperature.
Rf value: 0.40 (silica gel, tert.-butylmethylether) Example LXIV
Methyl 3-nitro-4-amino-5-methyl-benzoate Prepared by treating 3-nitro-4-acetylamino-5-methyl-benzoic acid with hydrogen chloride gas in methanol at ambient temperature and subsequently heating while refluxing.
Mass spectrum (ESI+): m/z = 211 [M+H]+
Rf value: 0.75 (silica gel, tert.-butylmethylether/acetic acid = 99:1) Example LXV
1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-((E)-1-buten-1-yl)-8-bromo-xanthin e 0.13 ml 35 % hydrogen peroxide solution are added to 290 mg of 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-(1-phenylsulphanyl-butyl)-8-bromo-xanthine in 6 ml hexafluoroisopropanol. The reaction mixture is stirred for one hour at ambient temperature, diluted with methylene chloride and washed with sodium thiosuiphate solution. The organic phase is dried over magnesium sulphate and evaporated down. The flask residue is taken up in 6 ml of toluene and refluxed for eight hours. Then the toluene is distilled off in vacuo and the crude product is purified through a silica gel column with methylene chloride/methanol (100:0 to 95:5) as eluant.
Yield: 104 mg (45 % of theory) Rf value: 0.61 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 417, 419 [M+H]+

The following compounds are obtained analogously to Example LXV:
(1) 3-methyl-7-(3-methyl-1-buten-1-yl)-8-bromo-xanthine Rf value: 0.24 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 313, 315 [M+H]+

Example LXVI
1-methanesulphonyloxymethyl-4-difluoromethoxy-naphthalene Prepared by reacting (4-difluoromethoxy-naphthalen-1-yl)-methanol with methanesulphonic acid chloride in methylene chloride in the presence of triethylamine.
The following compounds are obtained analogously to Example LXVI:
(1) (E)-1-methanesulphonyloxy-3-(2-nitro-phenyl)-2-propene (2) (E)-1-methanesulphonyloxy-3-pentafluorophenyl-2-propene (3) (E)-1-methanesulphonyloxy-3-(2-trifluoromethyl-phenyl)-2-propene (4) (E)-1-methanesulphonyloxy-3-(3-trifluoromethyl-phenyl)-2-propene (5) (E)-1-methanesulphonyloxy-3-(4-trifluoromethyl-phenyl)-2-propene Example LXVII
7-methyl-5phenyl-quinoxaline A mixture of 400 mg of 5-bromo-7-methyl-quinoxaline, 244 mg of phenylboric acid and 100 mg of tetrakis(triphenylphosphine)palladium in 12 ml dioxane, 4 ml of methanol and 3.6 ml 1 M aqueous sodium carbonate solution is refluxed for three hours under an argon atmosphere. Then the reaction mixture is evaporated down and the residue is distributed between ethyl acetate and water. The ethyl acetate phase is separated off, dried over magnesium sulphate and evaporated down. The crude product is purified by chromatography over a silica gel column with cyclohexane/ethyl acetate (85:15 to 70:30) as eluant.
Yield: 390 mg (66% of theory) Rf value: 0.36 (silica gel, petroleum ether/ethyl acetate = 5:1) Mass spectrum (ESI+): m/z = 221 [M+H]+

Example LXVIII
1-methyl-3-trifluoromethyl-isogui noline Prepared by treating 905 mg of 1-chloromethyl-3-trifluoromethyl-3,4-dihydro-isoquinoline with 420 mg of potassium-tert. butoxide in 10 ml of tetrahydrofuran at ambient temperature.
Yield: 755 mg of (98% of theory) Mass spectrum (ESI+): m/z = 212 [M+H]+

The following compounds are obtained analogously to Example LXVIII:
(1) 1-methyl-3-difluoromethyl-isoquinoline (Prepared from 1-methyl-3-trifluoromethyl-3,4-dihydro-isoquinoline) Mass spectrum (ESI+): m/z = 194 [M+H]+

Example LXIX
4-chloro-3-methoxy-1-methyl-isoguinoline Prepared by treating 3-methoxy-1-methyl-isoquinoline with sulphuryl chloride in methylene chloride.
Rf value: 0.30 (silica gel, cyclohexane) Mass spectrum (ESI+): m/z = 208, 210 [M+H]+
Example LXX
3-cyclopropyl-8-bromo-xanthine Prepared by reacting 3-cyclopropyl-xanthine with bromine in the presence of potassium carbonate in acetonitrile at 60 C.
Rf value: 0.65 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 271, 273 [M+H]+
Example LXXI
Ethyl 1,2, 3,4-tetra hydro-phenanth ridi n-6-yl-ca rboxylate Analogously to the method described by Gonsalves et al. (Tetrahedron 1992, 48, 6821) a solution of 3.90 g of ethyl 5,6,7,8-tetrahydro-benzo[1,2,4]triazin-carboxylate (Sagi et al., Heterocycles 1989, 29, 2253) in 20 ml dioxane is refluxed. Then 8.22 g of anthranilic acid and 7.02 g of isoamylnitrite, in each case dissolved in 20 ml dioxane, are simultaneously added dropwise within 25 minutes by means of two dropping funnels. The reaction mixture is refluxed for a further 30 minutes. For working up the cooled deep-brown reaction solution is diluted with 150 ml diethyl ether, washed with 100 ml of 2 N
sodium hydroxide solution and with water, dried over magnesium sulphate and evaporated down. The brown, oily flask residue is chromatographed through a silica gel column with ethyl acetate/petroleum ether (20:80 to 50:50) as eluant.
The product obtained is still somewhat contaminated, but is reacted further without any more purification.
Yield: 380 mg (8 % of theory) Rf value: 0.55 (silica gel, petroleum ether/ethyl acetate = 2:1) Mass spectrum (ESI+): m/z = 256 [M+H]+
Preparation of the final compounds:

Example 1 1,3-dimethyl-7-(2.6-dicyano-benzyl)-8-(3-amino-piperidin-1-yl)-xanthine 129 mg of 3-amino-piperidine-dihydrochioride are added to a mixture of 298 mg of 1,3-dimethyl -7-(2,6-dicyano-benzyl)-8-bromo-xanthine and 420 mg of potassium carbonate in 9 ml of N,N-dimethylformamide. The reaction mixture is stirred for three hours at 80 C. For working up the mixture is diluted with methylene chloride and washed with saturated sodium chloride solution. The organic phase is dried over magnesium sulphate and evaporated down. The crude product is purified by chromatography through a silica gel column with methylene chloride/methanol/conc. methanolic ammonia (95:5:1 to 80:20:1) as eluant.
Yield: 43 mg (14 % of theory) Rf value: 0.67 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 80:20:1) Mass spectrum (ESI+): m/z = 419 [M+H]+

The following compounds are obtained analogously to Example 1:

(1) 1-(2-cyano-ethyl)-3-methyl -7-(2-cyano-benzyl)-8-(3-amino-pi peridin-1-yl)-xanthine Rf value: 0.35 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 433 [M+H]+

Example 2 1-(2-{2-[(ethoxycarbonyl )methoxy]-ph enyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine A solution of 209 mg of 1-(2-{2-[(ethoxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine in 4 ml methylene chloride is combined with 1 ml of trifluoroacetic acid and stirred for half an hour at ambient temperature. For working up the reaction mixture is diluted with methylene chloride and washed with saturated potassium carbonate solution. The organic phase is dried, evaporated down and chromatographed through a silica gel column with methylene chloride/methanol (1:0 to 4:1) as eluant.
Yield: 153 mg of (87 % of theory) Mass spectrum (ESI+): m/z = 553 [M+H]+

The following compounds are obtained analogously to Example 2:

(1) 1-(2-{2-[(aminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine Mass spectrum (ESI+): m/z = 524 [M+H]+

(2) 1-(2-{3-[(methanesulphinyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine Rf value: 0.58 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 100:100:0.1) Mass spectrum (ESI+): m/z = 543 [M+H]+

(3) 1-(1-methyl-2-oxo-2-phenyl-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine Mass spectrum (ESI+): m/z = 465 [M+H]+

(4) 1-(2-phenoxy-ethyl)-3-methyl-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1-yl)-xanthine Rf value: 0.50 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 500 [M+H]+

(5) 1-(2-phenyl-2-oxo-ethyl)-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine Rf value: 0.58 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 80:20:1) Mass spectrum (ESI-): m/z = 435 [M-H]-(6) 1-(2-{3-[(ethoxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-l-yl)-8-(3-amino-piperidin-l-yl)-xanthine Mass spectrum (ESI+): m/z = 553 [M+H]+

(7) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-l-yl)-8-(3-amino-piperidin-l-yl)-xanthine Mass spectrum (ESI+): m/z = 538 [M+H]+

(8) 1-(2-{2-[(dimethylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-l-yl)-8-(3-amino-piperidin-l-yl)-xanthine Mass spectrum (ESI+): m/z = 552 [M+H]+

(9) 1-(2-methoxy-ethyl)-3-methyl -7-(2-cyano-benzyl)-8-(3-amino-piperidin-l-yl)-xanthine Rf value: 0.40 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 438 [M+H]+

(10) 1-methyl-3-[(methoxycarbonyl)methyl]-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1-yl)-xanthine Rf value: 0.40 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 452 [M+H]+

(11) 1-methyl-3-cyanomethyl-7-(2-cyano-benzyl)-8-(3-amino-pi peridin-l-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.20 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 419 [M+H]+

(12) 1-methyl-3-(2-propyn-1-yl)-7-(2-cyano-benzyl)-8-(3-amino-pipe ridin-1-yl)-xanthine Rf value: 0.40 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 418 [M+H]+

(13) 1-{2-[3-(2-oxo-imidazolidin-1-yl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-(3-amino-piperidin-1-yl)-xanthine Rf value: 0.54 (ready-made reversed phase TLC plate (E. Merck), aceton itrile/water/ trifluoroacetic acid = 100:100:0.1) Mass spectrum (ESI+): m/z = 535 [M+H]+

(14) 1-methyl-3-(2-propen-1-yl)-7-(2-cyano-benzyl)-8-(3-amino-piperidin-l-yl)-xanthine Rf value: 0.40 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 420 [M+H]+

(15) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine Mass spectrum (ESI+): m/z = 435 [M+H]+

(16) 1-(2-{2-[(ethylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1 -yl)-xanthine Rf value: 0.50 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/trifluoroacetic acid = 100:100:0.1) Mass spectrum (ESI+): m/z = 522 [M+H]+

(17) 1-methyl-3-phenyl-7-(2-cyano-benzyl)-8-(3-amino-piperidin-l-yl)-xanthine Rf value: 0.40 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 456 [M+H]+

(18) 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-((S)-3-amino-piperidin-1-yl)-xanthine Rf value: 0.50 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:0.1) Mass spectrum (ESI+): m/z = 466 [M+H]+

(19) 1-(2-phenyl-2-oxo-ethyl)-3-cyanomethyl-7-(3-methyl-2-buten-l-yl)-8-(3-amino-piperidin-l-yl)-xanthine Rf value: 0.07 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 476 [M+H]+
(20) 1-[(quinolin-2-yl)methyl]-3-methyl -7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.50 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 474 [M+H]+

(21) 1-[(2-oxo-2H-chromen-4-yl)methyl]-3-methyl -7-(3-methyl -2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Mass spectrum (ESI+): m/z = 491 [M+H]+
Rf value: 0.16 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) (22) 1-[(cinnolin-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1 -yl)-xanthine (1:1 mixture with 1-[(1,4-dihydro-cinnolin-4-yl)methyl]-3-methyl -7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine) (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.49 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 475 [M+H]+

(23) 1-[(1-methyl-2-oxo-1,2-dihydro-quinolin-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Melting point: 178-181 C
Mass spectrum (ESI+): m/z = 504 [M+H]+

(24) 1-[(4-oxo-3,4-dihydro-phthalazin-1-yl)methyl]-3-methyl-7-(3-methyl-2-buten-l-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.06 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) Mass spectrum (ESI+): m/z = 491 [M+H]+

(25) 1-[(quinazolin-4-yl)meth yl]-3-methyl-7-(3-methyl -2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.48 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 475 [M+H]+

(26) 1-[(5-methyl-3-phenyl-isoxazol-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.40 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:0.1) Mass spectrum (ESI+): m/z = 504 [M+H]+

(27) 1-[(isoquinoline-3-yl)methyl]-3-methyl-7-(3-methyl -2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.51 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 474 [M+H]+

(28) 1-[(3-phenyl-[1,2,4]oxadiazol-5-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.23 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:1) Mass spectrum (ESI+): m/z = 491 [M+H]+

(29) 1-[(4-phenyl-pyridin-2-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.51 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 500 [M+H]+

(30) 1-[(5-phenyl-pyridin-2-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.58 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 500 [M+H]+

(31) 1-[(3-methyl-4-oxo-3,4-dihydro-phthalazin-1-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine-hydrochloride (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride;
product precipitated as the hydrochloride) Rf value: 0.55 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:0.1) Mass spectrum (ESI+): m/z = 505 [M+H]+

(32) 1-[2-(3-methylsulphanyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-l-yl)-8-(3-amino-piperidin-1-yl)-xanthine Rf value: 0.34 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 497 [M+H]+

(33) 1-[2-(3-methanesulphinyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-l-yl)-8-(3-amino-piperidin-1-yl)-xanthine Rf value: 0.21 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 513 [M+H]+

(34) 1-[2-(3-methanesulphonyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine Rf value: 0.66 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 529 [M+H]+

(35) 1-[2-(3-carboxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine-hydrochloride (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride;
product precipitated as the hydrochloride) Rf value: 0.54 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 495 [M+H]+

(36) 1-[2-(3-methoxycarbonyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl -2-buten-1-yl)-8-(3-amino-pi peridin-1-yl)-xanthine-hydrochloride (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride;
product precipitated as the hydrochloride) Rf value: 0.47 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 509 [M+H]+

(37) 1-{2-[3-(methyl aminocarbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine-hydrochloride (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride;
product obtained as the hydrochloride) Rf value: 0.53 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 508 [M+H]+

(38) 1-{2-[3-(dim ethyl aminocarbonyl)-phenyl]-2-oxo-ethyl}-3-methyl -7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine-hydrochloride (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride;
product obtained as the hydrochloride) Rf value: 0.53 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 522 [M+H]+

(39) 1-{2-[3-(morpholin-4-yl-carbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine-hydrochloride (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride;
product obtained as the hydrochloride) Rf value: 0.53 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 564 [M+H]+

(40) 1-[2-(2-carboxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-l-yl)-8-(3-amino-piperidin-1-yl)-xanthine-hydrochloride (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride;
product obtained as the hydrochloride) Rf value: 0.53 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 495 [M+H]+

(41) 1-[2-(2-ethoxycarbonyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine-hydrochloride (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride;
product obtained as the hydrochloride) Rf value: 0.41 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 523 [M+H]+

(42) 1-{2-[2-(dimethylaminocarbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine-hydrochloride (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride;
product obtained as the hydrochloride) Rf value: 0.53 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 522 [M+H]+
(43) 1-{2-[2-(morpholin-4-yl-carbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl-2-buten-1-yi)-8-(3-amino-piperidin-1-yl)-xanthine-hydrochloride (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride;
product obtained as the hydrochloride) Rf value: 0.53 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 564 [M+H]+

(44) 1-[2-(2,6-dimethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-l -yl)-8-(3-amino-piperidin-1-yl)-xanthine-hydrochloride (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride;
product obtained as the hydrochloride) Rf value: 0.44 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 511 [M+H]+

(45) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-(2,3-dimethyl-2-buten-l-yl)-8-(3-amino-piperidin-1-yl)-xanthine-hydrochloride (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride;
product obtained as the hydrochloride) Rf value: 0.68 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 465 [M+H]+

(46) 1-((E)-3-phenyl-allyl)-3-methyl-7-(3-methyl -2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.38 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) Mass spectrum (ESI+): m/z = 449 [M+H]+

(47) 1-[(benzo[b]thiophen-3-yl)methyl]-3-methyl -7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.51 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 479 [M+H]+

(48) 1-[(1 H-indol-3-yl)methyl]-3-methyl-7-(3-methyl-2-buten-l-yl)-8-(3-amino-piperidin-1-yl)-xanthine Rf value: 0.48 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 462 [M+H]+

(49) 1-[(biphenyl-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yi)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.30 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) Mass spectrum (ESI+): m/z = 499 [M+H]+

(50) 1-[(1-naphthyl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.56 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 457 [M+H]+

(51) 1-[(1-methyl-2-oxo-l,2-dihydro-quinolin-4-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.40 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 488 [M+H]+

(52) 1-[(quinolin-4-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.52 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 458 [M+H]+

(53) 1-(2-cyclohexyl-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.48 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 457 [M+H]+

(54) 1-(3,3-dimethyl-2-oxo-butyl)-3-methyl -7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.49 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 431 [M+H]+

(55) 1-[(quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.20 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) Mass spectrum (ESI+): m/z = 459 [M+H]+

(56) 1-[(2-methyl-naphthalen-1-yl)methyl]-3-methyl -7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.25 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) Mass spectrum (ESI+): m/z = 471 [M+H]+

(57) 1-({5-[(methoxycarbonyl)methylamino]-isoquinolin-1-yl}methyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.43 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 561 [M+H]+

(58) 1-(2-dimethylamino-2-oxo-ethyl)-3-methyl -7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.38 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 418 [M+H]+

(59) 1-[2-(piperidin-1-yl)-2-oxo-ethyl]-3-methyl-7-(3-meth yl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.35 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 458 [M+H]+

(60) 1-[(2-methyl-1-oxo-l,2-dihydro-isoquinoline-4-yl)methyl]-7-(2-butyn-l-yl)-8-(3-amino-piperidin-l-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.17 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) Mass spectrum (ESI+): m/z = 488 [M+H]+

(61) 1-[(2-methyl-1-oxo-1,2-dihydro-isoquinoline-4-yl)methyl]-7-(3-methyl-2-buten-l -yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.13 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) Mass spectrum (ESI+): m/z = 504 [M+H]+
(62) 1-[(2-methoxy-naphthalen-l-yl)methyl]-3-methyl-7-(2-butyn-1-yi)-8-(3-amino-piperidin-l-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.17 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) Mass spectrum (ESI+): m/z = 487 [M+H]+

(63) 1-[(isoquinolin-l-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.42 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 458 [M+H]+

(64) 1-[(4-methoxy-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-l-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.14 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) Mass spectrum (ESI+): m/z = 487 [M+H]+

(65) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Melting point: 155-158 C
Mass spectrum (ESI+): m/z = 472 [M+H]+

(66) 1-[2-(2,3-dimethoxy-phenyl)-2-oxo-ethyl]-3-meth yl-7-(3-methyl -2-buten-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.40 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 511 [M+H]+
(67) 1-[(5-nitro-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.15 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) Mass spectrum (ESI+): m/z = 502 [M+H]+

(68) 1-[2-(pyrrolidin-1-yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.56 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 444 [M+H]+

(69) 1-[(4-methyl-isoquinoIin-1-yl)methyl]-3-methyl -7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.46 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 472 [M+H]+

(70) 1-[(2-naphthyl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl )-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.20 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) Mass spectrum (ESI+): m/z = 457 [M+H]+

(71) 1-[(4-oxo-3,4-dihydro-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.38 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:0.1) Mass spectrum (ESI+): m/z = 475 [M+H]+
(72) 1-[(quinolin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.15 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) Mass spectrum (ESI+): m/z = 458 [M+H]+

(73) 1-[(4-dimethylamino-naphthalen-l-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.18 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) Mass spectrum (ESI+): m/z = 500 [M+H]+

(74) 1-[(isoquinolin-1-yl)methyl]-3-methyl-7-((E)-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride;
the product still contains approx. 20 % of Z isomer) Rf value: 0.66 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:0.1) Mass spectrum (ESI+): m/z = 460 [M+H]+

(75) 1-[(3-methoxy-naphthalen-2-yl)methyl]-3-methyl-7-(2-butyn-l-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.25 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) Mass spectrum (ESI+): m/z = 487 [M+H]+

(76) 1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Mass spectrum (ESI+): m/z = 509 [M+H]+
(77) 1-[(3-methyl-4-oxo-3,4-dihydro-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.20 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) Mass spectrum (ESI+): m/z = 489 [M+H]+

(78) 1-[2-(3-methyl-2-oxo-2,3-dihydro-benzooxazol-7-yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-l-yi)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.47 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 522 [M+H]+

(79) 1-[2-(benzo[1,3]dioxoI-4-yl)-2-oxo-ethyl]-3-methyl -7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Mass spectrum (ESI+): m/z = 495 [M+H]+

(80) 1-[(quinazolin-2-yl)methyl]-3-methyl -7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Mass spectrum (ESI+): m/z = 459 [M+H]+

(81) 1-[(quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-l-yl)-8-((S)-3-amino-piperidin-l-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Mass spectrum (ESI+): m/z = 459 [M+H]+

(82) 1-[(quinazolin-2-yl)methyl]-3-methyl-7-((E)-2-buten-l-yl)-8-((S)-3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride;
the product still contains approx. 20 % of Z isomer) Rf value: 0.12 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) Mass spectrum (ESI+): m/z = 461 [M+H]+

(83) 1-[(quinazolin-2-yl)methyl]-3-methyl-7-((E)-2-buten-l-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride;
the product still contains approx. 15 % of Z isomer) Rf value: 0.12 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) Mass spectrum (ESI+): m/z = 461 [M+H]+

(84) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl -7-((E)-2-buten-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride;
the product still contains approx. 17 % of Z isomer) Rf value: 0.54 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 474 [M+H]+

(85) 1-[(3-methyl-isoquinolin-l-yl)methyl]-3-methyl-7-((E)-2-buten-1-yl)-8-((S)-3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride;
the product still contains approx. 17 % of Z isomer) Rf value: 0.54 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 474 [M+H]+

(86) 1-(2-{2-[(ethylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-l-yl)-8-((R)-3-amino-piperidin-l-yl)-xanthine Mass spectrum (ESI+): m/z = 536 [M+H]+

(87) 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-[(1-cyclopenten-1-yl)methyl]-8-(3-amino-piperidin-l -yl)-xanthine Mass spectrum (ESI+): m/z = 478 [M+H]+

(88) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-[(1-cyclopenten-1-yl)methyl]-8-(3-amino-piperidin-l-yl)-xanthine Mass spectrum (ESI+): m/z = 463 [M+H]+

(89) 1-(2-{2-[(methyl aminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-[(1-cyclopenten-1-yl)methyl]-8-(3-amino-piperidin-1-yl)-xanthine Mass spectrum (ESI+): m/z = 550 [M+H]+

(90) 1-methyl-3-isopropyl-7-(2-cyano-be nzyl)-8-(3-amino-piperidin-l-yl)-xanthine Rf value: 0.40 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 422 [M+H]+

(91) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine Mass spectrum (ESI+): m/z = 522 [M+H]+

(92) 1-(2-{2-[(ami nocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine Mass spectrum (ESI+): m/z = 508 [M+H]+

(93) 1-[2-(2-cyanomethylamino-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.50 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 505 [M+H]+

(94) 1-(2-{2-[(isopropylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine Rf value: 0.30 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 550 [M+H]+
(95) 1-[(isoquinolin-1-yl)methyl]-3-[(methoxycarbonyl)methyl]-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine Rf value: 0.21 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 532 [M+H]+

(96) 1-[2-(2-acetylamino-phenyl)-2-oxo-ethyl]-3-methyl-7-((E)-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (product contains approx. 10 % of Z isomer) Mass spectrum (ESI+): m/z = 494 [M+H]+

(97) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (product contains approx. 25 % of Z isomer) Rf value: 0.30 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 437 [M+H]+

(98) 1-(2-{2-[(isopropyloxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine Mass spectrum (ESI+): m/z = 567 [M+H]+

(99) 1-(2-{2-[(methyl aminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-l-yl)-xanthine Mass spectrum (ESI+): m/z = 522 [M+H]+

(100) 1-(2-{2-[(isopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (product contains approx. 10 % of Z isomer) Mass spectrum (ESI+): m/z = 522 [M+H]+

(101) 1-(2-{2-[(methyl aminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (product contains approx. 8 % of Z isomer) Rf value: 0.51 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/trifluoroacetic acid = 50:50:0.1) Mass spectrum (ESI+): m/z = 524 [M+H]+

(102) 1-(2-{2-[(ethylaminocarbonyl)methoxy]-phenyl)-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-((S)-3-amino-piperidin-1-yl)-xanthine Mass spectrum (ESI+): m/z = 536 [M+H]+

(103) 1-[2-(2-{[(ethoxycarbonylamino)carbonyl]amino}-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine Mass spectrum (ESI+): m/z = 581 [M+H]+

(104) 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-((E)-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine Rf value: 0.54 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:0.1) Mass spectrum (ESI+): m/z = 452 [M+H]+

(105) 1-[2-(2-acetylamino-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-((S)-3-amino-piperidin-l-yl)-xanthine Rf value: 0.48 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:0.1) Mass spectrum (ESI+): m/z = 508 [M+H]+

(106) 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-l-yl)-8-(3-amino-piperidin-1-yl)-xanthine Rf value: 0.31 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 450 [M+H]+

(107) 1-(2-{2-[(methyl aminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-((S)-3-amino-piperidin-l-yl)-xanthine Mass spectrum (ESI+): m/z = 522 [M+H]+
(108) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-l-yl)-8-((R)-3-amino-piperidin-l-yl)-xanthine (product contains approx. 22 % of Z isomer) Mass spectrum (ESI+): m/z = 437 [M+H]+

(109) 1-(2-{2-[(ethylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine Rf value: 0.40 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 536 [M+H]+

(110) 1-[2-(2-acetylamino-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1 -yl)-8-(3-amino-piperidin-1-yl)-xanthine Rf value: 0.23 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 492 [M+H]+

(111) 1-(2-{2-[2-oxo-2-(pyrrolidin-1 -yl)-ethoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1 -yl)-8-(3-amino-piperidin-1 -yl )-xanthine Rf value: 0.20 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 562 [M+H]+

(112) 1-(2-{2-[(methyl am inocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-l-yl)-8-((S)-3-amino-piperidin-1-yl)-xanthine Mass spectrum (ESI+): m/z = 538 [M+H]+

(113) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-(2-butyn-1 -yl)-8-((R)-3-amino-piperidin-1 -yl)-xanthine Mass spectrum (ESI+): m/z = 435 [M+H]+

(114) 1-(2-{2-[(ethylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-((R)-3-amino-piperidin-l-yl)-xanthine (product contains approx. 30 % of Z isomer) Mass spectrum (ESI+): m/z = 538 [M+H]+

- -------- ---(115) 1-methyl-7-(2-cyano-be nzyl)-8-(3-amino-piperidin-1-yl)-xanthine Mass spectrum (ESI+): m/z = 380 [M+H]+

(116) 1-(2-{2-[(isopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine Rf value: 0.40 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:0.1) Mass spectrum (ESI+): m/z = 536 [M+H]+

(117) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1 -yl)-8-((S)-3-amino-piperidin-1-yl)-xanthine (product contains approx. 23 % of Z isomer) Rf value: 0.42 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:0.1) Mass spectrum (ESI+): m/z = 437 [M+H]+

(118) 1-(2-{2-[(isopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine Rf value: 0.20 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 520 [M+H]+

(119) 1-[2-(2-acetylamino-ph enyl)-2-oxo-ethyl]-3-methyl -7-(2-butyn-1-yl)-8-((S)-3-amino-piperidin-1-yl)-xanthine Rf value: 0.15 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 492 [M+H]+

(120) 1 -(2-{2-[(i so propylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl -7-(2-butyn-l-yl)-8-((S)-3-amino-piperidin-l-yl)-xanthine Mass spectrum (ESI+): m/z = 520 [M+H]+

(121) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-(2-methyl-allyl)-8-(3-amino-piperidin-1-yl)-xanthine Rf value: 0.21 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 437 [M+H]+

(122) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-(3-bromo-allyi)-8-(3-amino-piperidin-1-yl)-xanthine Rf value: 0.14 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 501, 503 [M+H]+

(123) 1-(2-{2-[(methoxycarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine Rf value: 0.42 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:0.1) Mass spectrum (ESI+): m/z = 524 [M+H]+

(124) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-[(furan-2-yl)methyl]-8-(3-amino-piperidin-1-yl)-xanthine Rf value: 0.23 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 463 [M+H]+

(125) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-(2-chloro-allyl)-8-(3-amino-piperidin-1-yl)-xanthine Rf value: 0.18 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) (126) 1-{2-[2-(1-methoxycarbonyl-ethoxy)-phenyl]-2-oxo-ethyl}-3-methyl-7-(2-butyn-l-yl)-8-(3-amino-piperidin-1-yl)-xanthine Mass spectrum (ESI+): m/z = 537 [M+H]+

(127) 1-{2-[2-(1-aminocarbonyl-ethoxy)-phenyl]-2-oxo-ethyl}-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine Mass spectrum (ESI+): m/z = 522 [M+H]+
(128) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-(2-butyn-l-yl)-8-((S)-3-amino-piperidin-1-yl)-xanthine Mass spectrum (ESI+): m/z = 435 [M+H]+

(129) 1-[(3-methyl -isoquinolin-1-yl)methyl]-3-meth yl-7-(2-butyn-1-yl)-8-((S)-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Melting point: 155-156.5 C
Mass spectrum (ESI+): m/z = 472 [M+H]+

(130) 1-[(3-methyl- isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.52 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 472 [M+H]+

(131) 1-[(4-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((S)-3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.46 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 472 [M+H]+

(132) 1-[(4-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.46 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 472 [M+H]+

(133) 1-[(4-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-((E)-2-buten-l-yl)-8-((S)-3-amino-piperidin-l-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.48 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 474 [M+H]+

(134) 1-[(4-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-((E)-2-buten-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Melting point: 167.5-172 C
Mass spectrum (ESI+): m/z = 474 [M+H]+

(135) 1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-2-oxo-ethyl]-3-methyl -7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.34 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 493 [M+H]+

(136) 1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-l-yl)-8-(3-(S)-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Mass spectrum (ESI+): m/z = 493 [M+H]+

(137) 1-[(4-methoxy-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((S)-3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.52 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 487 [M+H]+

(138) 1-[(4-methoxy-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.52 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 487 [M+H]+

(139) 1-[2-(benzo[1, 3]dioxol-4-yl)-2-oxo-ethyl]-3-methyl -7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.41 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 479 [M+H]+

(140) 1-[2-(benzo[1,3]dioxol-4-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-((S)-3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Mass spectrum (ESI+): m/z = 479 [M+H]+

(141) 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(S)-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.51 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 473 [M+H]+

(142) 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-l-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Melting point: 198-202 C
Mass spectrum (ESI+): m/z = 473 [M+H]+

(143) 1-[2-(3-methyl-2-oxo-2,3-dihydro-benzooxazol-4-yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.53 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 522 [M+H]+

(144) 1-(2-{2-[(ethylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-((S)-3-amino-piperidin-1-yl)-xanthine Mass spectrum (ESI+): m/z = 538 [M+H]+

(145) 1-(2-{2-[(isopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-l-yl)-8-((S)-3-amino-piperidin-l-yl)-xanthine Rf value: 0.49 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:0.1) Mass spectrum (ESI+): m/z = 522 [M+H]+

(146) 1-(2-{2-[(ethylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1 -yl)-8-((R)-3-amino-piperidin-1 -yl)-xanthine Mass spectrum (ESI+): m/z = 508 [M+H]+

(147) 1 - [2-(2-acetyl am i no-phenyl)-2-oxo-ethyl]-3-methyl -7-((E)-2-buten-1-yl)-8-((R)-3-amino-pi peridin-1-yl)-xanthine Mass spectrum (ESI+): m/z = 494 [M+H]+

(148) 1-(2-{2-[(methyl aminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine Mass spectrum (ESI+): m/z = 524 [M+H]+

(149) 1-[2-(2-acetylamino-phenyl)-2-oxo-ethyl]-3-methyl-7-((E)-2-buten-1-yl)-8-((S)-3-amino-piperidin-l-yl)-xanthine Rf value: 0.49 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:0.1) Mass spectrum (ESI+): m/z = 494 [M+H]+

(150) 1-(2-{2-[(methyl aminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-((S)-3-amino-piperidin-l-yl)-xanthine Mass spectrum (ESI+): m/z = 524 [M+H]+
(151) 1-(2-{2-[(isopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-l-yl)-xanthine Mass spectrum (ESI+): m/z = 520 [M+H]+

(152) 1-(2-{2-[(isopropylcarbonyl)amino]-phenyl)-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-l-yl)-8-((R)-3-amino-piperidin-l-yl)-xanthine Mass spectrum (ESI+): m/z = 522 [M+H]+

(153) 1-(2-{2-[2-(morpholin-4-yl)-2-oxo-ethoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-l-yl)-8-(3-amino-piperidin-l-yl)-xanthine Mass spectrum (ESI+): m/z = 578 [M+H]+

(154) 1-(2-{2-[(ethylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-l-yl)-8-((S)-3-amino-piperidin-l-yl)-xanthine Rf value: 0.50 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:0.1) Mass spectrum (ESI+): m/z = 508 [M+H]+

(155) 1-(2-{2-[(ethylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-l-yl)-xanthine Mass spectrum (ESI+): m/z = 506 [M+H]+

(156) 1-(2-{2-[(ethylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-((S)-3-amino-piperidin-1-yl)-xanthine Rf value: 0.20 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 506 [M+H]+

(157) 1-[2-(2-acetylamino-ph enyl)-2-oxo-ethyl]-3-methyl -7-(2-butyn-l-yl)-8-((R)-3-a m i n o-p i pe ri d i n-1-yl)-xanth i n e Mass spectrum (ESI+): m/z = 492 [M+H]+

(158) 1-[2-(2-nitro-3-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-l-yl)-8-(3-amino-piperidin-l-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.49 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 526 [M+H]+

(159) 1-(2-{2-[(phenylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1 -yl)-8-(3-amino-piperidin-1-yl)-xanthine Rf value: 0.49 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/trifluoroacetic acid = 50:50:0.1) Mass spectrum (ESI+): m/z = 556 [M+H]+

(160) 1-[(2-acetyl-benzofuran-3-yl)methyl]-3-methyl-7-(2-butyn-l-yi)-8-(3-amino-piperidin-1-yl)-xanthine (Obtained as main product when 1-{2-[2-(2-oxo-propoxy)-phenyl]-2-oxo-ethyl}-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine is treated with trifluoroacetic acid in methylene chloride) Mass spectrum (ESI+): m/z = 489 [M+H]+

(161) 1-{2-[2-(1-ethoxycarbonyl-1-methyl-ethoxy)-phenyl]-2-oxo-ethyl}-3-methyl-7-(2-butyn-l-yl)-8-(3-amino-piperidin-1-yl)-xanthine Mass spectrum (ESI+): m/z = 565 [M+H]+

(162) 1-[2-(2-amino-3-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-l-yl)-8-(3-amino-piperidin-l-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.38 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 496 [M+H]+

(163) 1-[(4-dimethylamino-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine Rf value: 0.30 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:0.1) Mass spectrum (ESI+): m/z = 502 [M+H]+
(164) 1-[2-(2-oxo-2,3-dihydro-benzooxazol-7-yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine Rf value: 0.42 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 508 [M+H]+

(165) 1-(2-{2-[(ethoxycarbonyl)methylamino]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-((R)-3-amino-piperidin-l-yl)-xanthine Rf value: 0.51 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:0.1) Mass spectrum (ESI+): m/z = 538 [M+H]+
(166) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-((Z)-2-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yi)-xanthine Rf value: 0.29 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 451 [M+H]+
(167) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-((E)-2-methyl-2-buten-l-yl)-8-(3-amino-piperidin-1-yl)-xanthine Rf value: 0.59 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 80:20:1) Mass spectrum (ESI+): m/z = 451 [M+H]+
(168) 1-[(imidazo[1,2-a]pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.47 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 447 [M+H]+
(169) 1-[(quinoxalin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.50 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 459 [M+H]+
(170) 1-[2-(1,3-dimethyl-2-oxo-2,3-dihydro-1 H-benzoimidazol-4-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.55 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 519 [M+H]+
(171) 1-[(quinoxalin-6-yl)methyl]-3-methyl -7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Mass spectrum (ESI+): m/z = 459 [M+H]+
(172) 1-[(2-cyano-benzofuran-3-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine Mass spectrum (ESI+): m/z = 472 [M+H]+
(173) 1-[2-(2-oxo-2,3-dihydro-benzooxazol-4-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine Mass spectrum (ESI+): m/z = 492 [M+H]+
Rf value: 0.47 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) (174) 1-[(3-methyl-quinoxalin-2-yl)methyl]-3-methyl -7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine Melting point: 188.5-191 C
Mass spectrum (ESI+): m/z = 473 [M+H]+
(175) 1-[(3-phenyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.45 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 534 [M+H]+
(176) 1-(2-{2-[(methanesulphinyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-l-yl)-8-(3-amino-piperidin-l-yl)-xanthine x trifluoroacetic acid Mass spectrum (ESI+): m/z = 527 [M+H]+
(177) 1-[(benzofuran-3-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine (Produced when 1-{[2-(tert.-butylcarbonyl)-benzofuran-3-yl]methyl}-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine is treated with trifluoroacetic acid in methylene chloride) Mass spectrum (ESI+): m/z = 447 [M+H]+
(178) 1-[(3,4-dimethyl-isoquinolin-l-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine-hydrochloride (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.75 (aluminium oxide, methylene chloride/methanol = 10:1) Mass spectrum (ESI+): m/z = 486 [M+H]+
(179) 1-[(benzofuran-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine Mass spectrum (ESI+): m/z = 447 [M+H]+
(180) 1-{[4-(morpholin-4-yl)-quinazolin-2-yl]methyl}-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.45 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:0.1) Mass spectrum (ESI+): m/z = 544 [M+H]+
(181) 1-{[4-(piperidin-1-yl)-quinazolin-2-yl]methyl}-3-methyl-7-(2-butyn-1-yl)-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.55 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:0.1) Mass spectrum (ESI+): m/z = 542 [M+H]+
(182) 1-{[4-(piperazin-1-yl)-quinazolin-2-yl]methyl}-3-methyl-7-(2-butyn-l-yl)-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.23 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:0.1) Mass spectrum (ESI+): m/z = 543 [M+H]+
(183) 1-{[4-(pyrrolidin-1-yl)-quinazolin-2-yl]methyl}-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.50 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:0.1) Mass spectrum (ESI+): m/z = 528 [M+H]+
(184) 1-[2-(3-methyl-2-oxo-2,3-dihydro-1 H-benzoimidazol-4-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-l-yl)-8-(3-amino-piperidin-l-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.43 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 505 [M+H]+
(185) 1-[(4-cyano-naphthalen-1-yl)methyl]-3-methyl -7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-l-yl)-xanthine Rf value: 0.27 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 482 [M+H]+
(186) 1-[(imidazo[1,2-a]pyridine-3-yl)methyl] -3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.37 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 447 [M+H]+
(187) 1-[(8-methyl-imidazo[1,2-a]pyridin-2-yl)methyl]-3-methyl -7-(2-butyn-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.46 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 461 [M+H]+
(188) 1-[(4-amino-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-l -yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.40 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:0.1) Mass spectrum (ESI+): m/z = 474 [M+H]+
(189) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-((Z)-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine Mass spectrum (ESI+): m/z = 437 [M+H]+
(190) 1-[(8-methoxy-quinolin-5-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine x 2 trifluoroacetic acid Rf value: 0.45 (silica gel, methylene chloride/methanol = 5:1) Mass spectrum (ESI+): m/z = 488 [M+H]+
(191) 1-[(5-methoxy-quinolin-8-yl)methyl]-3-methyl-7-(2-butyn-l-yl)-8-(3-amino-piperidin-l-yl)-xanthine x trifluoroacetic acid Rf value: 0.20 (silica gel, ethyl acetate/methanol = 1:1) Mass spectrum (ESI+): m/z = 488 [M+H]+
(192) 1-[(4-phenyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-l-yi)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.60 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 535 [M+H]+
(193) 1-[(7-methyl-imidazo[1,2-a]pyridin-2-yl)methyl] -3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.48 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 461 [M+H]+
(194) 1-[(2-cyclopropyl-quinazolin-4-yl)methyl]-3-methyl-7-[(1-cyclopenten-1-yl)methyl]-8-(3-amino-piperidin-l-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.55 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 527 [M+H]+
(195) 1-(2-oxo-4-phenyl-butyl)-3-methyl-7-(2-butyn-l-yl)-8-((R)-3-amino-piperidin-l-yl)-xanthine x trifluoroacetic acid Mass spectrum (ESI+): m/z = 463 [M+H]+
(196) 1-(2-{2-[(methylaminocarbonyl)methylamino]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-l-yl)-8-((R)-3-amino-piperidin-l-yl)-xanthine Rf value: 0.52 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:0.1) Mass spectrum (ESI+): m/z = 523 [M+H]+
(197) 1-[2-(2-oxo-2,3-dihydro-1 H-benzoimidazol-4-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-l-yl)-8-(3-amino-piperidin-l-yl)-xanthine Rf value: 0.40 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 491 [M+H]+
(198) 1-[(3-difluoromethyl-isoquinolin-1-yl)methyl] -3-methyl-7-(2-butyn-l-yl)-(3-amino-piperidin-l-yl)-xanthine x trifluoroacetic acid Rf value: 0.75 (silica gel, methylene chloride/methanol = 10:1) Mass spectrum (ESI+): m/z = 508 [M+H]+
(199) 1-[2-(2,2-difluoro-benzo[1,3]dioxol-4-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-l-yl)-8-((R)-3-amino-piperidin-l-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.80 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 96:4:0.5) Mass spectrum (ESI+): m/z = 515 [M+H]+
(200) 1-[(3-methyl-imidazo[1,2-a]pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine Rf-Wet: 0.45 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 461 [M+H]+
(201) 1-[2-(2,2-difluoro-benzo[1,3]dioxol-4-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-((S)-3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Mass spectrum (ESI+): m/z = 515 [M+H]+
(202) 1-[(5-methyl-imidazo[1,2-a]pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-l -yl)-8-(3-amino-piperidin-l-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.53 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 461 [M+H]+
(203) 1-[(6-methyl-imidazo[1,2-a]pyridin-2-yl)methyl]-3-methyl -7-(2-butyn-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Melting point: 176.5-178 C
Mass spectrum (ESI+): m/z = 461 [M+H]+
(204) 1-[(3-benzyl-imidazo[1,2-a]pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Melting point: 201-204 C
Mass spectrum (ESI+): m/z = 537 [M+H]+
(205) 1-[(4-isopropyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-l-yl)-8-(3-amino-piperidin-l-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.50 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:0.1) Mass spectrum (ESI+): m/z = 501 [M+H]+
(206) 1-[(2,3-dihydro-benzo[1,4]dioxin-6-yl)methyl]-3-methyl-7-(2-butyn-l-yl)-8-(3-amino-piperidin-l-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.65 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 465 [M+H]+
(207) 1-[(1-methyl-1 H-indol-2-yl)methyl]-3-methyl-7-(2-butyn-1 -yl)-8-(3-amino-piperidin-1-yl)-xanthine-hydrochloride (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.60 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 460 [M+H]+
(208) 1-[(quinolin-3-yl)methyl] -3-methyl-7-(2-butyn-l-yl)-8-(3-amino-pi peridin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.50 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:0.1) Mass spectrum (ESI+): m/z = 458 [M+H]+
(209) 1-[(3-phenyl-imidazo[1,2-a]pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.50 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 523 [M+H]+
(210) 1-[(1 H-indol-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine-hydrochloride Rf value: 0.55 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 446 [M+H]+
(211) 1 -[2 -(naphtha le n - 1 -yl)-2-oxo-ethyl]-3-m ethyl -7-(2-butyn- 1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.60 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 485 [M+H]+
(212) 1-[(5-methoxy-isoquinolin-8-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine x trifluoroacetic acid Rf value: 0.50 (silica gel, methylene chloride/methanol = 5:1) Mass spectrum (ESI+): m/z = 488 [M+H]+
(213) 1-{[1-(1-cyano-1-methyl-ethyl)-isoquinolin-3-yl]methyl}-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.25 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 525 [M+H]+
(214) 1-(2-cyanoimino-2-phenyl-ethyl)-3-methyl -7-(2-butyn-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine x trifluoroacetic acid (E/Z-mixture) Mass spectrum (ESI+): m/z = 459 [M+H]+
(215) 1-[(1 H-benzoimidazol-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine x trifluoroacetic acid Mass spectrum (ESI+): m/z = 447 [M+H]+
(216) 1-[(1-methyl-1 H-benzoimidazol-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine Mass spectrum (ESI+): m/z = 461 [M+H]+
(217) 1-[(4-phenyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-l-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Mass spectrum (ESI+): m/z = 535 [M+H]+
(218) 1-[(2,3-dimethyl-quinoxaIin-6-yl)methyl]-3-methyl -7-(2-butyn-l -yl)-8-(3-amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.50 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:0.1) Mass spectrum (ESI+): m/z = 487 [M+H]+
(219) 1-[(2-methyl-1 H-benzoimidazol-5-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1 -yl)-xanthine Rf value: 0.35 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:0.1) Mass spectrum (ESI+): m/z = 461 [M+H]+
(220) 1-[(4-phenyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-l-yl)-8-((S)-3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Mass spectrum (ESI+): m/z = 535 [M+H]+
(221) 1-[2-(quinolin-8-yl-]-2-oxo-ethyl]-3-methyl-7-(2-butyn-l-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.48 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 486 [M+H]+
(222) 1-[(3,4-dimethyl-6,7-dihydro-5H-[2]pyridin-l-yl)methyl]-3-methyl-7-(2-butyn-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine x trifluoroacetic acid Rf value: 0.25 (aluminium oxide, methylene chloride/methanol = 20:1) Mass spectrum (ESI+): m/z = 476 [M+H]+
(223) 1-[(3,4-dimethyl-5,6,7,8-tetrahydro-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-l-yl)-8-(3-amino-piperidin-l-yl)-xanthine x trifluoroacetic acid Rf value: 0.50 (aluminium oxide, methylene chloride/methanol = 20:1) Mass spectrum (ESI+): m/z = 490 [M+H]+
(224) 1-[2-(1 H-indol-4-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine Rf value: 0.52 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 474 [M+H]+
(225) 1-[(1 H-benzoimidazol-5-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine Rf value: 0.50 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 447 [M+H]+
(226) 1-[(pyrazolo[1,5-a]pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.47 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 447 [M+H]+
(227) 1-[(1-methyl-2-oxo-1,2-dihydro-quinolin-6-yl)methyl] -3-meth yl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.40 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 488 [M+H]+
(228) 1-[(2-oxo-1,2-dihydro-quinolin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine Rf value: 0.23 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 474 [M+H]+
(229) 1-[(2,3,8-trimethyl-quinoxalin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.37 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 501 [M+H]+
(230) 1-[(8-methyl-quinoxalin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.35 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 473 [M+H]+
(231) 1-[(4-methyl-phthalazin-1-yl)methyl] -3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.55 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 473 [M+H]+
(232) 1-[(4-bromo-3-methoxy-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.40 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 566, 568 [M+H]+
(233) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-((E)-1-buten-l-yl)-8-(3-amino-piperidin-1-yl)-xanthine Rf value: 0.31 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 437 [M+H]+
(234) 1-[(4-d ifluoromethoxy-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine Rf value: 0.08 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:1) Mass spectrum (ESI+): m/z = 523 [M+H]+
(235) 1-[2-(1 H-indol-7-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine x trifluoroacetic acid Rf value: 0.46 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 474 [M+H]+
(236) 1-[(E)-3-(2-nitro-phenyl)-2-propen-1-yl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine Mass spectrum (ESI+): m/z = 478 [M+H]+
(237) 1-((E)-3-pentafluorophenyl-2-propen-1-yl)-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine Mass spectrum (ESI+): m/z = 523 [M+H]+
(238) 1-[(4-nitro-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine Rf value: 0.38 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 502 [M+H]+
(239) 1-{[1-(2-cyano-ethyl)-1 H-benzoimidazol-2-yl]methyl}-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine-hydrochloride (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.55 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:0.1) Mass spectrum (ESI+): m/z = 500 [M+H]+
(240) 1-({1-[(methylaminocarbonyl)methyl]-1 H-benzoimidazol-2-yl}methyl)-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine x trifluoroacetic acid Mass spectrum (ESI+): m/z = 518 [M+H]+
(241) 1-[(1-benzyl-1 H-benzoimidazol-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine Rf value: 0.47 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:0.1) Mass spectrum (ESI+): m/z = 537 [M+H]+
(242) 1-[(benzooxazol-2-y)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine x trifluoroacetic acid Rf value: 0.50 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:0.1) Mass spectrum (ESI+): m/z = 448 [M+H]+
(243) 1-[(5-nitro-benzooxazol-2-y)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine Rf value: 0.49 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:0.1) Mass spectrum (ESI+): m/z = 493 [M+H]+
(244) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(3-methyl-1-buten-1-yl)-8-((R)-3-amino-piperidin-l-yl)-xanthine Rf value: 0.21 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 488 [M+H]+
(245) 1-[(quinolin-7-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.55 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 458 [M+H]+
(246) 1-[([1,5]naphthyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-l-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.51 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 459 [M+H]+
(247) 1-[(8-methyl-quinoxalin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.49 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 473 [M+H]+
(248) 1-[(2,3,8-trimethyl-quinoxalin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-l-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.46 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 501 [M+H]+
(249) 1-[([1,6]naphthyridin-5-yl)methyl]-3-methyl-7-(2-butyn-l-yl)-8-(3-amino-piperidin-l-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.50 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 459 [M+H]+
(250) 1-[([1,8]naphthyridin-2-yl)methyl]-3-methyl-7-(2-butyn-l-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.45 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 459 [M+H]+
(251) 1-[(4-fluoro-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-l-yl)-8-((R)-3-amino-piperidin-l-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.50 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 475 [M+H]+
(252) 1-[([1,5]naphthyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Mass spectrum (ESI+): m/z = 459 [M+H]+
(253) 1-[2-(3-methyl-2-oxo-2,3-dihydro-benzooxazol-4-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Melting point: 187-189 C
Mass spectrum (ESI+): m/z = 506 [M+H]+
(254) 1-[(8-phenyl-quinoxalin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.50 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 535 [M+H]+
(255) 1-[([1,5]naphthyridine-4-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.52 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 459 [M+H]+
(256) 1-((E)-3-pentafluorophenyl-allyl)-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine Mass spectrum (ESI+): m/z = 523 [M+H]+
(257) 1-[(E)-3-(2-trifluoromethyl-phenyl)-allyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine Mass spectrum (ESI+): m/z = 501 [M+H]+
(258) 1-[(E)-3-(3-trifluoromethyl-phenyl)-allyl]-3-methyl-7-(2-butyn-l -yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine Mass spectrum (ESI+): m/z = 501 [M+H]+
(259) 1-[(E)-3-(4-trifluoromethyl-phenyl)-allyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine Mass spectrum (ESI+): m/z = 501 [M+H]+
(260) 1-[(3-trifluoromethyl-isoquinolin-l-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-((R)-3-amino-piperidin-l-yl)-xanthine x trifluoroacetic acid Mass spectrum (ESI+): m/z = 526 [M+H]+
(261) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-isopropyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (262) 1-[(3-methyl-isoquinolin-1-yl)methyl] -3-(4-fluorophenyl)-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (263) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.51 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 535 [M+H]+
(264) 1-[(3-d ifluoromethyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-((R)-3-amino-piperidin-l-yl)-xanthine Mass spectrum (ESI+): m/z = 508 [M+H]+
(265) 1-[(4-chloro-3-methoxy-isoquinolin-l-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Mass spectrum (ESI+): m/z = 522, 524 [M+H]+
Rf value: 0.40 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) (266) 1-[(4-ethoxy-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 1 M ethereal hydrochloric acid) Rf value: 0.60 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 503 [M+H]+
(267) 1-[(4-isopropyloxy-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.55 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 517 [M+H]+
(268) 1-[(2-methyl-benzothiazol-6-yl)methyl]-3-methyl-7-(2-butyn-l -yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Melting point: 167 C
Mass spectrum (ESI+): m/z = 478 [M+H]+
(269) 1-[(3-phenyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.45 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 534 [M+H]+
(270) 1-[(4-phenyloxy-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.60 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 551 [M+H]+
(271) 1-[(4-phenyl-quinazolin-2-yl)methyl]-3-cyclopropyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.45 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 561 [M+H]+
(272) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-cyclopropyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.55 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 498 [M+H]+
(273) 1-[(2-phenyl-quinazolin-4-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.50 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 535 [M+H]+
(274) 1-[2-(2-methoxy-phenyl)-2-oxo-ethyl]-3-methyl -7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.29 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 465 [M+H]+
(275) 1-[2-(3-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.27 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 465 [M+H]+
(276) 1-[2-(3-trifluoromethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.29 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 519 [M+H]+
(277) 1-[2-(biphenyl-2-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.35 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 511 [M+H]+
(278) 1-[2-(biphenyl-3-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.35 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 511 [M+H]+
(279) 1-[2-(3-isopropyloxy-phenyl)-2-oxo-ethyl]-3-methyl -7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.20 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 493 [M+H]+
(280) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-cyclopropyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.50 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 498 [M+H]+
(281) 1-[(4-phenyl-quinazolin-2-yl)methyl]-3-cyclopropyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-l-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.45 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 561 [M+H]+
(282) 1-[(4-cyano-naphthalen-1-yl)methyl]-3-cyclopropyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Melting point: 191 C
Mass spectrum (ESI+): m/z = 508 [M+H]+
(283) 1-[2-(2-phenyloxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.40 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 527 [M+H]+
(284) 1-[2-(3-ethoxy-phenyl)-2-oxo-ethyl]-3-methyl -7-(2-butyn-l-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.29 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 479 [M+H]+
(285) 1-[2-(3-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.28 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 465 [M+H]+
(286) 1-[2-(2-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-l-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.34 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 465 [M+H]+
(287) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl -7-(2-chloro-benzyl)-8-((R)-3-amino-piperidin-l-yl)-xanthine Mass spectrum (ESI+): m/z = 544, 546 [M+H]+
(288) 1-[(3-methyl-isoquinolin-l-yl)methyl]-3-methyl-7-(2-bromo-benzyl)-8-((R)-3-amino-piperidin-l-yl)-xanthine Mass spectrum (ESI+): m/z = 588, 590 [M+H]+
(289) 1-[(1,2,3,4-tetrahydro-phenanthrid in-6-yl)methyl] -3-methyl-7-(2-butyn-yl)-8-(3-amino-piperidin-1-yl)-xanthine x trifluoroacetic acid Rf value: 0.75 (aluminium oxide, methylene chloride/methanol = 10:1) Mass spectrum (ESI+): m/z = 512 [M+H]+
(290) 1-[2-(3-difluoromethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.28 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 501 [M+H]+
(291) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-ethynyl-benzyl)-8-((R)-3-amino-piperidin-l-yl)-xanthine (292) 1-[(3-methyl-isoquinolin-l-yl)methyl]-3-phenyl-7-(2-butyn-l-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (293) 1-[(phenanthren-9-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (294) 1-[(4-methyl-quinazolin-2-yl)methyl] -3-methyl-7-(2-chloro-benzyl)-8-((R)-3-amino-piperidin-1-yl)-xanthine Rf value: 0.35 (silica gel, methylene chloride/methanol/triethylamine =
90:10:1) Mass spectrum (ESI+): m/z = 545, 547 [M+H]+
(295) 1-[(4-phenyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-chloro-benzyl)-8-((R)-3-amino-piperidin-l-yl)-xanthine Rf value: 0.40 (silica gel, methylene chloride/methanol/triethylamine 90:10:1) Mass spectrum (ESI+): m/z = 607, 609 [M+H]+
Example 3 1-[2-(3-carboxymethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-vl)-8-(3-amino-piperidin-1-yl)-xanthine Prepared by saponifying 70 mg of 1-(2-{3-[(methoxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl -7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperid in-1-yl)-xanthine with 0.10 ml of 4 M potassium hydroxide solution in a mixture of 1 ml of tetrahydrofuran and 0.5 ml of methanol at ambient temperature.
Yield: 57 mg (84 % of theory) Rf value: 0.55 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:0.1) Mass spectrum (ESI+): m/z = 525 [M+H]+

The following compounds are obtained analogously to Example 3:

(1) 1-[2-(2-carboxymethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-l-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with sodium hydroxide solution) Mass spectrum (ESI-): m/z = 523 [M-H]-Example 4 Coated tablets containing 75 mg of active substance 1 tablet core contains:
active substance 75.0 mg calcium phosphate 93.0 mg corn starch 35.5 mg polyvinylpyrrolidone 10.0 mg hydroxypropylmethylcellulose 15.0 mg magnesium stearate 1.5 mg 230.0 mg Preparation:
The active substance is mixed with calcium phosphate, corn starch, polyvin-ylpyrrolidone, hydroxypropylmethylcellulose and half the specified amount of magnesium stearate. Blanks 13 mm in diameter are produced in a tablet-making machine and these are then rubbed through a screen with a mesh size of 1.5 mm using a suitable machine and mixed with the rest of the magnesium stearate. This granulate is compressed in a tablet-making machine to form tablets of the desired shape.
Weight of core: 230 mg die: 9 mm, convex The tablet cores thus produced are coated with a film consisting essentially of hydroxypropylmethylcellulose. The finished film-coated tablets are polished with beeswax.
Weight of coated tablet: 245 mg.
Example 5 Tablets containing 100 mg of active substance Composition:
1 tablet contains:
active substance 100.0 mg lactose 80.0 mg corn starch 34.0 mg polyvinylpyrrolidone 4.0 mg magnesium stearate 2.0 mg 220.0 mg Method of Preparation:
The active substance, lactose and starch are mixed together and uniformly moistened with an aqueous solution of the polyvinylpyrrolidone. After the moist composition has been screened (2.0 mm mesh size) and dried in a rack-type drier at 50 C it is screened again (1.5 mm mesh size) and the lubricant is added. The finished mixture is compressed to form tablets.
Weight of tablet: 220 mg Diameter: 10 mm, biplanar, facetted on both sides and notched on one side.

Example 6 Tablets containing 150 mg of active substance Composition:
1 tablet contains:
active substance 150.0 mg powdered lactose 89.0 mg corn starch 40.0 mg colloidal silica 10.0 mg polyvinylpyrrolidone 10.0 mg magnesium stearate 1.0 mg 300.0 mg Preparation:
The active substance mixed with lactose, corn starch and silica is moistened with a 20% aqueous polyvinylpyrrolidone solution and passed through a screen with a mesh size of 1.5 mm. The granules, dried at 45 C, are passed through the same screen again and mixed with the specified amount of magnesium stearate. Tablets are pressed from the mixture.

Weight of tablet: 300 mg die: 10 mm, flat Example 7 Hard gelatine capsules containing 150 mg of active substance 1 capsule contains:
active substance 150.0 mg corn starch (dried approx. 80.0 mg lactose (powdered) approx. 87.0 mg magnesium stearate 3.0 mg approx. 420.0 mg Preparation:
The active substance is mixed with the excipients, passed through a screen with a mesh size of 0.75 mm and homogeneously mixed using a suitable apparatus. The finished mixture is packed into size 1 hard gelatine capsules.
Capsule filling: approx. 320 mg Capsule shell: size 1 hard gelatine capsule.
Example 8 Suppositories containing 150 mg of active substance 1 suppository contains:
active substance 150.0 mg polyethyleneglycol 1500 550.0 mg polyethyleneglycol 6000 460.0 mg polyoxyethylene sorbitan monostearate 840.0 mg 2,000.0 mg Preparation:
After the suppository mass has been melted the active substance is homogeneously distributed therein and the melt is poured into chilled moulds.
Example 9 Suspension containing 50 mg of active substance 100 ml of suspension contain:
active substance 1.00 g carboxymethylcellulose-Na-salt 0.10 g methyl p-hydroxybenzoate 0.05 g propyl p-hydroxybenzoate 0.01 g glucose 10.00 g glycerol 5.00 g 70% sorbitol solution 20.00 g flavouring 0.30 g dist. water ad 100 ml Preparation:
The distilled water is heated to 70 C. The methyl and propyl p-hydroxybenzoates together with the glycerol and sodium salt of carboxymethylcellulose are dissolved therein with stirring. The solution is cooled to ambient temperature and the active substance is added and homogeneously dispersed therein with stirring. After the sugar, the sorbitol solution and the flavouring have been added and dissolved, the suspension is evacuated with stirring to eliminate air.
ml of suspension contain 50 mg of active substance.
Example 10 Ampoules containing 10 mq active substance Composition:
active substance 10.0 mg 0.01 N hydrochloric acid q.s.
double-distilled water ad 2.0 ml Preparation:

The active substance is dissolved in the necessary amount of 0.01 N HCl, made isotonic with common salt, filtered sterile and transferred into 2 ml ampoules.

Example 11 Ampoules containing 50 mg of active substance Composition:
active substance 50.0 mg 0.01 N hydrochloric acid q.s.
double-distilled water ad 10.0 ml Preparation:
The active substance is dissolved in the necessary amount of 0.01 N HCI, made isotonic with common salt, filtered sterile and transferred into 10 ml ampoules.

Claims (42)

CLAIMS:
1. A compound of general formula I
wherein R1 denotes a 2-quinazolinylmethyl, 4-methyl-2-quinazolinylmethyl or 4-quinazolinylmethyl group, R2 denotes a methyl group and R3 denotes a 2-buten-1-yl or a 2-butyn-1-yl group, a tautomer, enantiomer, diastereomer, mixture thereof or salt thereof.
2. The compound according to claim 1, a tautomer, enantiomer, diastereomer, mixture thereof or salt thereof, wherein R3 denotes a 2-butyn-1-yl group.
3. The compound:
1-[(quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine, 1-[(quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((S)-3-amino-piperidin-1-yl)-xanthine, 1-[(quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(S)-amino-piperidin-1-yl)-xanthine, or 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, a tautomer, enantiomer, diastereomer, mixture thereof or salt thereof.
4. The compound:

1 -[(quinazolin-2-yl)methyl]-3-methyl-7-((E)-2-buten-1-yl)-8-((S)-3-amino-piperidin-1-yl)-xanthine, or 1-[(quinazolin-2-yl)methyl]-3-methyl-7-((E)-2-buten-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine, a tautomer, enantiomer, diastereomer, mixture thereof or salt thereof.
5. A compound of general formula I according to claim 1 wherein R1 denotes a 4-methyl-2-quinazolinylmethyl group R2 denotes a methyl group and R3 denotes a 2-butyn-1-yl group, or a salt thereof.
6. A compound according to claim 5 which is of formula or a physiologically acceptable salt thereof.
7. The compound:
1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, or a salt thereof.
8. The compound:
1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1 -yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine.
9. Physiologically acceptable salt of:

a compound as defined in claim 1, 2, 3 or 4, a tautomer, enantiomer, diastereomer or mixture thereof; or a compound as defined in claim 5 or 6, with an inorganic or organic acid or base.
10. Physiologically acceptable salt of the compound 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, with an inorganic or organic acid.
11. A pharmaceutical composition containing:

a compound as defined in claim 1, 2, 3 or 4, a tautomer, enantiomer, diastereomer, mixture thereof or salt thereof;

a compound as defined in claim 5 or a salt thereof;

a compound as defined in claim 6 or a physiologically acceptable salt thereof;

the compound 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine; or a physiologically acceptable salt as defined in claim 9 or 10, together with one or more inert carriers and/or diluents.
12. A pharmaceutical composition containing the compound 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, or a physiologically acceptable salt of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine with an inorganic or organic acid, together with one or more inert carriers and/or diluents.
13. A pharmaceutical composition containing the compound 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine together with one or more inert carriers and/or diluents.
14. Use of:

a compound as defined in claim 1, 2, 3 or 4, a tautomer, enantiomer, diastereomer, mixture thereof or salt thereof;

a compound as defined in claim 5 or a salt thereof;

a compound as defined in claim 6 or a physiologically acceptable salt thereof;

the compound 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine; or a physiologically acceptable salt as defined in claim 9 or 10 for preparing a pharmaceutical composition for use in the treatment of type I or type II diabetes mellitus, arthritis, obesity, allograft transplantation or calcitonin-induced osteoporosis.
15. Use of the compound 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine or a physiologically acceptable salt of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine with an inorganic or organic acid for preparing a pharmaceutical composition for use in the treatment of type II diabetes mellitus or obesity.
16. Use of the compound 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine for preparing a pharmaceutical composition for use in the treatment of type II diabetes mellitus.
17. A pharmaceutical composition according to claim 11, 12 or 13 for use in the treatment of type I or type II diabetes mellitus, arthritis, obesity, allograft transplantation or calcitonin-induced osteoporosis.
18. A pharmaceutical composition according to claim 11, 12 or 13 for use in the treatment of obesity.
19. A pharmaceutical composition according to claim 11, 12 or 13 for use in the treatment of type II diabetes mellitus.
20. A pharmaceutical composition according to claim 11, 12, 13, 17, 18 or 19, which is an oral dosage form.
21. A pharmaceutical composition according to claim 20, wherein the oral dosage form is a tablet.
22. Use of:

a compound as defined in claim 1, 2, 3 or 4, a tautomer, enantiomer, diastereomer, mixture thereof or salt thereof;

a compound as defined in claim 5 or a salt thereof;

a compound as defined in claim 6 or a physiologically acceptable salt thereof;

the compound 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine; or a physiologically acceptable salt as defined in claim 9 or 10 for the treatment of type I or type II diabetes mellitus, arthritis, obesity, allograft transplantation or calcitonin-induced osteoporosis.
23. Use of the compound 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-l-yl)-xanthine or a physiologically acceptable salt of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine with an inorganic acid or base, for the treatment of type II diabetes mellitus or obesity.
24. Use of the compound 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine for the treatment of type II diabetes mellitus.
25. Use of the compound 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine for the treatment of obesity.
26. Use according to claim 22, 23, 24 or 25 in combination with an antidiabetic, lipid lowering agent, HDL-raising compound, a substance for the treatment of obesity, or a drug for the treatment of high blood pressure.
27. Use according to claim 22, 23 or 24 in combination with another compound which is an antidiabetic, for the treatment of type II diabetes mellitus.
28. Use according to claim 22, 23 or 24 in combination with metformin, a sulphonylurea, nateglinide, repaglinide, a thiazolidinedione, a PPAR-gamma-agonist, an alpha-glucosidase inhibitor, insulin or an insulin analogue, or GLP-1 or a GLP-1 analogue for the treatment of type II diabetes mellitus.
29. Use according to claim 22, 23 or 24 in combination with metformin, a sulfonylurea or a thiazolidinedione, for the treatment of type II diabetes mellitus.
30. Use according to claim 29, wherein the thiazolidinedione is pioglitazone.
31. Use of:

a compound as defined in claim 1, 2, 3 or 4, a tautomer, enantiomer, diastereomer, mixture thereof or salt thereof;

a compound as defined in claim 5 or a salt thereof;

a compound as defined in claim 6 or a physiologically acceptable salt thereof;

the compound 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine; or a physiologically acceptable salt as defined in claim 9 or 10 for the inhibition of dipeptidylpeptidase-IV (DPP-IV).
32. Process for preparing a pharmaceutical composition according to claim 11, 12 or 13 comprising incorporating a compound as defined in claim 1, 2, 3 or 4, a tautomer, enantiomer, diastereomer, mixture thereof or salt thereof;

a compound as defined in claim 5 or a salt thereof;

a compound as defined in claim 6 or a physiologically acceptable salt thereof;

the compound 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine; or a physiologically acceptable salt as defined in claim 9 or 10 in one or more inert carriers and/or diluents by a non-chemical method.
33. Process for preparing a pharmaceutical composition according to claim 12 comprising incorporating the compound 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, or a physiologically acceptable salt of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine with an inorganic or organic acid, in one or more inert carriers and/or diluents.
34. Process for preparing a pharmaceutical composition according to claim 13 comprising incorporating the compound 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine in one or more inert carriers and/or diluents.
35. Process for preparing a compound of general formula I according to claim 1 or 5 comprising reacting a compound of general formula wherein R1 to R3 are defined as in claim 1 or 5 and Z1 denotes a leaving group with 3-aminopiperidine, an enantiomer or salt thereof, and/or subsequently, optionally, cleaving any protecting groups used during the reaction and/or resolving the compound of general formula I thus obtained into its enantiomers or diastereomers and/or converting the compound of formula I thus obtained into a salt thereof.
36. Process for preparing a compound of general formula I according to claim 1 or 5 comprising deprotecting a compound of general formula wherein R1, R2 and R3 are defined as in claim 1 or 5, and/or resolving the compound of general formula I thus obtained into its enantiomers or diastereomers and/or converting the compound of formula I thus obtained into a salt thereof.
37. Process for preparing the compound 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, or a salt thereof, comprising reacting a compound of general formula wherein R1 denotes a 4-methyl-2-quinazolinylmethyl group, R2 denotes a methyl group and R3 denotes a 2-butyn-1-yl group, and Z1 denotes a leaving group, with (R)-3-aminopiperidine or a salt thereof, and/or subsequently, optionally, cleaving any protecting groups used during the reaction and/or converting the compound of formula I thus obtained into a salt thereof.
38. Process for preparing the compound 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, or a salt thereof, comprising deprotecting a compound of general formula wherein R1 denotes a 4-methyl-2-quinazolinylmethyl group, R2 denotes a methyl group and R3 denotes a 2-butyn-1-yl group, and/or converting the compound of formula I thus obtained into a salt thereof.
39. Process according to claim 35, wherein the leaving group is a halogen atom, a substituted hydroxy, mercapto, sulphinyl, sulphonyl or sulphonyloxy group.
40. Process according to claim 35, 36 or 39, wherein the salt is a physiologically acceptable salt with an inorganic or organic acid or base.
41. Process according to claim 37, wherein the leaving group is a halogen atom, a substituted hydroxyl, mercapto, sulphinyl, sulphonyl or sulphonyloxy group.
42. Process according to claim 37, 38 or 41, wherein the salt is a physiologically acceptable salt with an inorganic or organic acid.
CA2496249A 2002-08-21 2003-08-18 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments Expired - Lifetime CA2496249C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10238243.3 2002-08-21
DE10238243A DE10238243A1 (en) 2002-08-21 2002-08-21 New 8-(3-amino-piperidin-1-yl)-xanthine derivatives are dipeptidylpeptidase-IV inhibitors useful for, e.g. treating diabetes mellitus, arthritis or obesity
DE10312353A DE10312353A1 (en) 2003-03-20 2003-03-20 New 8-(3-amino-piperidin-1-yl)-xanthine derivatives are dipeptidylpeptidase-IV inhibitors useful for, e.g. treating diabetes mellitus, arthritis or obesity
DE10312353.9 2003-03-20
PCT/EP2003/009127 WO2004018468A2 (en) 2002-08-21 2003-08-18 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments

Publications (2)

Publication Number Publication Date
CA2496249A1 CA2496249A1 (en) 2004-03-04
CA2496249C true CA2496249C (en) 2012-01-24

Family

ID=31947613

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2496249A Expired - Lifetime CA2496249C (en) 2002-08-21 2003-08-18 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments

Country Status (38)

Country Link
EP (6) EP2070539A1 (en)
JP (6) JP4233524B2 (en)
KR (2) KR101111101B1 (en)
CN (4) CN100522962C (en)
AR (3) AR041025A1 (en)
AT (1) ATE453644T1 (en)
AU (2) AU2003253418B2 (en)
BE (1) BE2011C038I2 (en)
BR (2) BRPI0313648B8 (en)
CA (1) CA2496249C (en)
CY (3) CY1109928T1 (en)
DE (2) DE50312295D1 (en)
DK (1) DK1532149T3 (en)
EA (3) EA016166B1 (en)
EC (2) ECSP055617A (en)
EG (1) EG25011A (en)
ES (1) ES2339112T3 (en)
FR (1) FR11C0052I2 (en)
HK (1) HK1250708A1 (en)
HR (2) HRP20090665A2 (en)
HU (1) HUS1100028I1 (en)
IL (1) IL166964A (en)
IN (2) IN2015DN01133A (en)
LU (2) LU91889I2 (en)
ME (1) ME00396B (en)
MX (1) MXPA05001684A (en)
MY (2) MY137619A (en)
NO (4) NO333970B1 (en)
PE (1) PE20040897A1 (en)
PL (2) PL216134B1 (en)
PT (1) PT1532149E (en)
RS (2) RS52142B (en)
SA (1) SA03240448B1 (en)
SI (1) SI1532149T1 (en)
TW (3) TWI319320B (en)
UA (1) UA84275C2 (en)
UY (1) UY27946A1 (en)
WO (1) WO2004018468A2 (en)

Families Citing this family (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE336494T1 (en) * 2002-05-31 2006-09-15 Schering Corp METHOD FOR PRODUCING XANTHINE PHOSPHODIESTERASE V INHIBITORS AND THEIR PRECURSORS
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
EA016166B1 (en) * 2002-08-21 2012-02-28 Бёрингер Ингельхайм Фарма Гмбх & Ко. Кг 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7495005B2 (en) 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US7569574B2 (en) 2002-08-22 2009-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10251927A1 (en) * 2002-11-08 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 1,7,8-trisubstituted xanthine derivatives, are dipeptidylpeptidase-IV inhibitors useful e.g. for treating diabetes mellitus type I or II, arthritis or obesity
US7482337B2 (en) 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10254304A1 (en) * 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg New xanthine derivatives, their production and their use as medicines
KR20050122220A (en) 2003-03-25 2005-12-28 다케다 샌디에고, 인코포레이티드 Dipeptidyl peptidase inhibitors
WO2004098591A2 (en) 2003-05-05 2004-11-18 Probiodrug Ag Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases
WO2004103993A1 (en) 2003-05-14 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US7566707B2 (en) 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
US20050065148A1 (en) 2003-08-13 2005-03-24 Syrrx, Inc. Dipeptidyl peptidase inhibitors
DE10355304A1 (en) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel 8- (piperazin-1-yl) and 8 - ([1,4] diazepan-1-yl) xanthines, their preparation and their use as pharmaceuticals
DK1706403T3 (en) 2003-12-22 2012-04-23 Leuven K U Res & Dev IMIDAZO [4,5-C] PYRIDINE COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT
DE10360835A1 (en) 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg New bicyclic imidazole derivatives are dipeptidylpeptidase-IV inhibitors useful to treat e.g. arthritis, obesity, allograft transplantation and calcitonin-induced osteoporosis
AU2012202850B2 (en) * 2004-02-18 2015-08-20 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthine, the production thereof and the use in the form of a DPP inhibitor
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
WO2005085246A1 (en) * 2004-02-18 2005-09-15 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthine, the production thereof and the use in the form of a dpp inhibitor
DE102004009039A1 (en) * 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8- [3-Amino-piperidin-1-yl] xanthines, their preparation and use as pharmaceuticals
US7393847B2 (en) 2004-03-13 2008-07-01 Boehringer Ingleheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
CN102134229B (en) 2004-03-15 2020-08-04 武田药品工业株式会社 Dipeptidyl peptidase inhibitors
US7439370B2 (en) 2004-05-10 2008-10-21 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
DE102004030502A1 (en) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel imidazoles and triazoles, their preparation and use as medicines
US7790730B2 (en) 2004-07-27 2010-09-07 Gilead Sciences, Inc. Imidazo[4,5-d]pyrimidines, their uses and methods of preparation
DE102004043944A1 (en) * 2004-09-11 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel 8- (3-amino-piperidin-1-yl) -7- (but-2-ynyl) -xanthines, their preparation and their use as pharmaceuticals
DE102004044221A1 (en) 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 3-methyl-7-butynyl xanthines, their preparation and their use as pharmaceuticals
DE102004054054A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
AU2012205240B2 (en) * 2004-11-05 2015-03-26 Boehringer Ingelheim International Gmbh Method for producing chiral 8-(3-amino-piperidin-1-yl)-xanthines
JP2008524335A (en) 2004-12-21 2008-07-10 ギリアド サイエンシズ， インコーポレイテッド Imidazo [4,5-c] pyridine compounds and antiviral treatment methods
DOP2006000008A (en) 2005-01-10 2006-08-31 Arena Pharm Inc COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE BLOOD CONCENTRATION OF GLP-1
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
DE102005035891A1 (en) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8- (3-amino-piperidin-1-yl) -xanthines, their preparation and their use as pharmaceuticals
CN101374523B (en) 2005-09-14 2012-04-11 武田药品工业株式会社 Dipeptidyl peptidase inhibitors for the treatment of diabetes
CN102908350B (en) † 2005-09-14 2014-07-23 武田药品工业株式会社 Dipeptidyl peptidase inhibitors for treating diabetes
CN102675221A (en) 2005-09-16 2012-09-19 武田药品工业株式会社 Intermediate in method for preparing pyrimidinedione derivative
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
CA2632021A1 (en) * 2005-12-23 2007-06-28 Astrazeneca Ab Gaba-b receptor modulators
TW200803855A (en) * 2006-02-24 2008-01-16 Kalypsys Inc Quinolones useful as inducible nitric oxide synthase inhibitors
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
PE20071221A1 (en) 2006-04-11 2007-12-14 Arena Pharm Inc GPR119 RECEPTOR AGONISTS IN METHODS TO INCREASE BONE MASS AND TO TREAT OSTEOPOROSIS AND OTHER CONDITIONS CHARACTERIZED BY LOW BONE MASS, AND COMBINED THERAPY RELATED TO THESE AGONISTS
PE20080251A1 (en) 2006-05-04 2008-04-25 Boehringer Ingelheim Int USES OF DPP IV INHIBITORS
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CA2810522A1 (en) * 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Polymorphs
ES2339298T3 (en) 2006-07-07 2010-05-18 Gilead Sciences, Inc. PIRIDAZINE NOVEDOUS COMPOUND AND USE OF IT.
US8071583B2 (en) 2006-08-08 2011-12-06 Boehringer Ingelheim International Gmbh Pyrrolo[3,2-D] pyrimidines as DPP-IV inhibitors for the treatment of diabetes mellitus
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
ATE554085T1 (en) 2006-11-30 2012-05-15 Probiodrug Ag NEW INHIBITORS OF GLUTAMINYL CYCLASE
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
UA99466C2 (en) 2007-07-06 2012-08-27 Гилиад Сайенсиз, Инк. Crystalline pyridazine compound
PE20090597A1 (en) * 2007-08-16 2009-06-06 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION INCLUDING A DERIVATIVE OF PIRAZOL-O-GLUCOSIDE
PE20090938A1 (en) 2007-08-16 2009-08-08 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION INCLUDING A BENZENE DERIVATIVE SUBSTITUTED WITH GLUCOPYRANOSIL
EP3542801A1 (en) 2007-08-17 2019-09-25 Boehringer Ingelheim International GmbH Purin derivatives for use in the treatment of fap-related diseases
AR071175A1 (en) 2008-04-03 2010-06-02 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION THAT INCLUDES AN INHIBITOR OF DIPEPTIDIL-PEPTIDASA-4 (DPP4) AND A COMPARING PHARMACO
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
PE20100156A1 (en) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int NAFLD TREATMENT
KR20190016601A (en) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 Treatment for diabetes in patients inappropriate for metformin therapy
UY32030A (en) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN"
US20110190322A1 (en) * 2008-08-14 2011-08-04 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
MX2011002558A (en) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Combination therapy for the treatment of diabetes and related conditions.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
UY32177A (en) * 2008-10-16 2010-05-31 Boehringer Ingelheim Int TREATMENT OF DIABETES IN PATIENTS WITH INSUFFICIENT GLUCEMIC CONTROL TO WEIGHT THERAPY WITH DRUG, ORAL OR NOT, ANTIDIABÉTICO
CA2745037C (en) * 2008-12-23 2020-06-23 Boehringer Ingelheim International Gmbh Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8(3-(r)-amino-piperidin-1-yl)-xanthine
AR074990A1 (en) 2009-01-07 2011-03-02 Boehringer Ingelheim Int TREATMENT OF DIABETES IN PATIENTS WITH AN INAPPROPRIATE GLUCEMIC CONTROL THROUGH METFORMIN THERAPY
AR075204A1 (en) * 2009-01-29 2011-03-16 Boehringer Ingelheim Int DPP-4 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, USEFUL TO TREAT METABOLIC DISEASES IN PEDIATRIC PATIENTS, PARTICULARLY MELLITUS DIABETES TYPE 2
KR101694136B1 (en) 2009-02-13 2017-01-09 베링거 인겔하임 인터내셔날 게엠베하 Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a further antidiabetic agent and uses thereof
CN117547538A (en) 2009-02-13 2024-02-13 勃林格殷格翰国际有限公司 Antidiabetic drugs containing a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetic drugs
UY32427A (en) * 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL FORM, PROCEDURE FOR PREPARATION, METHODS OF TREATMENT AND USES OF THE SAME
AR077642A1 (en) 2009-07-09 2011-09-14 Arena Pharm Inc METABOLISM MODULATORS AND THE TREATMENT OF DISORDERS RELATED TO THE SAME
KR101755737B1 (en) 2009-09-11 2017-07-07 프로비오드룩 아게 Heterocyclic derivatives as inhibitors of glutaminyl cyclase
HUE029381T2 (en) 2009-09-30 2017-02-28 Boehringer Ingelheim Int A method for preparing a crystalline form of 1-chloro-4- (beta-D-glucopyranos-1-yl) -2- [4 - ((S) -tetrahydrofuran-3-yloxy) benzyl] benzene.
PT2486029E (en) 2009-09-30 2015-10-14 Boehringer Ingelheim Int Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
WO2011039367A2 (en) 2009-10-02 2011-04-07 Boehringer Ingelheim International Gmbh Therapeutic uses of pharmaceutical compositions
ES2760917T3 (en) 2009-11-27 2020-05-18 Boehringer Ingelheim Int Treatment of diabetic patients genotyped with DPP-IV inhibitors such as linagliptin
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
US8269019B2 (en) 2010-03-10 2012-09-18 Probiodrug Ag Inhibitors
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
EP2556056A1 (en) 2010-04-06 2013-02-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
KR101819609B1 (en) 2010-05-05 2018-01-17 베링거 인겔하임 인터내셔날 게엠베하 Sequential Combination Therapy by the Weight Reducing Treatment Followed by the DPP-4 Inhibitor
KR20130069615A (en) 2010-05-05 2013-06-26 베링거 인겔하임 인터내셔날 게엠베하 Pharmaceutical formulations comprising pioglitazone and linagliptin
ES2953123T3 (en) 2010-06-24 2023-11-08 Boehringer Ingelheim Int Diabetes therapy
PE20131371A1 (en) 2010-09-22 2013-11-25 Arena Pharm Inc GPR119 RECEPTOR MODULATORS AND THE TREATMENT OF RELATED DISORDERS
KR102117282B1 (en) * 2010-11-15 2020-06-01 베링거 인겔하임 인터내셔날 게엠베하 Vasoprotective and cardioprotective antidiabetic therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
UY33937A (en) 2011-03-07 2012-09-28 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITIONS CONTAINING DPP-4 AND / OR SGLT-2 AND METFORMIN INHIBITORS
JP6050264B2 (en) 2011-03-16 2016-12-21 プロビオドルグ エージー Benzimidazole derivatives as inhibitors of glutaminyl cyclase
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
CN103596954B (en) 2011-05-10 2016-10-26 桑多斯股份公司 The polymorph of benzoic acid BI 1356
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
KR101985384B1 (en) * 2011-07-15 2019-06-03 베링거 인겔하임 인터내셔날 게엠베하 Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20130123282A1 (en) 2011-11-16 2013-05-16 Leonid Metsger Solid state forms of linagliptin
US20130172244A1 (en) 2011-12-29 2013-07-04 Thomas Klein Subcutaneous therapeutic use of dpp-4 inhibitor
CN103254193B (en) * 2012-02-15 2015-04-22 上海医药工业研究院 Xanthine compound intermediate and preparation method thereof
CN103254192B (en) * 2012-02-15 2015-12-02 上海医药工业研究院 Xanthine derivative, its salt, intermediate, preparation method and application
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9879011B2 (en) 2012-03-12 2018-01-30 Cadila Healthcare Limited Amorphous form of linagliptin and process for preparation thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN103373999B (en) * 2012-04-28 2016-01-13 上海医药工业研究院 purine compound, intermediate, preparation method and application thereof
JP6218811B2 (en) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Xanthine derivatives as DPP-4 inhibitors for use in the treatment of SIRS and / or sepsis
EP2849755A1 (en) * 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
EP2854812A1 (en) 2012-05-24 2015-04-08 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP2015518843A (en) 2012-05-25 2015-07-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Use of keratinocytes as bioactive agents that may be combined with DPP-4 inhibitors in the treatment of wounds, for example diabetic wounds
CN103509023B (en) * 2012-06-20 2014-08-27 成都苑东药业有限公司 Xanthine derivative
CN103509022B (en) * 2012-06-20 2015-04-01 成都苑东药业有限公司 Xanthine derivative
IN2015DN00280A (en) 2012-08-13 2015-06-12 Sandoz Ag
WO2014045266A1 (en) 2012-09-24 2014-03-27 Ulf Eriksson Treatment of type 2 diabetes and related conditions
CN103709163B (en) * 2012-09-29 2016-12-21 齐鲁制药有限公司 Xanthine derivative, Preparation Method And The Use
UA116217C2 (en) 2012-10-09 2018-02-26 Санофі Exendin-4 derivatives as dual glp1/glucagon agonists
CN103319483B (en) * 2012-10-19 2016-08-03 药源药物化学（上海）有限公司 A kind of preparation method of important intermediate of linagliptin
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
EP2935266A1 (en) * 2012-12-17 2015-10-28 Mylan Laboratories Ltd. An improved process for the preparation of linagliptin
SG11201504215PA (en) 2012-12-21 2015-06-29 Sanofi Sa Functionalized exendin-4 derivatives
CN103936738B (en) * 2013-01-23 2016-11-23 成都苑东生物制药股份有限公司 Xanthine derivative
CN103936737B (en) * 2013-01-23 2016-09-14 成都苑东生物制药股份有限公司 Xanthine derivative
CN106008507B (en) * 2013-01-23 2017-11-28 成都苑东生物制药股份有限公司 Xanthine derivative
CN103936739B (en) * 2013-01-23 2016-08-31 成都苑东生物制药股份有限公司 Xanthine derivative
HK1218762A1 (en) 2013-03-15 2017-03-10 Takeda Pharmaceutical Company Limited Anti-plasma kallikrein antibodies
CN105188706A (en) 2013-03-15 2015-12-23 勃林格殷格翰国际有限公司 Use of linagliptin in cardio- and renoprotective antidiabetic therapy
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HK1215398A1 (en) 2013-04-05 2016-08-26 勃林格殷格翰国际有限公司 Therapeutic uses of empagliflozin
RS63042B1 (en) 2013-04-18 2022-04-29 Boehringer Ingelheim Int Pharmaceutical composition, methods for treating and uses thereof
KR102238860B1 (en) * 2013-06-14 2021-04-12 베링거 인겔하임 인터내셔날 게엠베하 Dpp-4 inhibitors for treating diabetes and its complications
CN104292228B (en) * 2013-07-16 2016-03-30 成都苑东生物制药股份有限公司 Polymorphic of a kind of Xanthine compounds and preparation method thereof, purposes
WO2015011609A1 (en) 2013-07-23 2015-01-29 Ranbaxy Laboratories Limited Process for the preparation of linagliptin and an intermediate thereof
CN104418857A (en) * 2013-08-22 2015-03-18 北京蓝丹医药科技有限公司 Amorphous linagliptin and preparation method thereof
TW201609796A (en) 2013-12-13 2016-03-16 賽諾菲公司 Non-acylated EXENDIN-4 peptide analogues
TW201609797A (en) 2013-12-13 2016-03-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
CN104725379A (en) * 2013-12-24 2015-06-24 杭州民生药物研究院有限公司 Preparation method and application of purine ketone derivatives and composition thereof
WO2015128453A1 (en) * 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
TW201625670A (en) 2014-04-07 2016-07-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
TW201625669A (en) 2014-04-07 2016-07-16 賽諾菲公司 Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
TW201625668A (en) 2014-04-07 2016-07-16 賽諾菲公司 Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN104557935B (en) * 2015-01-27 2016-08-17 江苏嘉逸医药有限公司 Preparation (R)-8-(3-amino piperidine-1-base)-xanthic method of purification
MA42450A (en) 2015-03-09 2018-05-23 Intekrin Therapeutics Inc TREATMENT METHODS FOR NON-ALCOHOLIC HEPATIC STEATOSIS AND / OR LIPODYSTROPHY
AR105319A1 (en) 2015-06-05 2017-09-27 Sanofi Sa PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
EP3313841A1 (en) 2015-06-25 2018-05-02 Boehringer Ingelheim International GmbH Process for the preparation of a xanthine-based compound
AR105284A1 (en) 2015-07-10 2017-09-20 Sanofi Sa DERIVATIVES OF EXENDINA-4 AS SPECIFIC DUAL PEPTIDE AGONISTS OF GLP-1 / GLUCAGÓN RECEPTORS
EP3359136A1 (en) 2015-10-09 2018-08-15 Hexal AG Pharmaceutical composition containing 8-[(3r)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[4-methyl-2-quinazolinyl)methyl]-1h-purine-2,6-dione or a pharmaceutically acceptable salt thereof
EP3156048A1 (en) 2015-10-13 2017-04-19 Galenicum Health S.L. Stable pharmaceutical composition of linagliptin in the form of immediate release tablets
CN105566271B (en) * 2015-12-03 2019-09-13 福建医科大学 Biflavone compound and its application for preparing medicine for treating cancer
EP3468562A1 (en) 2016-06-10 2019-04-17 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
MA46742A (en) 2016-11-10 2019-09-18 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION, METHODS OF TREATMENT AND THEIR USES
US11285180B2 (en) 2016-12-06 2022-03-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
CN110996951A (en) 2017-04-03 2020-04-10 科赫罗斯生物科学股份有限公司 PPARγ agonists for the treatment of progressive supranuclear palsy
KR102469957B1 (en) 2017-06-30 2022-11-24 한미약품 주식회사 Pharmaceutical composition comprising linagliptin and metformin with improved stability
CN107325114B (en) * 2017-07-04 2019-06-11 吉林省爱诺德生物工程有限公司 A kind of preparation method of Ceftaroline Fosamil intermediate
DK3461819T3 (en) 2017-09-29 2020-08-10 Probiodrug Ag GLUTAMINYL CYCLASE INHIBITORS
KR102500835B1 (en) 2017-10-24 2023-02-17 한미약품 주식회사 Complex Preparations Comprising Lingliptin and Metformin as an active ingredients and preparing method thereof
CN108299436B (en) * 2018-02-09 2020-01-17 上海慈瑞医药科技股份有限公司 Xanthine compound and pharmaceutical composition and application thereof
KR102208009B1 (en) * 2018-04-26 2021-01-28 주식회사 경보제약 Preparation methode of 5-phenyl pentyl hexahydro cyclopentafuran compounds and cycloheptanoate compounds
KR102647472B1 (en) 2018-07-31 2024-03-14 한미약품 주식회사 Solid composite formulation for oral administration comprising dipeptidyl peptidase-4 inhibitor and metformine, and a process for the preparation thereof
HU231374B1 (en) 2018-08-06 2023-04-28 Richter Gedeon Nyrt. Process for the preparation of boc-linagliptin
CN113543852A (en) 2019-03-06 2021-10-22 第一三共株式会社 Pyrrolopyrazole derivatives
CN110305131B (en) * 2019-07-03 2021-12-31 山东百诺医药股份有限公司 Novel crystal form of linagliptin and preparation method thereof
EP3811930A1 (en) 2019-10-24 2021-04-28 Authenda Pharmaceuticals AG Oral gliptin compositions and method for preparation thereof
WO2021109970A1 (en) * 2019-12-02 2021-06-10 成都苑东生物制药股份有限公司 Xanthine derivative pharmaceutical composition and preparation method therefor
CA3170233A1 (en) 2020-02-13 2021-08-19 Zaklady Farmaceutyczne Polpharma S.A. Pharmaceutical composition comprising linagliptin and metformin
CN112876409A (en) * 2021-01-20 2021-06-01 都创(上海)医药科技股份有限公司 Synthesis method of 2- (5-bromo-6-methoxypyridine-2-yl) acetonitrile and derivatives thereof
CN117858703A (en) 2021-07-22 2024-04-09 新梅斯托克公司 Method for preparing pharmaceutical composition comprising linagliptin and metformin hydrochloride
KR20230055762A (en) 2021-10-19 2023-04-26 한미약품 주식회사 Pharmaceutical composite formulation comprising metformin, linagliptin and meglumine
EP4482835A1 (en) 2022-02-21 2025-01-01 KRKA, D.D., Novo Mesto Process for purification of linagliptin
KR20230126664A (en) 2022-02-23 2023-08-30 주식회사 제뉴원사이언스 Pharmaceutical combination of controlled drug delivery comprising linagliptin or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof
CN114989147B (en) * 2022-06-20 2024-05-17 广东晨康生物科技有限公司 Benzopyrimidine compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof
EP4349837A1 (en) 2022-10-05 2024-04-10 Zaklady Farmaceutyczne "Polpharma" S.A. A pharmaceutical intermediate
CN120513087A (en) 2022-10-25 2025-08-19 星岩制药有限公司 Combination and rotational combination therapies for obesity and other conditions
CN118496229A (en) * 2024-05-13 2024-08-16 迪嘉药业集团股份有限公司 A new crystal form of linagliptin and preparation method thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4061753A (en) * 1976-02-06 1977-12-06 Interx Research Corporation Treating psoriasis with transient pro-drug forms of xanthine derivatives
FR2558162B1 (en) * 1984-01-17 1986-04-25 Adir NOVEL XANTHINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US4968672A (en) * 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
FR2654935B1 (en) * 1989-11-28 1994-07-01 Lvmh Rech USE OF XANTHINES, WHICH MAY BE INCORPORATED IN LIPOSOMES, TO PROMOTE PIGMENTATION OF THE SKIN OR HAIR.
US5965555A (en) * 1996-06-07 1999-10-12 Hoechst Aktiengesellschaft Xanthine compounds having terminally animated alkynol side chains
AU6797298A (en) 1997-04-15 1998-11-11 Genentech Inc. Halo-alkoxycarbonyl prodrugs
DE19828114A1 (en) * 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs of unstable inhibitors of dipeptidyl peptidase IV
EP1741447B1 (en) * 2000-01-21 2013-09-18 Novartis AG Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents
GB0008694D0 (en) * 2000-04-07 2000-05-31 Novartis Ag Organic compounds
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
PL360856A1 (en) * 2000-07-04 2004-09-20 Novo Nordisk A/S Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv)
EP1368349B1 (en) * 2001-02-24 2007-02-14 Boehringer Ingelheim Pharma GmbH & Co.KG Xanthine derivative, production and use thereof as a medicament
JP2005502624A (en) * 2001-07-03 2005-01-27 ノボ　ノルディスク　アクティーゼルスカブ Purine derivatives inhibiting DPP-IV for the treatment of diabetes
WO2003024965A2 (en) * 2001-09-19 2003-03-27 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
JP2005513165A (en) * 2002-01-11 2005-05-12 ノボ　ノルディスク　アクティーゼルスカブ Methods and compositions for the treatment of diabetes, hypertension, chronic heart failure and fluid retention
EA016166B1 (en) * 2002-08-21 2012-02-28 Бёрингер Ингельхайм Фарма Гмбх & Ко. Кг 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE10251927A1 (en) * 2002-11-08 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 1,7,8-trisubstituted xanthine derivatives, are dipeptidylpeptidase-IV inhibitors useful e.g. for treating diabetes mellitus type I or II, arthritis or obesity

Also Published As

Publication number Publication date
PT1532149E (en) 2010-02-17
NO20140234L (en) 2005-03-03
AU2010201384C1 (en) 2013-09-26
MEP59708A (en) 2011-05-10
JP2016199572A (en) 2016-12-01
CN105001222B (en) 2017-11-07
IL166964A (en) 2011-02-28
HRP20050157A2 (en) 2006-05-31
BR122012026540B1 (en) 2019-04-24
IN2015DN01133A (en) 2015-06-26
ATE453644T1 (en) 2010-01-15
JP2014177485A (en) 2014-09-25
PE20040897A1 (en) 2005-01-31
JP5351486B2 (en) 2013-11-27
EP2060573A3 (en) 2011-04-13
JP2009079061A (en) 2009-04-16
FR11C0052I2 (en) 2013-01-11
SI1532149T1 (en) 2010-05-31
NO2014008I2 (en) 2014-04-08
WO2004018468A3 (en) 2004-04-08
TWI388325B (en) 2013-03-11
EP2058311A2 (en) 2009-05-13
RS20050137A (en) 2007-11-15
HK1134076A1 (en) 2010-04-16
JP6139004B2 (en) 2017-05-31
AR077875A2 (en) 2011-09-28
TW200404542A (en) 2004-04-01
TWI469783B (en) 2015-01-21
UY27946A1 (en) 2004-03-31
JP2006503013A (en) 2006-01-26
UA84275C2 (en) 2008-10-10
HK1134077A1 (en) 2010-04-16
ME00396B (en) 2011-05-10
RS20120139A2 (en) 2012-10-31
JP2009001565A (en) 2009-01-08
FR11C0052I1 (en) 2012-01-06
SA03240448B1 (en) 2009-06-07
DE50312295D1 (en) 2010-02-11
EG25011A (en) 2011-05-25
NO333970B1 (en) 2013-11-04
CY2012001I2 (en) 2016-12-14
MY165643A (en) 2018-04-18
CN107674077A (en) 2018-02-09
AR041025A1 (en) 2005-04-27
EP3424926A1 (en) 2019-01-09
WO2004018468A2 (en) 2004-03-04
NO336641B1 (en) 2015-10-12
CN100522962C (en) 2009-08-05
CY2013002I1 (en) 2020-05-29
EP1532149B9 (en) 2011-04-20
KR101111101B1 (en) 2012-06-13
JP4971251B2 (en) 2012-07-11
EA200500302A1 (en) 2005-10-27
KR20050058375A (en) 2005-06-16
HK1183028A1 (en) 2013-12-13
CN105001222A (en) 2015-10-28
CN1675212A (en) 2005-09-28
BR122012026540B8 (en) 2021-05-25
CY2012001I1 (en) 2016-12-14
EP2308878A3 (en) 2011-10-26
EA024251B1 (en) 2016-08-31
DE122011100059I1 (en) 2012-04-05
KR20090047560A (en) 2009-05-12
PL216134B1 (en) 2014-03-31
NO2014008I1 (en) 2014-06-02
RS52142B (en) 2012-08-31
IN2015DN01132A (en) 2015-06-26
JP6114231B2 (en) 2017-04-12
CA2496249A1 (en) 2004-03-04
HK1250708A1 (en) 2019-01-11
NO20130968L (en) 2005-03-03
EA016166B1 (en) 2012-02-28
AU2003253418A1 (en) 2004-03-11
PL375342A1 (en) 2005-11-28
CN102964347A (en) 2013-03-13
TW201304782A (en) 2013-02-01
EP2060573A2 (en) 2009-05-20
LU92128I2 (en) 2013-03-11
DK1532149T3 (en) 2010-05-10
EA200702022A1 (en) 2008-06-30
AR087287A2 (en) 2014-03-12
HK1215439A1 (en) 2016-08-26
EA010303B1 (en) 2008-08-29
MXPA05001684A (en) 2005-04-19
EA201001167A1 (en) 2011-02-28
BE2011C038I2 (en) 2022-08-09
HUS1100028I1 (en) 2016-07-28
HRP20050157B1 (en) 2013-01-31
AU2003253418B2 (en) 2010-04-22
ECSP12005617A (en) 2012-04-30
TWI319320B (en) 2010-01-11
MY137619A (en) 2009-02-27
ES2339112T3 (en) 2010-05-17
CY1109928T1 (en) 2014-09-10
NO20050069L (en) 2005-03-03
LU91889I9 (en) 2019-01-03
BR0313648A (en) 2007-05-08
EP1532149B1 (en) 2009-12-30
JP2012162555A (en) 2012-08-30
KR101150449B1 (en) 2012-06-01
LU91889I2 (en) 2011-12-21
PL403104A1 (en) 2013-05-13
ECSP055617A (en) 2005-05-30
EP1532149A2 (en) 2005-05-25
EP2308878A2 (en) 2011-04-13
RS20120139A3 (en) 2015-02-27
TW200944209A (en) 2009-11-01
AU2010201384A1 (en) 2010-04-29
CN102964347B (en) 2015-11-18
BRPI0313648B8 (en) 2021-05-25
JP5623459B2 (en) 2014-11-12
HK1081552A1 (en) 2006-05-19
EP2070539A1 (en) 2009-06-17
EP2058311A3 (en) 2011-04-13
JP4233524B2 (en) 2009-03-04
HRP20090665A2 (en) 2010-07-31
AU2010201384B2 (en) 2013-05-02
BRPI0313648B1 (en) 2018-07-17

Similar Documents

Publication Publication Date Title
US10202383B2 (en) 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
CA2496249C (en) 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments
AU2013202252B2 (en) 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments
AU2013251292B2 (en) 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments
NZ564768A (en) 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments
HK1215439B (en) Compound of 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments
HK1134077B (en) 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments
HK1081552B (en) 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments
HK1134076B (en) 8-[3-amino-piperidin-1-yl]-xanthines
HK1183028B (en) Compound of 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20230818